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Abstract 
Adrenocortical carcinoma (ACC) is an aggressive malignancy with high recurrence rates and 
poor response to chemotherapy. With this work, we have evaluated a potential new treatment 
target focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide 
Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant 
pathways, which protect cells from oxidative stress. Our hypothesis was that NNT silencing 
will expose cells to cytotoxic levels of oxidative stress.  We knocked down NNT transiently 
in NCI-H295R ACC cells in vitro; this led to an increase in cellular oxidative stress and a 
strong cytotoxic and cytostatic effect. With stable NNT knockdown, we observed the 
emergence of a partially compensated phenotype over the course of time, with restored redox 
balance. Surprisingly, steroidogenesis was stimulated by transient NNT loss, challenging 
current perceptions about the impact of oxidative stress on steroidogenesis.  
In our clinical study, we evaluated a new diagnostic tool for biochemical detection of ACC 
recurrence. Serial post-operative urine samples were collected from a large cohort of patients 
who had undergone complete ACC resection. Standardised review of longitudinal steroid 
measurements resulted in detection of disease recurrence prior to or concurrently with 
imaging with high sensitivity in cases where a pre-operative steroid profile had been 
provided.
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1.1 The organ: the adrenal gland and adrenal steroidogenesis  
1.1.1 Development and anatomy of the adrenal gland 
The adrenal glands, first described by Eustachius in 1563, are two endocrine glands located in 
the retroperitoneal space above the kidneys. The right adrenal is pyramidal in shape, while the 
somewhat larger left gland is semilunar. Normal adrenal glands do not size more than 5x3 cm 
and do not weigh more than 7-10 g.  Each gland consists of two parts, the outer cortex and the 
inner medulla, with distinct embryogenic extractions and biosynthetic orientations. The 
adrenal cortex arises from the urogenital ridge of the mesoderm during early foetal life, thus 
sharing the same origin as testicular Leydig cells. Conversely, the medulla arises from the 
neural crest, part of the ectoderm, and eventually migrates to the adrenal primordium around 
gestational week seven. The foetal adrenal cortex consists of two zones: the temporary foetal 
zone, which undergoes apoptotic demise after birth, and the definitive adult zone. Molecular 
pathways which have been implicated in the embryonic development of the adrenal gland 
include the b-catenin and sonic hedgehog pathways (Wood and Hammer, 2011). 
 
 The adult adrenal cortex consists of three parts, named according to their microscopic 
structure:  
a) The outer zona glomerulosa, site of mineralocorticoid hormone secretion  
b) The central zona fasciculata, site of glucocorticoid secretion 
c) The inner zona reticularis, site of sex steroid precursor secretion 
The adrenal medulla specialises in the synthesis of catecholamines (adrenalin, noradrenalin 
and dopamine).    
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Arterial blood supply to the adrenal gland is provided through three main branches: the 
superior suprarenal artery (from the inferior phrenic artery), the middle suprarenal artery 
(directly from the aorta) and the inferior suprarenal artery (from the renal artery). Venous 
drainage is through a central adrenal vein; on the right this is short and drains directly to the 
inferior vena cava, while on the left venous flow follows a longer route, the adrenal vein 
draining to the left renal vein (Fig. 1-1, 1-2).  
 
 
 
Figure 1-1. The adrenal glands. Source:(Ritchie and Balasubramanian, 2011). Reproduced 
with permission of Elsevier. 
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Figure 1-2 Adrenal histology. The adrenal cortex consists of 3 distinct zones, each 
specialising in the secretion of a different class of steroid hormones: the outer zona 
glomerulosa (ZG - mineralocorticoids), the intermediate zona fasciculata (ZF -
glucocorticoids) and the inner zona reticularis (ZR - androgens). This nomenclature springs 
from the respective microscopic appearance of each zone. The adrenal medulla comprises the 
core of the gland and synthesizes catecholamines (adrenalin/noradrenalin/ dopamine). Image 
provided by Dr K Skordilis from her personal archive. 
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1.1.2 Steroidogenesis 
1.1.1.1 Regulation 
Steroid synthesis in each zone of the adrenal cortex is regulated by distinct trophic hormones 
and negative feedback loops.  
a) Zona glomerulosa. Mineralocorticoid (e.g. aldosterone) synthesis in the external zone 
of the adrenal cortex occurs within the context of the renin-angiotensin-aldosterone 
axis. Briefly, renin is generated in the juxtaglomerular cells of the kidneys and 
mediates the cleavage of angiotensin I in the liver. Angiotensin I is converted to 
angiotensin II by the angiotensin-converting enzyme, and binds to the angiotensin type 
II receptor in the adrenal cortex to stimulate aldosterone synthesis. Aldosterone 
stimulates sodium reabsorption and potassium excretion in the renal tubules; the same 
electrolytes regulate renin production, closing the feedback loop.  
 
b) Zona fasciculata. Glucocorticoid (e.g. cortisol) synthesis in this middle zone of the 
adrenal cortex is stimulated by the pituitary peptide adrenocorticotropic hormone 
(ACTH), which is released in response to the hypothalamic hormone CRH 
(corticotropin-releasing hormone).  ACTH release follows a pulsatile pattern which 
underpins the characteristic circadian rhythm of cortisol excretion by the adrenal 
glands. Circulating glucocorticoids exert negative feedback on the hypothalamus 
(CRH) and the pituitary (ACTH), completing the loop. Stressful stimuli (trauma, 
sepsis, surgery, psychological stress) can acutely potentiate ACTH excretion and, 
consequently, augment glucocorticoid synthesis. 
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c) Zona reticularis. The release of adrenal androgen precursors DHEA and 
androstenedione is also regulated by ACTH; those can be converted in the periphery 
to active androgens and oestrogens.  
 
1.1.2.1 Adrenal steroidogenic pathways 
Adrenal steroidogenesis is a complex, multi-stage biosynthetic process leading to the 
generation of mineralocorticoids (aldosterone, zona glomerulosa), glucocorticoids (cortisol, 
zona fasciculata) and androgen precursors (DHEA/androstenedione, zona reticularis) from the 
common initial precursor cholesterol. ACTH is implicated in the first stages of cholesterol 
handling by the adrenocortical cells:  ACTH interaction with the melanocortin 2 receptor 
(MC2R) stimulates intracellular cyclic AMP (cAMP) formation, triggering the protein kinase 
A signalling pathway; this accelerates both ingress of cholesterol esters into adrenocortical 
cells and intracellular cleavage of esters to cholesterol. The ensuing steps of cholesterol 
metabolism are mediated by two broad categories of enzymes: a) cytochrome P450 enzymes 
and b) hydroxysteroid dehydrogenases. The former can be further grouped into mitochondrial 
(type I) P450 enzymes (side chain cleavage enzyme, CYP11A1; 11β-hydroxylase, CYP11B1; 
aldosterone synthase, CYP11B2) and microsomal (type II) P450 enzymes (17α-hydroxylase, 
CYP17A1; 21-hydroxylase, CYP21A2; aromatase, CYP19A1) (Miller, 2005, Payne and 
Hales, 2004). All P450 enzymes catalyse monooxygenase reactions, inserting one atom of 
oxygen into organic substrates while the other oxygen atom is reduced to water; for this they 
require co-factor proteins which supply the essential electrons. Adrenodoxin/ adrenodoxin 
reductase (also referred to as ferrodoxin/ ferrodoxin reductase) is the protein couple donating 
electrons to all mitochondrial P450 enzymes, using reduced nicotinamide adenine 
dinucleotide (NADPH) as their cofactor. Endoplasmic reticulum-based P450 enzymes receive 
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their essential electron flow from P450 oxidoreductase (POR) (Miller, 2005). Cholesterol (27 
carbons) is transported across the mitochondrial membrane by the steroid acute regulatory 
protein (StAR), where it is converted to pregnenolone (21 carbons) by the cholesterol side-
chain cleavage enzyme (CYP11A1) in a reaction requiring three oxygen molecules and three 
NADPH molecules. The glucocorticoid pathway involves conversion of pregnenolone to 
progesterone by 3β-hydroxysteroid dehydrogenase type II (HSD3B2) activity, hydroxylation 
to 17-hydroxyprogesterone by 17a-hydroxylase (CYP17A1), further hydroxylation at carbon 
21 by 21-hydroxylase (CYP21A2) and, finally, 11β-hydroxylation by 11β-hydroxylase 
(CYP11B1) to form cortisol. In the mineralocorticoid pathway, progesterone is first converted 
to deoxycorticosterone by 21-hydroxylase activity, followed by three CYP11B2-mediated 
hydroxylation steps leading to the ultimate generation of aldosterone via the intermediate 
precursors corticosterone and 18-hydroxycorticosterone. Finally, androgen synthesis requires 
consecutive 17a-hydroxylase and 17-20 lyase activities of the enzyme CYP17A1, which 
utilises its dual enzymatic potential to successively hydroxylate pregnenolone to 17-
hydroxypregnenolone and then convert the latter to dehydroepiandrostenedione (DHEA). 
DHEA is predominantly secreted by the adrenal in the form of its sulfate ester, DHEAS, 
generated from unconjugated DHEA by DHEA sulfotransferase (SULT2A1). Glucocorticoid 
and mineralocorticoid hormones consist of 21 carbon atoms, while androgens consist of 19 
and oestrogens of 18 carbon atoms. A schematic outline of adrenal steroidogenesis is 
provided in Fig. 1-3. Table 1-1 summarises the characteristics of adrenal steroidogenic 
enzymes. 
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Figure 1-3. Steroidogenesis includes three biosynthetic pathways: the mineralocorticoid 
pathway (zona glomerulosa), the glucocorticoid pathway (zona fasciculata) and the 
androgen pathway (zona reticularis). Each pathway involves steps mediated by 
endoplasmic reticulum (ER) enzymes and mitochondrial enzymes. 
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Gene Enzyme Protein Tissue 
expression 
Subcellular 
localization 
CYP11A1 Cholesterol 
side-chain 
cleaving 
enzyme 
CYP11A1, 
P450scc 
Adrenal cortex, 
ovary, testis, 
placenta 
Mitochondria 
CYP11B1 11β-
hydroxylase 
CYP11B1, 
P450c11 
Adrenal cortex 
(zona 
fasciculata/ 
reticularis) 
Mitochondria 
CYP11B2 Aldosterone 
synthase 
CYP11Β2, 
P450c18 
Adrenal cortex 
(zona 
glomerulosa) 
Mitochondria 
CYP17A1 17α-
hydroxylase- 
17/20 lyase 
CYP17A1, 
P450c17 
Adrenal cortex, 
ovary, testis 
Endoplasmic 
reticulum 
CYP21A2 21-hydroxylase CYP21A2, 
P450c21 
Adrenal cortex Endoplasmic 
reticulum 
HSD3B2 3β-
hydroxysteroid 
dehydrogenase 
type II 
HSD3B2, 3β-
HSDII  
Adrenal cortex  Endoplasmic 
reticulum  
 
 
1.2 The disease: Adrenocortical Carcinoma 
1.2.1 Epidemiology of adrenocortical carcinoma 
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy arising from the adrenal 
cortex. The exact incidence of ACC is unknown, but data from cancer registries in the United 
States and Europe suggest an estimate of 0.7-2 cases per million population per year (1975, 
Kerkhofs et al., 2013, Fassnacht et al., 2011). This statistic is in striking contrast to the high 
prevalence of adrenal masses in general, which are encountered in 3-10% of the population 
according to radiological and autopsy series and are usually benign (Bovio et al., 2006, Kloos 
Table 1-1 Enzymes participating in adrenal steroidogenesis  
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et al., 1995, Fassnacht et al., 2016). A singularity in global ACC epidemiology is observed in 
Southern Brazil, an area afflicted by a 2.9-4.2 case-per-million incidence of paediatric ACC 
(worldwide incidence = 0.2 cases per million per year), largely due to the correspondingly 
high prevalence of mutations in the tumour suppressor gene TP53 (Custodio et al., 2012). 
ACC appears to have a bimodal age distribution, with a relative peak in the first decade of life 
and a second, higher peak in the fourth and fifth decade (Wajchenberg et al., 2000). Gender 
distribution is characterised by female preponderance (1.5:1). Interestingly, this predilection 
for the female sex seems to apply exclusively to hormonally functional tumours (Wooten and 
King, 1993, Fassnacht and Allolio, 2009). Limited observational data suggest that long-term 
use of oral contraceptives may be an additional risk factor (hazard ratio = 1.8, confidence 
interval 1-3.2) (Hsing et al., 1996). This suggests oestrogens may be involved in the 
pathogenesis of ACC in some cases; indeed, there is in vitro evidence of a pro-proliferative 
effect of oestrogens on ACC cells (Montanaro et al., 2005, Somjen et al., 2003). The same 
case-control study identified smoking history as a risk factor in male patients (hazard ratio 2, 
95% confidence interval 1-4.4). This finding was corroborated by another series of 250,000 
US veterans, as well as rodent studies involving tobacco exposure; the paucity of histological 
confirmation of ACC in the aforementioned clinical studies, however, mandates caution in the 
interpretation of these data (Hsing et al., 1996, Chow et al., 1996, Dalbey et al., 1980). 
Another interesting, and thus far unexplained, epidemiological feature of ACC is the 
predominance of left-sided tumours over right-sided ones. A literature review of 14 recent 
publications identified 2607 left-sided vs. 2169 right-sided (Mihai, 2015). Selection bias has 
been proposed as a potential explanation for this disparity: right-sided tumours are more often 
inoperable due to liver invasion or vena cava involvement, which may render them less likely 
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to be reported (Mihai, 2015). Bilateral ACCs are extremely rare and it is usually unclear 
whether they represent independent tumours or metastases to the contralateral adrenal gland. 
 
1.2.2 Presentation 
The majority (45-60%) of new ACC patients present with symptoms of hormone excess, most 
commonly glucocorticoid (50-80% of hormone secreting ACCs) and/or androgen hormone-
related (40-60% of hormone secreting ACCs) (Else et al., 2014, Allolio and Fassnacht, 2006, 
Luton et al., 1990). Clinical manifestations of glucocorticoid excess (Cushing’s syndrome) 
include centripetal obesity, supraclavicular/ dorsocervical fat pads, facial plethora, skin 
atrophy, easy bruising, violaceous abdominal striae, oligomenorrhoea (<9 menstrual periods 
per year), amenorrhoea (total cessation of menses for more than 6 months), diabetes mellitus, 
osteoporosis with pathological fractures and psychiatric symptoms of depressive or psychotic 
character (Fassnacht et al., 2011, Else et al., 2014, Libe, 2015). Hypertension and 
hypokalaemia are often observed in the context of glucocorticoid excess, as the overabundant 
cortisol can saturate the protective renal enzyme 11β-hydroxysteroid dehydrogenase type II 
(inactivates cortisol to cortisone) and activate the mineralocorticoid receptor. Androgen 
excess can become clinically manifest in female patients as hirsutism, acne or, in more 
extreme cases, virilism (androgenetic alopecia, voice masculinisation, clitoromegaly) (Fig. 1-
4). In men, overall androgen activity is predominated by testicular testosterone, which 
obscures the incipient adrenal androgen excess. Oestrogen excess is uncommon (1-5% of 
cases) and can present as feminisation (gynaecomastia, loss of libido, testicular atrophy) in 
males or menstrual perturbations in female patients (Allolio and Fassnacht, 2006, Else et al., 
2014). Concurrent secretion of glucocorticoids and androgens is not uncommon 
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(approximately 50% of functional ACCs) and portends underlying adrenocortical malignancy 
(Else et al., 2014). Aldosterone-producing ACCs are rarely encountered; in such cases, drug-
resistant hypertension is the clinical hallmark of mineralocorticoid excess (Seccia et al., 2005, 
Abiven et al., 2006) .  
 
 
Loco-regional manifestations due to mass expansion occur at diagnosis in about 20% of ACC 
patients, including abdominal discomfort, nausea and vomiting (Berruti et al., 2010, Luton et 
Figure 1-4 Severe virilisation in a female patient with cortisol and androgen- producing 
ACC. Reproduced with permission of Prof W. Arlt from her personal archive with patient 
consent. 
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al., 1990, Else et al., 2014). Nonspecific symptoms of malignancy (fever, weight loss, 
myalgia, malaise) are rarely the presenting complaint.  Pathological fractures as a result of 
bone metastases can be the initial symptom in patients presenting with advanced disease. 
Finally, about 10-20% of new ACCs are discovered incidentally in the context of abdominal 
cross-sectional imaging requested for reasons other than the suspicion of adrenal disease 
(adrenal incidentalomas) (Fassnacht and Allolio, 2011). This proportion is expected to rise 
progressively with the ever-increasing use of computed tomography (CT) and magnetic 
resonance imaging (MRI).  
ACCs are generally large tumours at presentation, averaging 10-13 cm in diameter (Berruti et 
al., 2010, Abiven et al., 2006, Sturgeon et al., 2006). Since 2009, the European Network for 
the Study of Adrenal Tumours (ENSAT) classification has replaced the International Union 
Against Cancer (UICC) staging classification, as it demonstrated a higher prognostic accuracy 
with respect to disease recurrence and overall survival. The new classification emerged from 
the study of 492 ACC patients from the German Registry (mean follow-up of 36 months) and 
was subsequently validated in a North American Population of 573 patients (Fassnacht et al., 
2009, Lughezzani et al., 2010).  According to this system (Table 1-2), malignant adrenal 
tumours associated with periadrenal fat extension, adjacent organ invasion or local lymph 
node involvement are classified as stage III disease and are associated with poorer prognosis 
than localised tumours of any size. Stage IV consists solely of patients with distant metastases 
and is associated with a very poor prognosis. A modified version of this classification system 
was recently proposed by Libe et al. This involves a) a shift of all tumours with local lymph 
node involvement to stage IV, as this is a finding with dismal prognostic implications and b) 
definition of three stage IV subgroups depending on the number of organs that are affected 
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(IVa: 2 organs, IVb: 3 organs, IVc: > 3 organs; primary tumour and local lymph node 
involvement count as one organ each) (Libe et al., 2015).  
As with many other malignancies, the percentage of patients presenting with advanced 
tumours has decreased in recent decades with the widespread use of cross-sectional imaging, 
which allows earlier diagnosis. In a meta-analysis of studies published from 1952-1992, 49% 
of patients presented with metastatic disease, while less than a third of patients presented with 
localised tumour (stage I or II) (Wooten and King, 1993). In more recent series, 25-30% of 
ACC patients appear to present with metastatic disease, and stage II disease has become the 
most common stage at presentation. ACCs measuring less than  5 cm at presentation remain 
uncommon (about 5% of cases at presentation) (Fassnacht and Allolio, 2011, Else et al., 
2014). In patients with advanced disease, the lungs and the liver are the most common 
metastatic sites (each affecting 40-80% of metastatic cases), followed by the skeleton (5-20%) 
(Bilimoria et al., 2008, Fassnacht and Allolio, 2011). 
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ENSAT ACC Classification System 
Stage TNM classification TNM Definitions 
I T1, N0, M0 T1, tumor ≤5 cm 
  N0, no positive lymph node 
  M0, no distant metastases 
II T2, N0, M0 T2, tumor >5 cm 
  N0, no positive lymph node 
  M0, no distant metastases 
III T1–T2, N1, M0 N1, positive lymph node(s) 
 T3–T4, N0–N1, M0 M0, no distant metastases 
  T3, tumor infiltration into surrounding tissue 
  T4, tumor invasion into adjacent organs or 
venous tumor thrombus in vena cava or 
renal vein 
IV T1–T4, N0–N1, M1 M1, presence of distant metastases 
 
 
1.2.3 Diagnosis 
1.2.3.1 Biochemistry 
Securing a thorough adrenal hormone profile is indispensable in the work-up of newly 
discovered adrenal lesions for a number of clinical reasons. Firstly, the functional status of the 
tumour will often inform management decisions (surgical vs. conservative management) and 
can accurately diagnose medullary lesions (phaeochromocytomas). Secondly, it is imperative 
to identify patients with glucocorticoid excess before surgery: these patients are at very high 
risk of post-operative adrenal suppression, which can lead to a life-threatening ‘adrenal crisis’ 
if appropriate hydrocortisone replacement is not in place. Finally, routine evaluation of 
Table 1-2 ENSAT ACC Classification 
Chapter 1                                                                                                                                                       General Introduction 
16 
 
adrenal steroidogenesis can sometimes provide helpful diagnostic clues to the underlying 
nature of the lesion (benign adenoma vs ACC), as androgen and/or oestrogen production is 
extremely uncommon in benign adenomas. Urinary adrenal steroid profiling by mass 
spectrometry-based techniques represents an emerging diagnostic tool to differentiate benign 
from malignant adrenocortical tumours, with very promising results in retrospective studies 
(Arlt et al., 2011).  
A comprehensive way of excluding adrenal hormone excess is described in Table 1-3. 
Screening for glucocorticoid hypersecretion is typically based on the overnight 
dexamethasone suppression test (ONDST), which involves morning serum cortisol 
measurement after night-time administration of 1mg dexamethasone; the drug’s potent 
glucocorticoid activity suppresses endogenous cortisol in healthy individuals, generally to a 
serum concentration of <50 nmol/L. Abnormal ONDSTs should be corroborated by second-
line tests such as 24-hour urinary free cortisol and salivary midnight cortisol. Morning or 
random serum cortisol is of little diagnostic value. Most patients with autonomous adrenal 
glucocorticoid hypersecretion will also have a suppressed plasma ACTH (Nieman et al., 
2015, Fassnacht et al., 2016).  
Screening for mineralocorticoid excess is mandatory in patients with adrenal tumours and 
concurrent hypertension or hypokalaemia but should always be done if ACC is suspected. 
High plasma aldosterone with suppressed renin is suggestive of mineralocorticoid excess 
(Conn’s syndrome) (Nieman et al., 2015, Fassnacht et al., 2016).   Screening for adrenal sex 
steroid excess includes plasma DHEAS, androstenedione, oestradiol, testosterone and 17-
hydroxyprogesterone and should be performed in all patients with clinical evidence of 
hyperandrogenism/ hyperoestrogenism or in patients with high clinical/ radiological suspicion 
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of ACC (Fassnacht et al., 2016). Analysis of 24-h urine samples by Gas Chromatography-
Mass Spectrometry (GC-MS) is a more sensitive means of detecting androgen excess, but is 
not readily available in all centres at present (Arlt et al., 2011, Kerkhofs et al., 2015). Finally, 
exclusion of a medullary chromaffin tumour (phaeochromocytoma) is essential in all patients 
with adrenal masses, not least because of the risk of a potentially fatal adrenergic crisis if 
surgery is attempted without prior institution of alpha adrenergic receptor blockade. Plasma or 
urine metanephrines (metabolites of adrenalin and  noradrenalin) have overtaken urine 
catecholamines as the best performing screening test, able to detect phaeochromocytomas 
with a sensitivity of 98% and specificities above 90% (Lenders et al., 2014).   
 
Adrenal zone Hormone class Screening tests Comments 
Zona 
glomerulosa 
Mineralocorticoids Aldosterone, renin Essential if 
concurrent 
hypertension or 
suspicion of ACC 
Zona 
fasciculata 
Glucocorticoids Overnight dexamethasone 
suppression test (ONDST) 
24-hour urine free cortisol 
(UFC) 
Paired (day/night) salivary 
cortisol 
ACTH 
Abnormal response 
in ONDST should 
be confirmed by 
second-line tests 
Zona reticularis Androgens, 
oestrogens 
Testosterone, DHEAS, 
Androstenedione, 17-OH-
Progesterone, Oestradiol, 
Progesterone 
Essential if clinical 
suspicion of sex 
hormone excess or 
ACC 
Adrenal 
medulla 
Catecholamines Plasma or urine 
metanephrines 
Repeat in supine 
position if modestly 
raised 
 
Table 1-3 Overview of adrenal steroidogenesis 
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1.2.3.2  Imaging 
Adrenal lesions are most commonly discovered in the context of cross-sectional imaging 
undertaken for reasons other than the suspicion of adrenal pathology (adrenal 
incidentalomas). Imaging remains instrumental in the diagnostic work-up of a new adrenal 
lesion, providing useful clues that aid the differentiation of benign adrenocortical adenomas 
(ACAs) from ACCs and other adrenal pathologies (e.g. phaeochromocytomas, metastases, 
myelolipomas). Imaging-based characterisation is largely based on the tendency of ACCs to 
be larger than ACAs and lipid-poor.  
Computed tomography (CT) is the most commonly used imaging modality in the work-up of 
adrenal lesions. Generally, adrenal adenomas tend to have a diameter of < 4cm (mean size 
3.5cm) while ACCs tend to measure > 6 cm; however, it is worth noting that no more than 
25% of adrenal masses > 6 cm  turn out to be ACCs (Mantero et al., 2000, Adams et al., 
1983). A diagnostic cut-off of > 4 cm provides a sensitivity of 97% for ACC detection, but its 
specificity is disappointingly low at 52%. Raising the cut-off to 6cm improves specificity to 
80% at the cost of a diminished sensitivity of 91%, which is unsatisfactory for definitive 
cancer diagnostics (Sturgeon et al., 2006).  Non-contrast attenuation reflects the lipid content 
of the lesion; lesions with attenuation < 10 Hounsfield Units (HU) are lipid-rich, a trait which 
is common in adrenal adenomas but is never encountered in ACCs. Consequently, baseline 
attenuation lower than 10 HU is 100% specific for benignity and can be safely relied on to 
exclude malignancy (Dinnes et al., 2016). However, it should be noted that up to 30% of 
adenomas have an attenuation of >10 HU (lipid-poor adenomas), which is diagnostically 
unavailing. In patients with previous history of extra-adrenal malignancies and, consequently, 
higher risk of adrenal metastasis from the primary tumour, false-negatives (i.e. missed cases 
of malignancy) can occur using >10 HU as a diagnostic cut-off (estimated up to 7%) (Dinnes 
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et al., 2016). Heterogeneity is most commonly a feature of ACCs, due to the frequent 
presence of necrosis, haemorrhage or calcification within the malignant tumour, as is 
irregularity of tumour perimeter. 
In cases where attenuation cannot help to differentiate between benign and malignant 
tumours, contrast washout studies can provide further diagnostic clues, as contrast retention 
within the tumour tends to be more prolonged with malignancy. Contrast washout of > 50% 
after 15 mins is suggestive of  ACA, but available evidence on the test’s performance is poor 
(Dinnes et al., 2016). Finally, CT of chest, abdomen and pelvis including intravenous contrast 
remains the first-line investigation to exclude metastases and stage ACC in most centres. 
Magnetic Resonance Imaging (MRI) can also be of value in the characterisation of adrenal 
tumours. ACCs appear isointense to hypo-intense relative to the liver parenchyma on T1-
weighted images and hyper-intense relative to the liver parenchyma on T2-weighted images. 
A particularly useful feature is the loss of signal intensity comparing in-phase to out-of-phase 
T1-weighted imaging with chemical-shift MRIs, indicative of high lipid content. Persistence 
of signal intensity on out-of-phase imaging provided a sensitivity of 90% and specificity of 
85% for malignancy detection in a small study (Ream et al., 2015), but further studies are 
required to establish the actual diagnostic performance of this imaging modality (Dinnes et 
al., 2016).  
Fluorodeoxyglucose- Positron Emission Tomography/ Computed Tomography (18F-FDG-
PET/CT). 18F-FDG-PET/CT technology has been increasingly used in diagnostic oncology in 
recent years, predicated on the principle that malignant cells tend to have higher glycolytic 
rates than healthy cells (Warburg effect). Consequently, administered glucose will be taken up 
by malignant masses, which will appear as ‘hot spots’ on the scan (Kunikowska et al., 2014). 
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3 small studies have explored the diagnostic performance of 18F-FDG-PET/CT in the work-up 
of adrenal tumours; pooled estimates suggest a sensitivity of 84% and specificity of 90% but 
evidence quality remains poor (Dinnes et al., 2016).  
In summary, no single imaging modality appears to display sufficient accuracy to function 
independently as a reliable diagnostic test in a high-stake clinical context (considerable pre-
test probability of malignancy). Moreover, most relevant studies are plagued by poor 
methodology and/or small sample size. On this background, the only diagnostic strategy 
really supported by good quality evidence is excluding malignancy in lesions with non-
contrast attenuation of <10 HU in patients with no previous history of malignancy. In 
moderate/ high attenuation lesions, clinicians and patients still have to live with uncertainty, 
precariously placed on a clinical field covered by a very thin ground of evidence.  
 
1.2.3.3 Pathology 
As in all malignancies, histopathology provides the conclusive diagnosis of ACC; 
nevertheless, the differentiation between benign and malignant adrenal tumours can often be 
challenging even on a microscopic level. A recent retrospective study suggested that 13% of 
adrenocortical tumours assessed in Germany are incorrectly classified on surgical histology 
(Johanssen et al., 2010). Importantly, transcutaneous core biopsy of an adrenal lesion cannot 
differentiate between ACA and ACC in the absence of metastases and may lead to disease 
dissemination (needle canal seeding); therefore its role in the work-up of patients with 
suspected ACC is very limited  (Fassnacht et al., 2016, Bancos et al., 2016). In whole-tumour 
specimens provided post-operatively, a number of features are used to diagnose ACC, 
including nuclear grade, mitotic rates, atypical mitoses, cytoplasmic morphology, microscopic 
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architecture, necrosis, venous or sinusoidal invasion and capsular invasion (Fig. 1-5). These 
have been incorporated in validated scoring systems that are widely used to diagnose ACC, 
most notably the Weiss scoring system (Table 1-4) (Weiss et al., 1989). Tumours with a 
Weiss score of 3 or above are considered malignant, while scores 0-2 are diagnostic of ACA. 
Aubert et al. subsequently proposed a modification of the Weiss system, excluding four 
criteria with substantial inter-observer variability (Table 1-4) (Aubert et al., 2002); despite its 
claim to diagnostic superiority, however, the modified Weiss model has not managed to 
overtake its predecessor in clinical practice (Papotti et al., 2011).  
Ki67 is a proliferation marker that is also diagnostically relevant, as the vast majority  of 
ACCs have a Ki67 value of > 3% (Libe, 2015). High Ki67 values are generally associated 
with more aggressive behaviour, although rare cases of metastatic ACCs with Ki67 <1% have 
also been described (Libe et al., 2015, Berruti et al., 2012, Beuschlein et al., 2015). 
Immunohistochemical features that are employed to distinguish adrenocortical from 
medullary tumours include positivity for steroidogenic factor 1 (SF1), inhibin, melan A, 
calretinin and synaptophysin, and negativity for chromogranin A, epithelial membrane 
antigen and cytokeratin (Weiss, 1984, Papotti et al., 2011, Sbiera et al., 2010).  
Histologic variants of ACC include oncocytic ACC, myxoid ACC and sarcomatoid ACC. 
Oncocytic ACC is the most common of the three and is characterised by an abundance of  
cells with granular cytoplasm due to accumulation of mitochondria and endoplasmic 
reticulum (Wong et al., 2011, Macchi et al., 1998). The Weiss score is less accurate in this 
context and can lead to over-diagnosis of malignancy (Else et al., 2014). 
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        Histologic criteria               Comments Score  
(Weiss system) 
Score  
(Aubert 
modification) 
Nuclear grade 3 or 4 
(Fuhrman criteria) 
 1 Not included 
>5 mitoses per 50 high-
power visual fields 
  2 
Atypical mitoses Defined by abnormal 
distribution of 
chromosomes or 
excessive number of 
mitotic spindles 
1 1 
<25% of tumour cells 
are clear cells 
Resembling the normal 
zona fasciculata 
1 2 
Diffuse architecture More than one third of 
tumours forming 
patternless sheets of cells 
1 Not included 
Necroses  1 1 
Venous invasion Tumour cells within 
endothelium-lined vessel 
with smooth muscle as 
wall component 
1 Not included 
Sinusoidal invasion Tumour cells within 
endothelium-lined vessel 
with little or no 
supporting tissue 
1 Not included 
Capsular invasion  1 1 
Maximum score  9 7 
 
Table 1-4 Weiss criteria for histologic ACC diagnosis, as per a) the classical Weiss model 
(Weiss et al, 1989) and b) its subsequent modification by Aubert et al (Aubert et al, 2002).  
Each criterion scores one point if present. Total scores ³ 3 are diagnostic of ACC. 
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1.2.3.4  Emerging modalities – urinary steroid profiling 
An intriguing alternative approach which has gained impetus in  recent years utilises 
biochemistry to distinguish between benign and malignant lesions, employing mass 
spectrometry-based approaches which can overcome the major limitations of routine 
biochemistry (cross-reactivity, low specificity) and provide a much more comprehensive 
steroid profile (Taylor et al., 2015). 24-h urine collections analysed by mass spectrometry 
allow quantification of steroid hormones whose plasma concentration is too low, and also 
neutralise the effects of diurnal variation which can be significant in adrenal biochemistry.  
ACCs present an inefficient pattern of steroidogenesis, characterised by relative abundance of 
Figure 1-5 ACC histology. A) Macroscopic view of an excised ACC; B) High-grade ACC with 
nuclear polymorphism; C) ACC with necrotic area; D) ACC (brown) with capsular invasion 
and infiltration of surrounding fat (yellow). Images provided by Dr K. Skordilis from her 
personal archive.  
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precursor steroids produced during the intermediate steps of steroidogenesis. This distinct 
steroid fingerprint, attributed to the typical dedifferentiation, and therefore relative 
immaturity, of malignant adrenocortical cells, can be of diagnostic value (Arlt et al., 2011). 
Sporadic case reports published over 60 years ago noted the excretion of ‘atypical’ steroid 
hormones in ACC patients, most notably the glucocorticoid precursor metabolite 11-
tetrahydrodeoxycorisol (THS) and the androgen metabolite pregnenetriol (5-PT), 
corresponding to intermediate steps of steroidogenesis (Hirschmann and Hirschmann, 1950, 
Touchstone et al., 1954, Okada et al., 1959). Similar findings were reproduced independently 
in two small case series comparing ACAs to ACCs, published over the next three decades 
(Biglieri et al., 1963, Minowada et al., 1985). A subsequent small study compared plasma 
levels of 11-deoxycorticosterone, corticosterone, 11-deoxycortisol and cortisol between 4 
paediatric patients with ACC and 4 with ACA. The ratio of corticosterone/ 11-
deoxycorticosterone was lower in ACC  and increased post-operatively, suggesting 11β-
hydroxylase deficiency (Doerr et al., 1987). Grondal et al. analysed the urinary steroid profile 
of 24 patients with ACCs, comparing them to ACAs and healthy controls. 23/24 ACCs 
displayed increased excretion of 3 beta-hydroxy-5-ene steroids and cortisol precursor 
metabolites, indicative of 3 beta-hydroxysteroid dehydrogenase/delta isomerase and 11β-
hydroxylase deficiency (Grondal et al., 1990). Similar findings were reported in a series of 5 
ACC patients, revealing low ratios of cortisol metabolites/ tetrahydrocortisol metabolites and 
high levels of the androgen metabolite pregnenetriol (Tiu et al., 2009). Obviously, the small 
cohorts used in these studies represent a major limitation. This was overcome in a recent 
international retrospective study, which managed to recruit a sizeable cohort of 102 ACA and 
45 ACC patients (Arlt et al., 2011). Urinary steroid profiling using gas chromatography-mass 
spectrometry provided an extensive panel of 32 steroid metabolites. Computational analysis 
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generated a machine learning-based prediction algorithm able to differentiate ACCs from 
ACAs with a sensitivity and specificity of 90%, a performance superior to that of any 
available imaging modality (Arlt et al., 2011). Nine steroid biomarkers were selected as the 
most diagnostically relevant ones in this context, and utilisation of their values alone yielded a 
sensitivity/specificity of 90% (Fig. 1-6). These results were corroborated in a subsequent 
smaller retrospective study (27 ACCs, 107 ACAs) also demonstrating disparate urinary 
steroid excretion patterns between benign and malignant adrenocortical tumours. THS was the 
biomarker with the highest accuracy at discriminating ACCs from ACAs (Kerkhofs et al., 
2015). Finally, a recent retrospective study in a similar cohort (31 ACCs, 108 ACAs) also 
ascertained increased urinary excretion of THS and DHEAS in ACCs, as well as evidence of 
lower CYP11A1 and CYP11B1 activity based on product/substrate ratios (Velikanova et al., 
2016). An ongoing prospective study (EURINE-ACT) will endeavour to validate these results 
and establish urine steroid metabolomics as a diagnostic tool for the differential diagnosis of 
adrenal tumours, in a cohort exceeding 2,000 patients. 
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1.2.4 Prognosis 
ACC is generally a disease with poor prognosis, with overall 5-year survival rates ranging 
from 16-44% in different series (Fassnacht and Allolio, 2009). This considerable inter-study 
variability has been ascribed to selection bias leading to under-reporting of operated patients 
in some series with particularly grim survival estimates. 
The ENSAT staging system has been the foundation of prognostication in ACC patients in the 
last decade. Stage I is associated with the highest 5-year survival rates (66-82%); this drops to 
58-64% for stage II and 24-50% for stage III. Prognosis is extremely poor for patients with 
metastatic disease, with reported 5-year survival rates in the range of 0-17% (Fassnacht et al., 
2009, Icard et al., 1992, Kerkhofs et al., 2013, Lughezzani et al., 2010) (Fig. 1-7). 
Figure 1-6 Differences in secretion of 9 urinary steroid metabolites between ACAs and ACCs. 
THS: tetrahydrodeoxycortisol; 5-PT: 5-pregnenetriol; 5-PD: pregnenediol; PT: 
pregnanetriol; THDOC: tetrahydrocorticosterone; 5α-ΤΗΑ: 5α-tetrahydro-11-
deoxycorticosterone; Etio: etiocholanolone; 5a-THF: 5a-tetrahydrocortisol; PD: 
pregnanediol.  Source: (Arlt et al., 2011). Reproduced with permission of the Endocrine 
Society.   
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Importantly, lymph node involvement is a particularly ominous sign, associated with 13% 5-
year survival in a recent retrospective study in the North American population (Bilimoria et 
al., 2008). Patients younger than 55 years of age display higher survival rates than their older 
counterparts (Bilimoria et al., 2008). 
 
 
Figure 1-7 Disease-specific survival according to ENSAT stage, based on data from the 
German Registry. Source: (Fassnacht and Allolio, 2009). Reproduced with permission of the 
Endocrine Society. 
 
Post-operatively, tumour resection status appears to be the most important predictor of 
outcome. Microscopically complete (R0) resection is associated with 50% 5-year survival, 
while prognosis for patients with microscopically (R1) or macroscopically (R2) incomplete 
resection is clearly poorer (5-year survival 20% and 15%, respectively) (Bilimoria et al., 
2008). Amongst patients who have undergone complete resection, the proliferation marker 
Ki67 is the most significant predictor of recurrence-free and overall survival, as demonstrated 
recently in a large retrospective study including 2 independent European cohorts (Beuschlein 
et al., 2015). In another recent retrospective study in patients with advanced ACC (stage III-
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IV), poor prognosis was portended by the following factors: patient age > 50 years, 
symptomatic disease at presentation, incomplete resection, presence of multiple metastatic 
sites and high tumour grade (Weiss score  ≥ 6 and/or Ki67 ≥ 20%) (Libe et al., 2015). 
Genomic and epigenomic markers of prognostic relevance (hyper-methylation status, driver 
gene mutations, miRNA profile) have recently started to emerge and represent a dynamic 
field of high potential in ACC research (Assie et al., 2014). 
 
1.2.5 Molecular pathology  
The last 2 decades have seen radical progress in our understanding of the molecular basis of 
ACC, although this has not, as yet, been translated into changes in the clinical management of 
these patients. 
 
1.2.5.1  Clonality and chromosomal aberrations 
ACCs consist of  a monoclonal cell population; this suggests a biological history of clonal 
expansion in response to genetic mutations, eventually leading to cancer formation 
(Beuschlein et al., 1994, Gicquel et al., 1994). Aneuploidy is highly prevalent in ACCs and 
rare in ACAs, but it is as yet unclear whether the resulting genomic instability is a driver of 
carcinogenesis. Phenotypically, diploidy was associated with poor prognosis in one study 
(Haak et al., 1993). Structural chromosomic defects are also more frequent in ACCs than in 
ACAs, as revealed by a number of comparative genomic hybridisation (CGH) studies. 
Chromosomal gains at chromosome 5, 7, 12, 16, 19, and 20, as well as losses at chromosome 
13 and 22, appear to be the most common aberrations observed in ACCs at this level 
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(Kjellman et al., 1996, Kjellman et al., 1999, Gicquel et al., 2001, Dohna et al., 2000, Barreau 
et al., 2013). 
 
1.2.5.2  Gene expression 
Global gene expression studies (gene expression arrays) have identified a number of foci and 
patterns of altered gene expression in ACCs. A study comparing 33 ACCs to 22 ACAs 
distinguished chromosomal regions of enhanced (12q and 5q) or repressed (11q, 1p, 17p) 
expression (Giordano et al., 2009). Increased expression of genes involved in cellular 
proliferation is an important feature of ACC; this is contrary to the pattern of increased 
expression of steroidogenic genes which characterises ACAs (de Fraipont et al., 2005). 
Interestingly, two distinct clusters of gene expression were discovered in ACCs in a 
subsequent study, each carrying different prognostic implications. Increased expression of 
genes involved in cellular proliferation was associated with poor patient survival, while 
overexpression of genes involved in cell differentiation, metabolism, and intracellular 
transport resulted in a less aggressive clinical phenotype (de Reynies et al., 2009). Combined 
overexpression of  BUB1B and PINK1, genes involved in cell cycle regulation, was 
independently associated with poor outcome, a finding which was corroborated in a 
subsequent independent study (de Reynies et al., 2009, Fragoso et al., 2012).  
 
1.2.5.3  Gene mutations  
ACC is a genetically diverse malignancy. The most commonly reported somatic mutations on 
loss of heterozygosity (LOH) studies involve TP53 (tumour protein p53), MEN1 (menin), 
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IGF2 (insulin-like growth factor 2), IGF2R (IGF2 receptor),  p16/INK4A (CDKN2A) and 
CTNNB1 (β-catenin) (Else et al., 2014). The tumour suppressor gene TP53, involved in the 
molecular pathogenesis of several cancer types, is the most commonly affected gene, with 
mutations found in about a third of ACC patients (Barzon et al., 2001, Ohgaki et al., 1993, 
Reincke et al., 1994, Reincke et al., 1996). TP53 is involved in cell cycle control, impeding 
cell cycle progression in response to certain insults.  It has a pivotal role within the apoptotic 
pathways, affecting the expression of genes that facilitate mitochondrial apoptosis or 
increasing the expression of cell death receptors.  Molecular inducers of TP53 mutations 
include DNA damage by UV light, redox stress and chemotherapy (Else et al., 2014, Malkin 
et al., 1990). Loss of TP53 function results in uncontrolled cellular proliferation, with failure 
to respond to apoptotic triggers. TP53 mutations in ACC can be either somatic or, less 
commonly, germline mutations in the context of Li-Fraumeni syndrome (Malkin et al., 1990, 
Wu et al., 2006). Germline mutations are rare in adult ACC patients (4%) but the commonest 
mutation in paediatric ACC (50-80% of cases) (Fassnacht et al., 2011).  Li-Fraumeni patients 
have an exceedingly high lifetime cancer risk (> 70% in males, almost 100% in females) (Wu 
et al., 2006).  
Insulin growth factors 1 and 2 (IGF-1 and IGF-2) are important inducers of adrenal cell 
proliferation and steroidogenesis. High IGF-2 and/or IGF-1 levels are encountered in >80% of 
sporadic ACCs and are associated with a more aggressive clinical behaviour with high 
recurrence rates (Gicquel et al., 2001, de Reynies et al., 2009). Overgrowth syndromes driven 
by mutations in the IGF-2 locus leading to up-regulation of IGF-2 (Beckwith-Wiedemann 
syndrome and Idiopathic Hemihypertrophy) are also associated with a higher risk of ACC, 
which appears to comprise 7-15% of malignant tumours observed in such patients 
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(Lapunzina, 2005, Wiedemann, 1997). Overgrowth syndromes are also associated with a high 
prevalence of adrenocortical adenomas and cysts (Lapunzina, 2005). 
The WNT/beta-catenin pathway is instrumental in foetal adrenal development. Activating 
mutations in the catenin gene CTNNB1 are present in at least 25% of both ACCs and ACAs 
(Gaujoux et al., 2008, Tadjine et al., 2008). WNT/beta-catenin signalling can lead to 
mesenchymal transformation promoting cell invasion, and beta-catenin overexpression 
portended aggressive disease course in one study of ACC patients (Ragazzon et al., 2010). 
Cases of ACC have been reported in patients with Familial Adenomatous Polyposis, an 
inherited syndrome of multiple intestinal polyps which is molecularly underpinned by 
constitutive beta-catenin activation, but it is unclear whether this reflects a genuine 
association or mere statistical coincidence of two rare conditions (Else, 2012). 
Other genetic syndromes for whom an association with a higher ACC risk has been suggested  
include Multiple Endocrine Neoplasia type 1 (MENIN gene) and Neurofibromatosis type 1 
(neurofibromatin gene); however, the epidemiological evidence supporting these associations 
is so far less than convincing (Else, 2012). 
 
1.2.5.4 Recent advances - Epigenetic changes and integrated genomic characterisation 
On an epigenetic level, gene promoter hyper-methylation leading to altered gene expression 
was ascertained in a series of 51 ACCs and was correlated with poor clinical outcomes 
(Barreau et al., 2013).  
Two recent studies applied state-of-the-art integrated genomic analysis and identified discrete 
clusters of ACCs. Assie et al. analysed a group of 45 ACCs and identified two subgroups: a 
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group characterised by high number of mutations and methylation alterations (C1A) and a 
group defined by specific deregulation of two miRNA clusters (C1B) (Assie et al., 2014). 
Clinical outcomes were disparate between the two groups, C1A tumours being associated 
with poor prognosis. Two years later, genomic analysis in a cohort of 76 ACCs identified 
three broad molecular clusters of ACCs, integrating data from four platforms (DNA copy 
number, DNA methylation, mRNA expression, miRNA expression) (Zheng et al., 2016). 
Importantly, each cluster was associated with different outcomes (Fig. 1-8). 
 
Figure 1-8 Cluster of clusters molecular analysis in a cohort of 76 ACC patients (source: 
Zheng et al., 2016). A) Cluster of clusters analysis integrating data from four different 
platforms (DNA copy number, black; MRNA expression, red; DNA methylation, blue; miRNA 
expression, purple) identifies three distinct clusters (groups). Black bars represent sample 
positivity for the corresponding molecular parameter. CIMP: CpG island methylation 
phenotype. C1A and C1B refer to the gene expression profiles defined by de Reynies et al, 
2009 B) Event-free survival analysis of the three groups shows correlation of molecular 
clustering with patient outcomes. Reproduced with permission of Elsevier. 
Chapter 1                                                                                                                                                       General Introduction 
33 
 
1.2.6 Management 
1.2.6.1 Surgery 
Surgery for primary tumours. The only hope of cure for ACC patients is complete (R0) 
tumour resection. Radical surgery with curative intent should be offered to all fit for surgery 
patients with localised, resectable tumours. This includes all patients with ENSAT stage I-II 
disease and most patients with stage III disease (Mihai, 2015, Fassnacht and Allolio, 2009). 
There is still debate as to the optional mode (open vs. laparoscopic) and extent of surgery (e.g. 
inclusion of local lymph nodes). There is no definitive clinical evidence for the superiority of 
an open vs a laparoscopic approach; however, most experts would advocate open 
adrenalectomy in suspicious adrenal tumours, especially if the size is such that renders full 
excision without breach of the tumour capsule technically challenging (e.g. tumour diameter > 
5-6 cm), or if there is radiological suspicion of locally infiltrative disease with lymph node 
involvement (Berruti et al., 2010, Libe, 2015, Mihai, 2015). Lymph node dissection (LND) is 
not a formal part of radical adrenalectomy but has become more topical in recent years, after a 
retrospective study demonstrating reduced recurrence rates in ACC patients having undergone 
LND (Reibetanz et al., 2012).  
In cases where complete tumour resection is not feasible, debulking surgery may have a role 
in functional tumours associated with clinically distressing hormone excess (e.g. 
glucocorticoids) that is difficult to control medically (Mihai, 2015). There is no evidence to 
support the value of debulking resection in non-functional tumours, although some authors 
suggest it should be considered in slow-growing tumours (low Ki67) where over 90% of total 
tumour load can be resected (Schteingart et al., 2005). 
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Surgery for local recurrence or metastasis. Surgery also has a role in select patients who 
develop recurrent or metastatic disease after primary tumour resection. Three retrospective 
studies have suggested that resection of locally recurrent disease can improve survival, 
especially in cases where complete resection of the recurrent tumour is possible or patients 
who recurred more than 12 months after resection of the primary tumour (Schulick and 
Brennan, 1999, Erdogan et al., 2013, Dy et al., 2013). The role of metastasectomy in patients 
with low-volume distant metastatic disease (e.g. 1-2 small metastatic foci) is contentious and 
the number of described cases in the literature remains low. Data from small retrospective 
studies suggest some survival benefit may be conferred on patients with fully resectable lung 
or liver metastases, particularly if the metastasis occurred more than 12 months after the first 
surgery (Mihai, 2015, Assie et al., 2007, Di Carlo et al., 2006, op den Winkel et al., 2011, 
Datrice et al., 2012). Patients who recur less than 12 months from surgery have very poor 
prognosis and metastasectomy does not appear to have a role, as emergence of disseminated, 
multi-focal disease is all but inexorable (Mihai, 2015).  
 
1.2.6.2 Mitotane  
Mitotane (o,p’-DDD) is an analogue of the insecticide dichlorodiphenydichloroethane (DDD). 
It has been well established as the first line of recurrent/metastatic ACC management since 
the 1960s and, more than 5 decades later, remains the only drug specifically approved for this 
use by the Food and Drug Agency and the European Medicine Executive Agency (Hahner 
and Fassnacht, 2005, Terzolo, 2012). Mitotane is used as monotherapy in patients with 
inoperable recurrent disease of limited volume, or within combination chemotherapy 
regimens in patients with more advanced and/or aggressive disease. Despite its long history of 
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use, evidence supporting the efficacy of mitotane actually emanates from retrospective or 
small prospective studies, many of which used hormonal control rather than radiographic or 
survival data as indicator of clinical response. No randomised-controlled trial has ever 
formally compared mitotane to other treatment options (Hahner and Fassnacht, 2005, Berruti 
et al., 2010, Terzolo, 2012). Within these methodological limitations, available evidence 
suggests modest response rates ranging from 13-33% of treated patients; results tend to be 
short-lived. Mitotane has a narrow therapeutic window, as blood levels of at least 14 mg/l 
have to be attained to facilitate satisfactory anti-tumour activity, while levels above 20 mg/l 
are associated with high rates of toxicity (Terzolo, 2012, Else et al., 2014). In clinical 
practice, tolerability is highly variable, with some patients developing toxicity in sub-
therapeutic levels while others tolerating levels above 20 mg/l perfectly well. Adverse effects 
include gastrointestinal manifestations (nausea, vomiting, diarrhoea), hepatotoxicity and 
neurotoxicity (dysarthria, ataxic gait, confusion) (Hahner and Fassnacht, 2005). 
Hypogonadism and gynaecomastia are often observed, due to disturbance of testicular 
steroidogenesis, elevation of the steroid hormone binding globulin and inhibition of 5a-
reductase (Hahner and Fassnacht, 2005, Chortis et al., 2013). Another important feature of 
mitotane treatment is the invariable induction of adrenal insufficiency. This has been ascribed 
both to the drug’s adrenolytic activity (i.e. damage of the healthy adrenal gland) and to 
CYP3A4 enzyme induction leading to acceleration of cortisol breakdown. High-dose 
hydrocortisone replacement is therefore essential to avoid a life-threatening adrenal crisis 
(Chortis et al., 2013). Induction of the microsomal CYP3A4 enzymatic system by mitotane is 
also inopportune in view of its effects on other medications ACC patients may receive. 
Indeed, more than 50% of current formulary drugs are metabolised by this system, and dose 
adjustments may be necessary to avoid treatment failure. This includes several of the most 
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commonly used cytotoxic chemotherapy options in these patients (Chortis et al., 2013, Kroiss 
et al., 2011).  
Aside from its role in the treatment of active disease, mitotane is commonly used as adjuvant 
treatment after primary tumour resection. The ability of adjuvant mitotane to reduce 
recurrence rates in patients with surgically excised ACC was demonstrated in a large 
retrospective study comparing three cohorts of patients who had undergone complete tumour 
resection. One group received mitotane treatment post-operatively, while the other two were 
placed on observation only. Recurrence-free survival was significantly higher in the mitotane-
treated group; overall survival was significantly higher only with reference to one of the two 
control groups (Terzolo et al., 2007).  It is now widely accepted that adjuvant mitotane should 
be the norm in patients with high-risk features (proliferation marker Ki67 >10%, 
macroscopically or microscopically incomplete resection). An ongoing international, 
randomised prospective trial (ADIUVO) is exploring the value of mitotane administration 
post-operatively in the select group of patients with complete resection and low proliferation 
index (Ki67 <10%).  
 
1.2.6.3 Systemic chemotherapy 
Monotherapy. A number of cytotoxic drugs have been tried as single-agent treatment in ACC 
patients, mostly in the context of small case series or case reports. Modest clinical response 
has been displayed in case reports or series with doxorubicin, alkylating-like agents and 
cisplatin (Berruti, 2012). Doxorubicin (Adriamycin) is an anthracycline compound which 
causes DNA damage, cell cycle arrest and apoptotic cell death. Limited data from small case 
series and a phase II study suggest modest response rates of 19-25% (Berruti, 2012, Decker et 
Chapter 1                                                                                                                                                       General Introduction 
37 
 
al., 1991, Haq et al., 1980, Pommier and Brennan, 1992). Administration to patients who had 
failed to respond to mitotane was to no avail in this cohort of cases. Cisplatin, a platinum-
based compound, is the agent with the highest efficacy as monotherapy against advanced 
ACC. It induces programmed cell death interfering with DNA replication. Out of 13 patients 
with advanced ACC included in three small series, seven showed initial response to treatment 
(Chun et al., 1983, Tattersall et al., 1980, Terzolo, 2012). Promising results were initially 
achieved by suramin, a polyanionic compound with adrenolytic activity, in vitro and in small 
case series; however, a subsequent stage II study revealed only modest, short-lived anti-
tumour effects with unacceptable toxicity (La Rocca et al., 1990a, La Rocca et al., 1990b, Arlt 
et al., 1994). Gossipol, a plant toxin with promising in vitro and in vivo effects in pre-clinical 
ACC models, was used in a phase II clinical trial in advanced ACC patients who failed to 
respond to mitotane chemotherapy. 3/18 patients showed clinical response which lasted 
several months; after these results the drug never found its way to clinical practice. Finally, 
paclitaxel is an agent with considerable in vitro efficacy against adrenocortical cancer cell 
lines, but very scant clinical evidence to support its application in advanced ACC, with only 
isolated case reports and a phase I study. Overall, mitotane remains the undisputed first-line 
monotherapy option in routine clinical practice, primarily by virtue of its favourable side-
effects profile in comparison to systemic cytotoxic chemotherapy.  
Combination chemotherapy. Combination chemotherapy is offered to ACC patients who 
either present with advanced malignancy of high tumour load or  fail to respond to mitotane 
monotherapy (Terzolo, 2012) (Table 1-5). Mitotane is usually employed in combination with 
one or more cytotoxic agents. Multidrug resistance is a common clinical feature of ACC and 
has been associated with high levels of expression of multidrug resistance genes (MDR1, 
ABCB1), which enhance drug efflux from cancer cells. Mitotane has displayed an opportune 
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capacity to interfere with this resistance mechanism and increase intratumoural drug 
accumulation, which provides a strong rationale for including it in combination chemotherapy 
(Bates et al., 1991). A pertinent caveat is the CYP3A4-inducing effect of mitotane which can 
accelerate the breakdown of numerous drugs in the liver, as alluded to earlier (Chortis et al., 
2013, Kroiss et al., 2011). A number of cytotoxic regimens including mitotane have been 
evaluated in phase II clinical trials (Table 1-5), with response rates varying from 9-48%. The 
two best performing regimens, Mitotane + Etoposide/ Doxorubicin/Cisplatin (M+EDP) and 
Mitotane + Streptozotocin (M+S) were recently compared in the first ever randomised 
prospective study in ACC (n=304 patients with metastatic disease), through collaboration of 
several European Centres affiliated with the European Network for the Study of Adrenal 
Tumours (Fassnacht et al., 2012).  M+EDP afforded better progression-free survival (5 
months vs 2.1 months) and objective response rates (23.2% vs 9.2%) than M+S. Importantly, 
the effect on overall survival was meagre and not statistically different between the two 
regimens (15 vs 12 months) (Fig. 1-9). In light of these results, M+EDP is now considered the 
first-line cytotoxic chemotherapy option in patients not responding to mitotane monotherapy, 
for want of more effective treatment options.  In non-responding cases, the combination of 
gemcitabine and capecitabine has been proposed as salvage chemotherapy, leading to disease 
stabilization for at least 6 months in 29% of patients when offered as second-line 
chemotherapy according to a phase II trial (Sperone et al., 2010) 
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Study Drugs Patient n % patients 
with 
response 
% patients 
with 
response or 
stable 
disease 
Response 
duration 
(months) 
(van Slooten and 
van Oosterom, 
1983) 
CP/ P/ D 11 18 73 10-23 
(Schlumberger et 
al., 1991) 
5FU/ P/ D 13 31 54 6-42 
(Bukowski et al., 
1993) 
M/ P 37 30 NR 8 (median) 
(Bonacci et al., 
1998) 
E/ P/ (M) 18 33 44 9-26 
(Berruti et al., 
1998) 
M/ E/ D/ P  28 54 82 24 (median) 
(Williamson et 
al., 2000) 
E/ P 37 14  NR 
(Khan et al., 
2000) 
M/ S 23 30 52 7 (median) 
(Abraham et al., 
2002) 
M/ E/ D/ V 35 23 NR 12 (mean) 
(Baudin et al., 
2002) 
M/ I 12 0 25 NR 
(Khan et al., 
2004) 
CP/ V/ C/ T 11 18 82 7 (median) 
(Berruti et al., 
2005) 
M/ E/ D/ P 72 49 NR 18 (median) 
(Sperone et al., 
2010) 
M/ G/ 5FU 
or Cap 
28 7 46 10 (median) 
(Fassnacht et al., 
2012)* 
M/ E/ D/ P 151 21 56 5 (median) 
(Fassnacht et al., 
2012)* 
M/ S 153 8 30 2 (median) 
 
Table 1-5 Prospective studies of combination chemotherapy in ACC. * randomized-controlled 
trial. Abbreviations: CP: cyclophosphamide; P: cisplatin; D: doxorubicin; 5FU: 5-
Fluoruracil; E: Etoposide; M: Mitotane; S: Streptozotocin; V: Vincristin; I: Irinotecan; G: 
Gemcitabine; Cap: Capecitabin. Source: (Else et al., 2014). Adapted and reproduced with 
permission of the Endocrine Society. 
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In recent years, considerable effort has been expended towards the development of targeted 
therapies for ACC, mostly focusing on proteins that are highly expressed in malignant 
adrenocortical tumours. The epidermal growth factor receptor (EGFR) and the vascular 
endothelial growth factor (VEGF) were the first two genes to be targeted. In both cases the 
clinical results were disappointing with failure to yield any objective response, at least in 
patients with chemotherapy-resistant disease (Quinkler et al., 2008, Wortmann et al., 2010). A 
trial with the multi-tyrosine kinase inhibitor sorafenib in combination with paclitaxel had to 
be abandoned upon recruitment of 10 patients, as all demonstrated disease progression on first 
clinical evaluation (Berruti et al., 2012). Another tyrosine kinase inhibitor, sunitinib, was 
Figure 1-9 Overall survival in patients with metastatic ACC randomized to combination 
chemotherapy with Mitotane, Etoposide, Doxorubicin and Cisplatin (EDP-M) or Mitotane 
and Streptozotocin (Sz-M) (Fassnacht et al., 2012). Reproduced with permission of the 
Massachusetts Medical Society.  
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evaluated in a phase II study on patients with metastatic ACC who failed to respond to 
mitotane and first-line chemotherapy; only 5 out of 35 patients achieved disease stabilisation 
(14%) (Kroiss et al., 2012).  
More recently, Insulin Growth Factor-I Receptor (IGF1-R) inhibitors have been tried in 
clinical studies. Cixutumumab showed some modest success in combination with 
temsirolomus (inhibitor of mechanistic targets of Rapamycin - mTOR) with 42% of patients 
achieving stable disease (Naing et al., 2013). Combination treatment with Cixutumumab and 
mitotane, however, failed to show any effectiveness in a phase II study (Lerario et al., 2014). 
A similar agent (linstinib, IGF1-R inhibitor) was overall no better than placebo at yielding 
clinical response in a recent phase III trial, although a small group of patients enjoyed 
sustained response over long periods (Fassnacht et al., 2015). Overall, despite rather 
auspicious pre-clinical data, targeted therapies so far have failed to demonstrate effectiveness 
in clinical studies and improve the outcome of patients with advanced disease. 
 
1.2.6.4 Medical treatment to control hormone excess 
Medical control of the detrimental hormone excess is often a secondary treatment aim in 
ACC. Glucocorticoid excess is the most common hormonal perturbation emanating from 
ACCs and its clinical sequelae involve the classic constellation of symptoms and signs 
comprising Cushing’s syndrome. Aside from its adrenolytic activity, mitotane has additional 
adrenostatic effects, i.e. direct inhibitory effects on steroidogenesis. These include CYP11A1 
inhibition, as well as cortisol breakdown through CYP3A4 induction (Chortis et al., 2013, 
Else et al., 2014). Of note, mitotane can inhibit steroidogenesis at lower levels than the 
threshold for its antineoplastic effect (Baudry et al., 2012, Nieman et al., 2015).  
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Metyrapone is a specific inhibitor of CYP11B1 which is commonly used in the medical 
control of cortisol excess. It has a rather favourable side-effect profile (mainly mild 
gastrointestinal symptoms), with the caveat that it can exacerbate underlying androgen excess 
and induce adrenal insufficiency (Daniel et al., 2015).  
Ketoconazole inhibits CYP17A1, CYP11A1 and CYP11B1 and is still used in many 
countries, but carries a risk of severe idiosyncratic hepatotoxicity and interacts with other 
drugs through inhibition of liver microsomal enzymes (e.g. CYP3A4) (Nieman et al., 2015). 
Etomidate is an anaesthetic agent which can inhibit CYP11A1 and CYP11B1 even at low 
doses. It is used as intravenous infusion at non-anaesthetic doses for rapid control  of 
glucocorticoid excess in some centres in challenging cases of florid Cushing’s, but requires 
close inpatient monitoring (Schulte et al., 1990).  
Finally, mifepristone is a glucocorticoid receptor antagonist which completes the modern 
armamentarium for Cushing’s syndrome control. Its main disadvantage is its inability to block 
the action of excessive cortisol on the mineralocorticoid receptor, which can cause 
hypertension and hypokalaemia. Therefore, additional treatment with mineralocorticoid 
receptor blockers (e.g. spironolactone) may be required (Nieman et al., 2015). In challenging 
cases, recourse to combination therapy with two or even three of the above agents is common, 
as the success rates of any monotherapy in mitigating overwhelming glucocorticoid excess are 
limited (Nieman et al., 2015) (Fig. 1-10).  
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Androgen excess may require medical treatment when it manifests itself clinically as severe 
hirsutism or virilisation in female patients. Options include a number of agents with anti-
androgenic effects, including spironolactone (mineralocorticoid and androgen receptor 
blocker), finasteride (5a-reductase inhibitor) and flutamide (Else et al., 2014). Furthermore, it 
has been shown that mitotane is a powerful inhibitor of 5a-reductase activity, thereby 
reducing the activation of testosterone to 5a-dihydrotestosterone and ameliorating androgen 
excess, but also compromising androgen action in male patients without androgen excess 
(Chortis, 2013). 
Oestrogen excess causing severe gynaecomastia in male patients can be addressed by 
institution of aromatase inhibitors or oestrogen receptor antagonists, although this is very 
rarely encountered in clinical practice (Else et al., 2014).   
Figure 1-10 Effects of adrenostatic agents on adrenal steroidogenesis. Red lines indicate 
inhibition.  
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1.2.6.5  Other treatment options 
Radiotherapy has not found a wide application in ACC, but is occasionally employed either as 
adjuvant treatment post-operatively or to palliate patients with advanced disease. Adjuvant 
radiotherapy administration has only been explored in three retrospective studies, all based on 
small patient cohorts (< 20 patients). Two of the studies showed reduced incidence of local 
recurrence; however, no improvement in overall survival was demonstrated (Else et al., 2014, 
Fassnacht et al., 2006, Habra et al., 2013). No firm conclusions can be drawn on the ground of 
such slender evidence. Some experts advocate the use of radiotherapy in cases of incomplete 
tumour resection (Berruti et al., 2010). There may be a role for radiotherapy in patients with 
metastatic disease of limited volume, but pertinent evidence is so far limited to small 
retrospective studies (Polat et al., 2009, Ho et al., 2013, Hermsen et al., 2010). Effective pain 
alleviation has been reported in a number of small case series, especially in the event of spinal 
metastases (Else et al., 2014). Successful control of hormone excess has also been reported in 
a small case series (Magee et al., 1987). 
Radiofrequency ablation is occasionally employed in cases with isolated local or distal 
disease recurrence of low volume, especially in patients who are considered poor surgical 
candidates in view of poor overall performance status and/or comorbidities. Successful 
applications (e.g. in liver metastases) have been reported, but no clinical trials have formally 
assessed the performance of this intervention (Ripley et al., 2011). Generally, primary ACCs 
(high bleeding risk) and proximity to large vessels constitute contra-indications (Ripley et al., 
2011). Topical arterial chemoembolization is not widely used but may have a role in the 
palliative treatment of small (<3 cm) disease foci of high lipidol uptake (Soga et al., 2009). 
Finally, following up on the discovery that [123/131I]iodometomidate (IMTO) tracer is taken up 
avidly by adrenocortical tissue on single-photon emission CT, radionuclide treatment with  
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[123/131I]IMTO was recently attempted in a small cohort of 11 ACC patients. The results were 
promising, with one patient achieving partial remission and five patients achieving disease 
stabilisation for a median period of 14 months (Hahner et al., 2012). [123/131I] azetidinylamide 
(IMAZA), an IMTO metabolite, was recently introduced, boasting the relative advantage of 
more selective and durable adrenal uptake (Hahner, 2015). 
 
1.2.7 Follow-up 
The optimal protocol for the post-operative follow-up of patients with complete ACC 
resection has not been established, the low disease prevalence having hampered the 
development of evidence-based guidance. Empirically devised protocols are imaging-centred 
and aim to detect recurrences as early as possible, so that prompt treatment can be instigated. 
In principle, the high risk of disease recurrence, especially in the first two post-operative 
years, has to be weighed against the high radiation exposure which is ineluctably associated 
with regular whole-body CT scans. A commonly followed protocol involves contrasted CT 
scans of chest and abdomen (or CT chest with MRI of abdomen and pelvis in less 
parsimonious healthcare systems) every three months for the first two post-operative years, 
followed by six-monthly imaging for the next three years (Fassnacht and Allolio, 2009, Else 
et al., 2014, Arlt et al., 2011). FDG-PET scans are also employed in some centres as a more 
sensitive but costly surveillance method. (Fassnacht and Allolio, 2009). In post-operative 
years 6-10, a period associated with a very low recurrence risk (<5%), imaging typically takes 
place on an annual basis (Else et al., 2014). A typical modern ACC managing algorithm, 
representative of our practice at the Queen Elizabeth Hospital Birmingham, is displayed in 
Fig. 1-11. 
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Biochemical follow-up to detect recurrent adrenal steroid hormone excess has an ancillary 
role in the post-operative surveillance of ACC, with the important limitation that capturing the 
hormonal output of minuscule metastatic lesions in routine clinical biochemistry is difficult 
and usually radiological manifestation of recurrent disease precedes the development of 
deranged biochemistry. Routine clinical biochemistry in patients with history of ACC 
includes serum androgens, 17-hydroxyprogesterone, oestradiol, aldosterone and urinary free 
cortisol.  
Figure 1-11 ACC management algorithm. EDP: combination chemotherapy with Etoposide, 
Doxorubicin and Cisplatin 
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Diagnostic ambiguity in early stages of recurrence/ metastasis is not uncommon and may lead 
to delays in reaching a firm diagnosis and commencing treatment. FDG-PET scans or 
percutaneous biopsies are sometimes employed in such cases (Fassnacht and Allolio, 2009, 
Else et al., 2014). 
Urinary steroid profiling holds some promise as a future monitoring tool in operated patients. 
Disturbed steroidogenesis in the context of ACC and the emerging ability of urine steroid 
profiling by mass spectrometry to capture such changes and distinguish benign from 
malignant adrenal tumours has been discussed in previous sections. It may be reasonable to 
apply the same principle in the clinical context of recurrent ACC, anticipating that this will be 
accompanied by similar, progressive perturbations of steroidogenesis, possibly recapitulating 
the pre-operative profile. In a case series, Wangberg et al. obtained pre-operative and serial 
post-operative urinary steroid profiles from five operated patients with ACC. In two of them, 
disease recurrence was heralded biochemically by the re-emergence of the pre-operative 
secretion pattern (Wangberg et al., 2010). Interestingly, in one patient presenting with liver 
metastases and combined androgen-glucocorticoid excess, removal of the primary tumour 
was followed by a shift in the steroidogenic fingerprint, with persistence of glucocorticoid 
excess but disappearance of androgen excess. No other studies have attempted to formally 
evaluate the role of steroid profiling as a post-operative surveillance tool so far. 
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1.3 The target: Nicotinamide Nucleotide Transhydrogenase 
1.3.1 Nicotinamide Nucleotide Transhydrogenase and Familial Glucocorticoid 
Deficiency. 
In the search for novel therapeutic approaches in ACC, useful insights may be provided by 
recent advances in our understanding of adrenal pathophysiology. In 2012, SNP array 
genotyping studies revealed that antioxidant pathway defects are causally implicated in a rare 
form of hereditary primary adrenal insufficiency called Familial Glucocorticoid Deficiency 
(FGD) (Meimaridou et al., 2012). FGD is a rare autosomal recessive disorder which is 
characterised by congenital inability of the adrenal glands to produce sufficient amounts of 
cortisol despite sufficient ACTH stimulation by the pituitary (Meimaridou et al., 2013). 
Patients typically present in the first months of life with recurrent infections, failure to thrive, 
hypoglycaemic episodes, seizures or haemodynamic instability. Adrenal biochemistry 
characteristically reveals very low or undetectable cortisol with high ACTH and failure to 
respond to ACTH stimulation (short SYNACTHEN test), indicating primary adrenal 
insufficiency (Clark et al., 2009, Metherell et al., 2005).  Renin and aldosterone tend to be 
normal. Until recently, three gene mutations had been identified in association with this 
condition, accounting for 50% of reported cases. These included genes encoding proteins that 
mediate the transport of cholesterol to the adrenal cells (MC2R, MRAP and StAR), which 
represents the first step of steroidogenesis in response to ACTH stimulation (Clark et al., 
2009, Metherell et al., 2005). In their 2012 study, Meimaridou et al. identified a new genetic 
cause performing targeted exome sequencing in cryptogenic FGD patients of consanguineous 
parentage (Meimaridou et al., 2012). The new culprit, the chromosome 5-situated gene NNT, 
encodes a mitochondrial proton pump called Nicotinamide Nucleotide Transhydrogenase 
(NNT). NNT serves as one of the major mitochondrial generators of reduced nicotinamide 
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adenine dinucleotide phosphate (NADPH) and constitutes an essential component of the 
mitochondrial antioxidant pathways (Rydstrom, 2006, Leung et al., 2015).  In the original 
study, 19 NNT mutations were identified in 13 individuals, out of a total cohort of 100 
patients with FGD of unknown cause (Meimaridou et al., 2012). All affected individuals were 
homozygotes or compound heterozygotes, indicating an autosomal recessive pattern of 
inheritance. No NNT mutations had hitherto been discovered in humans, but since this 
discovery 34 NNT mutations have been reported in 41 patients with unexplained 
glucocorticoid deficiency. The majority of discovered mutations are either nonsense or 
frameshift mutations, predicted to lead to premature protein truncation; the rest comprise 
missense mutations affecting vital protein domains (Yamaguchi et al., 2013, Novoselova et 
al., 2015, Weinberg-Shukron et al., 2015, Jazayeri et al., 2015, Roucher-Boulez et al., 2016, 
Hershkovitz et al., 2015, Meimaridou et al., 2012). In a minority of described cases there was 
co-existent aldosterone deficiency (high renin, low aldosterone), consistent with global 
adrenal insufficiency  (Weinberg-Shukron et al., 2015, Roucher-Boulez et al., 2016).  
Despite NNT’s ubiquitous expression in all human tissues (Meimaridou et al., 2012), the 
clinical phenotype associated with inactivating NNT mutations is remarkably specific, only 
affecting the adrenal glands in the vast majority of patients. This interesting clinical 
observation indicates a selective susceptibility of adrenocortical cells to NNT loss. Rare extra-
adrenal ailments described in these patients include testicular adrenal rest tumours, likely 
secondary to high ACTH (2 cases); cryptorchidism (2 cases); Leydig cell adenoma of the 
testicles (2 cases); congenital hypothyroidism (2 cases) and left ventricular hypertrophy (1 
case) (Hershkovitz et al., 2015, Roucher-Boulez et al., 2016).    
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1.3.2 Structure and physiology 
Current knowledge of NNT physiology provides putative biological mechanisms to explain 
this novel association. NNT is a redox-driven proton pump with inherent enzymatic activity, 
which resides in the inner mitochondrial membrane of eukaryotic cells, catalysing the 
reversible reduction of NADP+ to NADPH according to the reaction: 
            NADH + NADP+ + H+intermembrane  ↔  NAD+ + NADPH + H+matrix 
The physiological transmembrane proton gradient shifts the reaction strongly to the right, 
maintaining a high mitochondrial ratio of NADPH/NADP+ under physiological conditions 
(Arkblad et al., 2005, Rydstrom, 1974, Rydstrom, 2006, Rydstrom et al., 1998). Reversal of 
the direction of the reaction, so that NADH can be produced from NADPH with concurrent 
H+ pumping against the transmembrane gradient, appears to be possible under hypoxic 
conditions (Ying, 2008). In normoxic conditions, however, the biological role of NNT is to 
replenish the mitochondrial pool of NADPH, powered by the transmembrane proton gradient.  
NNT (molecular weight 114 kD) is a homodimer; each half consists of a lipophilic, 
membrane-embedded domain (DII) and two hydrophilic domains (DI and DIII) protruding 
into the inner mitochondrial matrix (eukaryotic cells) or cytosol (bacteria) (Yamaguchi et al., 
1988, Leung et al., 2015). DI binds NAD(H), while DIII binds NADP(H) (Fig. 1-12). The 
structure of the hydrophilic domains has been successfully studied in a number of species, 
including Homo sapiens, but the structure of the transmembrane domain that facilitates proton 
pumping remained elusive. Recently, Leung et al. managed to elucidate the whole protein 
structure in Thermus thermophilus, using a combination of crystallography and cryo-electron 
microscopy (Leung et al., 2015). This elegant study revealed a peculiar pattern: while the two 
membrane-bound domains (DII) are symmetrical, each containing a putative proton channel, 
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NNT as a whole displays a striking asymmetry as the two DIII domains have opposite 
orientations. The authors hypothesised that this asymmetry facilitates division of labour 
between the two subunits in alternating cycles, so that one of the two DIII domains mediates 
hydride transfer from NADH to NADPH, while its counterpart participates in proton transfer. 
                  
 
It is still unknown what percentage of the total mitochondrial NADPH pool is contributed by 
NNT. Studies on redox balance in Escherichia coli suggested that NNT generates 
approximately 45% of the total NADPH pool (Rydstrom, 2006, Sauer et al., 2004), but more 
recent studies have underscored the complexity of NADPH-generating networks in eukaryotic 
cells and indicated that the relative contribution of each pathway can vary according to cell 
type and metabolic circumstances (Lewis et al., 2014, Fan et al., 2014). Our current 
 
Figure 1-12 Schematic representation of NNT structure and function. The NAD(H) binding 
domain (dI) and the NADP(H) binding domain (dIII) catalyse hydride transfer between 
nicotinamide nucleotides, with concurrent translocation of protons to the mitochondrial 
matrix. Source: (Leung et al., 2015). Reproduced with permission of the American 
Association for the Advancement of Science. 
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understanding of cytosolic and mitochondrial pathways of NADPH synthesis is described 
separately in the succeeding section.  
The existence of many redundant biosynthetic pathways generating NADPH is explained by 
the important biological roles of this versatile electron carrier. Contrary to NADH, which 
predominantly acts as an electron donor to the mitochondrial electron transfer chain to fuel 
ATP synthesis, NADPH is involved in two distinct areas: reductive biosynthesis and 
antioxidant defence. Maintaining a constant NADPH supply to fuel lipid, aminoacid and 
nucleotide biosynthesis is of major importance in highly proliferating cells (Fan et al., 2014, 
Vander Heiden et al., 2009). With regard to its second role as a safeguard of cellular redox 
homeostasis, NADPH acts as an essential electron donor to the two most important 
antioxidant pathways: the glutathione pathway and the thioredoxin pathway, both of which 
mediate the detoxification of chemically reactive oxygen molecules (reactive oxygen species, 
ROS) to H2O (Prasad et al., 2014b). ROS are constantly generated intracellularly as by-
products of aerobic metabolism, and their efficient scavenging represents an existential need 
for all cells (Gupta et al., 2012). Reduced glutathione (GSH) has a well-established, central 
role in the mitochondrial redox balance system as it is involved in the detoxification of the 
major ROS molecule hydrogen peroxide (H2O2), both directly and through the action of 
glutathione peroxidise (GPX) (Prasad et al., 2014a, Mari et al., 2009, Andreyev et al., 2005). 
The second major mitochondrial antioxidant system (thioredoxin pathway) involves reduction 
of mitochondrial thioredoxin by thioredoxin reductase (TXNRD2), using two electrons from 
NADPH. Reduced thioredoxin in its turn regenerates reduced peroxiredoxin 3 (PRDX3) from 
its oxidised form. Two molecules of  reduced PRDX3 can then serve to reduce H2O2 to H2O, 
while they are oxidized to a disulfide-linked peroxiredoxin dimer (Mustacich and Powis, 
2000).  
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In summary, NNT generates NADPH to support anabolic processes and fuel the 
mitochondrial antioxidant defence network with reducing equivalents, preventing oxidative 
damage caused by excessive ROS accumulation (oxidative stress) (Fig. 1-13).  A more 
thorough description of ROS and their scavenging pathways is provided in subsequent 
sections. 
 
               
 
As expected, NNT inhibition has been shown to compromise NADPH synthesis, hamper ROS 
scavenging and alter the cellular redox status (i.e. the balance between oxidising and reducing 
Figure 1-13 Interaction between NNT and the mitochondrial antioxidant pathways. ETC: 
electron transfer chain; ATP: adenosine triphosphate; GSR: glutathione reductase; GSSG: 
oxidised glutathione; GSH: reduced glutathione; GPX1: Glutathione peroxidase 1; TXNRD2: 
thioredoxin reductase 2; TXN: oxidised thioredoxin; TXN-SH: reduced thioredoxin; GPX3: 
peroxiredoxin 3; O2
.-: superoxide; H2O2: hydrogen peroxide                  
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elements) in various cell lines, as indicated by a number of pertinent metabolic parameters 
(NADPH/NADP+ ratio, reduced/oxidised glutathione ratio, ROS concentration)    (Ripoll et 
al., 2012, Arkblad et al., 2005, Meimaridou et al., 2012, Yin et al., 2012). Transient 
knockdown (KD) of NNT in PC12 rat phaeochromocytoma cells also resulted in impaired 
mitochondrial metabolism, most notably inhibition of oxidative phosphorylation with 
decreased oxygen consumption rates (Yin et al., 2012). This was ascribed to the paradoxically 
decreased ratio of NADH/NAD+ observed in the aftermath of NNT inhibition, potentially due 
to inhibition of the Kreb’s cycle enzyme pyruvate dehydrogenase through redox-controlled 
signalling (e.g. JNK-mediated). Perturbation of mitochondrial respiration was accompanied 
by increased levels of apoptosis. In an elegant metabolic in vitro study on melanoma and renal 
carcinoma cells, Gameiro et al. showed that NNT KD impedes glutamine utilisation in Kreb’s 
cycle, due to functional inhibition of isocitrate dehydrogenase by the low NADH/NAD+ ratio 
(Gameiro et al., 2013). This increased the dependence of malignant melanoma cells on 
glucose to derive anabolic carbons for their proliferation. Indeed, NNT-KD cells were more 
sensitive to glucose deprivation. Overexpression of NNT had the opposite effects, increasing 
reductive carboxylation of glutamine. Finally, xenografts derived from NNT-KD melanoma 
cells showed at least a tendency towards lower proliferation than their controls (Gameiro et 
al., 2013). In another recent study on neuronal cells, NNT KD disrupted the thioredoxin 
pathway, limiting reduced peroxiredoxin availability and, consequently, increasing ROS 
levels. This enhanced cellular susceptibility to chemically-induced oxidative stress (paraquat 
treatment) (Lopert and Patel, 2014)  
A number of in vivo studies have explored the sequelae of NNT dysfunction in rodents. 
Rather opportunely, a spontaneous loss-of-function Nnt mutation was discovered in 
C57BL/6J mice in 2005 (Toye et al., 2005). The first metabolic perturbation identified in this 
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mouse strain was impaired glucose tolerance, as a result of deficient insulin secretion  
(Freeman et al., 2006, Shimomura et al., 2009, Toye et al., 2005). The same phenotype was 
reproduced in a different mouse strain upon Nnt knockout. The mechanism underlying this 
association remains elusive (Parker et al., 2009). Ronchi et al. evaluated the metabolic effects 
of Nnt mutation in the same strain with ex vivo studies on liver mitochondria. In keeping with 
in vitro data, they showed that Nnt mutant mice had liver mitochondria with a lower ratio of 
NADPH/NAPD, impaired redox balance (decreased reduced/ oxidised glutathione ratio) and 
inability to detoxify exogenous ROS, when compared to a BL6 strain with wild-type Nnt. Of 
note, the ratio of NADH/NAD+ was higher in Nnt mutant mice, which is at odds with the 
results of the aforementioned in vitro studies (Ronchi et al., 2013). Meimaridou et al. 
demonstrated a decrease in circulating corticosterone (the major glucocorticoid and 
mineralocorticoid hormone in rodents) in Nnt mutant mice, underpinned by histological 
findings of disorganised structure and increased apoptosis in the zona fasciculata of the mouse 
adrenals (Meimaridou et al., 2012). Blunted corticosterone response to restrain stress was 
observed in NNT knockout mice by Picard et al., as well as augmentation of the 
hyperglycaemic response to stress due to deficient insulin secretion (Picard et al., 2015). 
Recently, the first study evaluating the effects of NNT mutations in FGD patients 
(homozygotes) and carriers (heterozygotes) ex vivo using circulating lymphocytes was 
published. Suppression of NNT activity to <60% of normal (homozygotes and heterozygotes) 
resulted in decreased mitochondrial mass and mitochondrial DNA copies. Suppression to 
<30% of normal activity (homozygotes only) additionally resulted in impaired oxidative 
phosphorylation and high rates of mitochondrial gene deletions, presumably reflecting 
oxidative DNA damage (Fujisawa et al., 2015).  
Chapter 1                                                                                                                                                       General Introduction 
56 
 
Interestingly, it has been long known that NADPH (and by inference NNT) also serves as an 
essential electron donor to a number of steroidogenic cytochrome P450 enzymes that reside in 
the mitochondria (CYP11A1, CYP11B1, CYP11B2) (Hanukoglu, 2006). This provides a 
putative mechanism to explain the association of NNT dysfunction with adrenal insufficiency, 
alongside the possibility of adrenal cortex damage due to oxidative stress.  
  
1.3.3  NADPH metabolism 
The role of NNT as a mitochondrial NADPH generator is best appreciated if considered 
within the complete network of biosynthetic pathways that can produce NADPH alongside it. 
The total NADPH pool can be divided into cytosolic NADPH and NADPH located within 
intracellular orgenelles (most notably mitochondria). Cellular membranes appear to be 
impermeable to NADP(H) and NAD(H), and transfer of reducing equivalents across them 
requires multi-step reaction pathways such as the malic acid cycle (Nikiforov et al., 2011, 
Pollak et al., 2007). The ability to rapidly reduce NADP to NADPH in response to oxidative 
stimuli or starvation is important. This can be facilitated by a number of enzymes: 
a) Isocitrate dehydrogenase (ICDH). ICDHs catalyse the oxidative decarboxylation of 
isocitrate to a-ketoglutarate in the tricarboxylic acid (TCA) cycle, a reaction during 
which NAD(P)H is generated. Three isoforms of ICDH have been described in 
mammals: mitochondrial NAD+-dependent ICDH (IDH), mitochondrial NADP+-
dependent dehydrogenase (IDPm) and cytosolic NADP+-dependent dehydrogenase 
(IDPc). IDPm, also known as ICDH type II, catalyses the following reaction, 
contributing to the mitochondrial NADPH pool:   
Isocitrate + NADP+ + H+           IDPm              α-ketoglutarate + NADPH   (Jo et al., 2001) 
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b) Malic enzyme. Malate dehydrogenase or NADP-malic enzyme is an oxidoreductase 
catalysing the carboxylation of malate to pyruvate, generating NADPH. 
(S)-malate + NADP+     malic enzyme       pyruvate + CO2 + NADPH      (Peron et al., 1975) 
Malate and pyruvate can be transported across the mitochondrial membrane, thus 
allowing some flexibility in reducing power shifts between the cytosol and the 
mitochondria (malate-pyruvate shuttle). For instance, cells can invest cytosolic 
NADPH to generate malate and transport it to the mitochondria, where it can be used 
by malic enzyme to generate NADPH locally (Fan et al., 2014).  
 
c) Glucose-6-Phosphate dehydrogenase (G6PD). This enzyme is considered the major 
cytosolic NADPH generator, but is not expressed in mammalian mitochondria. It 
catalyses the first and rate-limiting step of the Pentose Phosphate Pathway:  
Glucose-6-Phosphate + NADP++ H+    G6PD         6-Phosphoglucono-delta-lactose + 
NADPH    (Frederiks et al., 2007, Ursini et al., 1997). 
 
G6PD is the sole NADPH generator in red cells. G6PD deficiency is the most 
common enzyme deficiency in humans and is particularly prevalent in Asian, African 
and Mediterranean populations due to the phenotype of partial resistance to malaria it 
confers to carriers. Clinically, it only appears to be associated with haemolytic 
anaemia in response to oxidative stress triggered by various agents (fava beans, drugs, 
ketoacidosis), while patients with mild deficiency are completely asymptomatic 
(Beutler, 1996). 
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d) Tetrahydrofolate reductase. The importance of folate-dependent NADPH synthesis 
has been highlighted by modern metabolic mammalian cell studies based on hydrogen 
tracing.  Folate-dependent NADPH-generating pathways involve transfer of a single 
carbon from serine to tetrahydrofolate (THF) to produce methylene-THF. The latter is 
subsequently oxidised by methylene-THF reductase (MTHFD) to form the purine 
precursor formyl-THF, in a reaction involving NADPH generation. MTHFD exists in 
both a cytosolic and a mitochondrial form. Recent studies suggest this pathway may 
contribute up to a quarter of the total NADPH pool in mammalian cells (Fan et al., 
2014, Lewis et al., 2014). 
An overview of known sources of mitochondrial NADPH is provided in Figure 1-14. 
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1.3.4 Reactive oxygen species (ROS) – basic physiology 
Reactive oxygen species (ROS) are chemically reactive, oxygen-containing molecules which 
can be further subdivided into radical ROS [containing one or more unpaired electrons, such 
as superoxide (O2-), hydrocyl radical (OH-), nitric oxide (NO)] and non-radical ROS 
[hydrogen peroxide (H2O2), ozone (O3), organic hydroxyperoxide (Fruehauf and Meyskens, 
2007, Gupta et al., 2012). ROS are constantly generated within cells, their production 
Figure 1-14 Mitochondrial sources of NADPH. THF: tetrahydrofolate; SHMT2: serine 
hydroxymethyltransferase 2; MTHFD2: methylenetetrahydrofolate dehydrogenase; IDH2: 
isocitrate dehydrogenase type II; a-KG: alpha-ketoglutarate; OAA: oxaloacetate  
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ineluctably intertwined with aerobic metabolism entailing electron transfer reactions. The 
main intracellular generation loci include 
Peroxisomes: xanthine oxidase and other oxidases generate superoxide and hydroxyl radicals 
(del Rio et al., 1992) 
Cell membrane: Membrane-bound enzymes from the NADPH oxidase (NOX) family 
generate ROS (Bedard and Krause, 2007) 
Endoplasmic reticulum (ER): ROS are generated within the ER during protein folding and 
disulphide bond formation by oxidoreductin 1, disulphide isomerase and NOX4 (Gupta et al., 
2012). 
Mitochondria: The major ROS generating area within eukaryotic cells. A number of 
mitochondrial sources of ROS can be enumerated: 
The tricarboxylic acid cycle (TCA cycle) or Kreb’s cycle. The TCA cycle (Fig. 1-15) is a 
series of reactions oxidising carbohydrates, fats and proteins to generate CO2 and energy 
(ATP).  NADH and NADPH are generated during the cycle and serve as electron transporters 
from TCA substrates to the electron transfer chain. Several TCA enzymes can produce ROS 
as by-products during electron transfer (NADH dehydrogenase, pyruvate dehydrogenase, a-
ketoglutarate dehydrogenase, succinate dehydrogenase). All these enzymes use flavin-
containing groups to facilitate electron transfer; during this process some electrons remain 
stranded in the flavin groups and eventually leak generating superoxide (Sabharwal and 
Schumacker, 2014). Consequently, inhibition of any enzymatic step along the TCA cycle 
results in increased ROS generation as more free electrons accumulate (Sabharwal and 
Schumacker, 2014). 
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The Electron transport chain (ETC). The ETC involves a series of mitochondrial membrane-
abiding enzymes (complexes I-V) which mediate the transfer of electrons generated in the 
TCA cycle to O2, with synchronous generation of energy in the form of ATP (oxidative 
Figure 1-15 ROS production in the TCA cycle. CoASH: coenzyme A; PDH: pyruvate 
dehydrogenase; IDH: isocitrate dehydrogenase; a-KG: alpha-ketoglutarate; a-KGDH: 
alpha-ketoglutarate dehydrogenase; SCoA-S: SuccinylCoenzyme A synthase; MDH: malate 
dehydrogenase; OAA: oxaloacetate; GDP: guanosine diphosphate; GTP: guanosine 
triphosphate 
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phosphorylation). ROS (superoxide) are generated during this process through premature, 
single electron transfer to O2 in complexes I (NADH dehydrogenase) and III (Cytochrome C 
reductase) (Sabharwal and Schumacker, 2014). Depending on the exact site of their 
generation, ETC-derived ROS may be directed to the mitochondrial matrix or the 
mitochondrial intermembrane space. Escape from the matrix to the intermembrane space and 
from there to the cytosol can also occur, as ROS can cross membranes through aquaporins 
and anion channels (Sabharwal and Schumacker, 2014, Bienert et al., 2007, Han et al., 2003). 
Mitochondrial CYP450 Type I enzymes. These include the cholesterol side chain cleavage 
enzyme (CYP11A1 or P450scc), 11β-hydroxylase (CYP11B1 or P450c11) and its isoenzyme 
aldosterone synthase (CYP11B2 or P450c11AS).  The hydroxylation reactions catalysed by 
these enzymes involve electron transfer from NADPH, which can lead to electron leakage to 
O2 generating superoxide. The interaction between ROS and steroidogenesis is complex and 
is analysed in more details in a subsequent section.  
Cytochrome b5 reductase. This outer mitochondrial membrane enzyme oxidises NAD(P)H 
and reduces cytochrome b5. Superoxide production at high rates has been reported (Whatley 
et al., 1998, Andreyev et al., 2005). 
Monoamine oxidases A and B. Also located in the outer mitochondrial membrane, these 
enzymes catalyze the oxidation of biogenic amines. Hydrogen peroxide is produced during 
this reaction (Andreyev et al., 2005) (Fig. 1-16). 
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Aside from these intracellular sources, ROS can be generated by a plenitude of external/ 
environmental triggers, including smoking, asbestos, inflammation, hypoxia, chemotherapy 
and radiotherapy (Gupta et al., 2012). Increased levels of ROS can cause oxidative damage to 
Figure 1-16 Main sources of ROS in adrenal mitochondria. Superoxide is produced during 
electron leakage in respiratory chain complexes I - III, mitochondrial steroidogenesis (P450 
monooxygenases) and the TCA cycle. CoQ: coenzyme Q; CytC: cytochrome C; Preg: 
pregnenolone; S: deoxycortisol; F: cortisol; B: corticosterone; Aldo: aldosterone; SOD2: 
mitochondrial superoxide dismutase 
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DNA, proteins and lipids, disrupting cellular function and, in severe cases, triggering cell 
death. This deleterious impact of high intracellular ROS levels is commonly referred to as 
oxidative stress, and can be a result of high endogenous ROS production, exogenous insults or 
impaired scavenging mechanisms (antioxidant pathways) (Gupta et al., 2012, Fruehauf and 
Meyskens, 2007, Schieber and Chandel, 2014). Different ROS display different degrees of 
reactivity with cell macromolecules. Superoxide (O2-) is the most commonly produced 
intracellular ROS and is only mildly reactive. It is rapidly converted to hydrogen peroxide 
(H2O2) by superoxide dismutase 1 (cytosol, mitochondrial intermembrane space) or 2 
(mitochondrial matrix). H2O2 is moderately reactive with cellular macromolecules. When 
allowed to accumulate inordinately, it can be converted to highly reactive hydroxyl radicals 
(Schieber and Chandel, 2014, Sabharwal and Schumacker, 2014).  
In the last two decades, it has become increasingly evident that oxidative stress is but one 
dimension of ROS (patho)physiology, which is mainly pertinent in the context of ROS 
excess. When present in moderation, ROS are involved in various signalling pathways (redox 
signalling), hence serving a useful biological role as mediators of adaptive cellular responses 
to various environmental stress inducers (Schieber and Chandel, 2014).  A good example of 
this ‘virtuous to vicious’ spectrum of ROS activity can be found in their interaction with 
proteins. Low-level hydrogen peroxide (H2O2) oxidises cysteine residues to sulfenic anions 
(Cys-SOH). This triggers allosteric changes in protein structure that modify their function and 
can initiate signalling cascades. Sulfenic anions can be reduced back to thiolate anions (Cys-
S-) by thioredoxin reductase and glutaredoxin; hence, this reversible oxidation can serve as a 
temporary signalling transduction mechanism. When H2O2 is allowed to accumulate 
excessively, however, it causes irreversible oxidation of cysteine residues to sulfinic (SO2H) 
or sulfonic (SO3H) species, permanently damaging the affected protein (Schieber and 
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Chandel, 2014). Redox signalling regulates numerous cell processes including proliferation, 
survival, angiogenesis, lipid metabolism, immune response and aging (Schieber and Chandel, 
2014, Gupta et al., 2012).  
The following sections focus on the role of ROS in steroidogenesis and cancer 
pathophysiology, which are most relevant to this work. 
 
1.3.5 ROS and steroidogenesis 
The interaction between ROS and steroidogenesis has yet to be fully elucidated, but appears 
to be bidirectional. Mitochondrial steroidogenesis is ineluctably associated with ROS 
generation in the reactions catalyzed by CYP11A1, CYP11B1 and CYP11B2, all cytochrome 
P450 monooxygenases which transfer reducing equivalents and an oxygen atom to steroid 
substrates, according to the following hydroxylation reaction: 
 Substrate-H + NADPH + H+ + O2 → Substrate-OH + NADP+ + H2O (Hornsby, 1980, 
Hanukoglu and Hanukoglu, 1986) 
 
Electron transfer from NADPH to the steroid substrate occurs via two intermediate electron 
transfer proteins, adrenodoxin reductase (FAD-containing flavoenzyme) and adrenodoxin 
(ferrodoxin-type iron-sulfur protein) (Grinberg et al., 2000, Ziegler et al., 1999).  
Adrenodoxin and adrenodoxin reductase are ubiquitously expressed, but predominantly so in 
the adrenal cortex and corpus luteum (Brentano and Miller, 1992, Hanukoglu and Hanukoglu, 
1986). Of note, they are not substrate-specific, i.e. a single form of adrenodoxin reductase and 
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adrenodoxin react with all mitochondrial P450 steroidogenic enzymes. The order of electron 
transfer is always the same: 
 
NADPH             Adrenodoxin reductase           Adrenodoxin               P450 (Hanukoglu, 2006) 
 
The efficiency of this process, however, is never 100%, and superoxide (O2-) is also generated 
as a by-product when an unpaired electron is transferred to O2. This is often described as 
‘electron leakage’ or ‘uncoupling of electron transfer’. Electron leakage has been studied in 
reconstituted forms of CYP11A1 and CYP11B1, which showed that about 15% and 40% of 
the total electron flow through each enzymic system, respectively, is directed to ROS 
formation (Rapoport et al., 1995). By comparison, leakage within the mitochondrial electron 
transfer chain occurs at an estimated rate of only 0.15% of the total electron flow (St-Pierre et 
al., 2002). Interestingly, uncoupling of CYP11A1 appears to be inversely proportional to 
substrate availability, while in CYP11B1 uncoupling increases with increasing concentrations 
of deoxycorticosterone (Rapoport et al., 1995). Within the adrenal cortex, expression of P450 
mitochondrial enzymes is much higher (up to ten-fold) than the expression of other electron 
transfer chain enzymes or microsomal P450 enzymes (Hanukoglu and Hanukoglu, 1986). 
Therefore, it can be surmised that they account for a substantial proportion of total ROS 
generation within adrenocortical cells.  This fact can potentially explain the higher 
concentration of antioxidants (e.g. Vitamin C, selenium) in the adrenal gland in comparison to 
other tissues (Prasad et al., 2014a). Derouet-Humbert et al. were able to demonstrate ROS-
associated mitochondrial apoptosis is various cell lines overexpressing adrenodoxin or 
CYP11A1 (Derouet-Humbert et al., 2005). 
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The opposite direction of this interaction, i.e. the impact of oxidative stress on 
steroidogenesis, has been explored in a small number of in vitro studies, often with conflicting 
results. In 1980, Hornsby et al., working on cultured bovine adrenocortical cells, showed that 
treatment with antioxidants can ameliorate the decrease in CYP11B1 activity that is seen in 
response to treatment with cortisol, and augment the stimulation of CYP11B1 activity seen in 
response to ACTH treatment (Hornsby, 1980). 10 years later, Behrman et al. found that 
hydrogen peroxide (H2O2) has a specific inhibitory effect on cholesterol transport to the 
mitochondria in rat luteal cells, but did not seem to affect downstream steroidogenesis 
(Behrman and Aten, 1991). In another study, an inhibitory effect of H2O2 on 3beta-
hydroxysteroid dehydrogenase was demonstrated in MA-10 Leydig tumour cells (Stocco and 
Ascoli, 1993).  Similarly, Diemer et al. showed that treatment of MA-10 Leydig tumour cells 
with H2O2 suppressed CYP11A1 activity after 3h of cAMP stimulation in a dose-dependent 
manner, as evidenced by lower progesterone synthesis, although CYP11A1 expression was 
not affected. Exogenous xanthine oxidase administration, leading to superoxide generation, 
was associated with down-regulation of StAR and suppression of progesterone production 
(Diemer et al., 2003). Interestingly, Zhao et al. demonstrated a biphasic relationship between 
chemically induced oxidative stress and steroidogenesis in rat Leydig cells. Moderate 
oxidative stress increased testosterone synthesis activating CYP11A1, 3β-HSD and 17β-HSD, 
while higher levels had the opposite effect (Zhao et al., 2012). 
There is hardly any evidence on the effects of oxidative stress on mineralocorticoid synthesis. 
The only relevant in vitro study of aldosterone synthesis on NCI-H295R (ACC) cells 
surprisingly showed that CYP11B2 (aldosterone synthase) is actually up-regulated by 
oxidative stress (Rajamohan et al., 2012).   
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In clinical medicine, a number of familial forms of adrenal insufficiency have been associated 
with impaired redox status, including triple A syndrome, X-linked adrenoleukodystrophy and, 
as discussed previously, Familial Glucocorticoid Deficiency (FGD) (Prasad et al., 2014b). 
Triple A syndrome (Allgrove’s syndrome) is an autosomal recessive disease characterized by 
the clinical constellation of alacrima (absence of tears), oesophageal achalasia and primary 
adrenal insufficiency. This is often accompanied by a progressive neurodegenerative process 
(Allgrove et al., 1978).  The genetic culprit, AAAS, encodes a nucleoporin (ALADIN) whose 
exact role has yet to be elucidated. Dermal fibroblasts from Triple A patients display high 
levels of ROS. It is unclear what drives this oxidative stress and to what extent this is causally 
linked to the clinical syndrome. Histological evidence of atrophic zona fasciculata and 
reticularis have been reported (Prasad et al., 2014b, Allgrove et al., 1978). In a recent study, 
stable knockdown of Aaas in NCI-H295R ACC cells increased oxidative stress and led to a 
suppression of cortisol synthesis and expression of CYP11B1 and StAR; CYP11A1 did not 
appear to be affected (Prasad et al., 2013). These results were subsequently contradicted by 
Juhlen et al., who found that ALADIN knockdown in NCI-H295R-S1 (substrain 1) cells only 
has an impact on the CYP450 type II microsomal enzymes CYP17A1 and CYP21A2, and 
their electron donor enzyme POR. Steroidogenically, only 17-hydroxyprogesterone, 11-
deoxycortisol and androstenedione were significantly suppressed (Juhlen et al., 2015). 
Interestingly, Aaas knockout in mice fails to reproduce the features of human patients 
(Huebner et al., 2006). 
Adrenoleukodystrophy is another rare genetic disease (X-linked) afflicting the central nervous 
system (progressive demyelination) and the adrenal glands (primary adrenal insufficiency). It 
is caused by mutations of ABCD1, a gene encoding the ALP protein, which mediates 
intracellular transfer of very long chain fatty acids (VLCFA) into the peroxisomes for beta-
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oxidation (van Roermund et al., 2008). Accumulation of VLFCA results in ROS generation, 
although the exact mechanism is poorly understood (Ivashchenko et al., 2011). Abcd1 
knockout mice, however, have a much milder phenotype and the adrenal glands are spared 
(Forss-Petter et al., 1997, Prasad et al., 2014b). 
In 2014, whole exon sequencing in three related patients with FGD revealed they all shared an 
inactivating mutation of mitochondrial thioredoxin reductase type 2 (Prasad et al., 2014a). 
This discovery of a second gene (after NNT) participating in the mitochondrial antioxidant 
defence network in FGD patients consolidated the importance of redox homeostasis for the 
adrenal gland. Whether glucocorticoid deficiency in these patients arises as a consequence of 
ROS-induced adrenal cell damage, developmental failure of adrenal cortex formation due to 
aberrant redox signalling or functional inhibition of steroidogenic enzymes remains unknown 
(Prasad et al., 2014a). 
 
1.3.6 ROS and cancer 
The multi-layered relationship between ROS and cancer has been extensively explored in the 
last two decades and several levels of interaction have been identified. It is now recognised 
that ROS are involved in signalling pathways implicated in oncogenesis (malignant cellular 
transformation), response to hypoxia, cell proliferation, cell viability and angiogenesis, all 
important parameters of malignant pathophysiology (Fruehauf and Meyskens, 2007, Gupta et 
al., 2012, Schumacker, 2006) (Fig. 1-17).  
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1.3.6.1 ROS and malignant transformation 
Oncogenesis or malignant cellular transformation refers to the process whereby healthy cells 
acquire properties of malignant cells, either through activation of oncogenes or inactivation of 
tumour suppressor genes.  Our understanding of ROS involvement in malignant cell 
transformation is still incomplete, but an ever-increasing body of work has accrued evidence 
supporting ROS involvement in this process (Fruehauf and Meyskens, 2007, Sabharwal and 
Schumacker, 2014, Schumacker, 2006, Gupta et al., 2012). Stimulation of malignant 
transformation by oxidising agents (Radisky et al., 2005, Azad et al., 2010) and suppression 
of malignant transformation by antioxidants (Wang et al., 2011, Irani et al., 1997, Yan et al., 
2009)  have been demonstrated in vitro. ROS-induced DNA damage leading to genomic 
Figure 1-17 Interaction between ROS and important cellular processes involved in cancer 
pathophysiology. Double arrows represent bidirectional relationships.  
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instability and oncogene activation is a putative pathophysiological link (Gupta et al., 2012, 
Fruehauf and Meyskens, 2007). Mitochondrial DNA is particularly susceptible to ROS-
induced damage owing to its proximity to the electron transfer chain, and its mutations can 
lead to loss of function of crucial cell cycle ‘checkpoints’, a hallmark feature of malignant 
cells (Schumacker, 2006). 
Malignant cells generally have higher levels of oxidative stress than normal cells. This 
difference is partly due to the higher metabolic rates of cancer cells, leading to higher rates of 
ROS generation in the electron transfer chain. Elegant in vitro studies involving immortalised 
benign cell lines as controls, however, indicated that the increased oxidative stress of 
malignant cells is probably an attribute related to the malignant transformation itself, even 
allowing for the differences in metabolic rates between malignant and healthy cells 
(Trachootham et al., 2006). Maintaining modestly elevated ROS levels may be beneficial to 
malignant cells in a number of ways, including accelerated proliferation, resilience to hypoxia 
and stimulation of angiogenesis, as detailed in the following paragraphs. 
 
1.3.6.2 ROS and hypoxia 
Dealing with a hypoxic microenvironment is a challenge almost invariably facing cancer 
cells. Malignant cell response to hypoxic stress is mediated by the hypoxia-inducible factor 1 
(HIF-1). HIF-1 is a cytosolic heterodimer consisting of HIF-1α and HIF-1β. In response to 
hypoxia, it translocates to the nucleus and induces the transcription of a number of target 
genes; the end effect is enhanced cell proliferation and stimulation of angiogenesis. Under 
normoxic conditions, HIF-1 is quickly inactivated through hydroxylation of proline residues 
by PHD (prolyl hydroxylase), followed by degradation by the ubiquitin–proteasome system. 
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PHD uses O2 as a substrate and thus its action is inhibited by hypoxia, allowing free 
expression of HIF-1 and, consequently, the whole panel of hypoxia-response genes which 
mediate cellular resistance to hypoxic conditions (Pugh and Ratcliffe, 2003). The effect of 
ROS on HIF-1 is not as yet fully elucidated and existing evidence is contradictory. A series of 
in vitro studies have demonstrated that both exogenous and endogenous ROS can augment 
HIF-1a stabilization and binding and, consequently, augment cell survival, proliferation and 
angiogenesis (Duyndam et al., 2001, Brauchle et al., 1996, Chandel et al., 2000, Guzy et al., 
2007, Wang et al., 1995). However, other studies have demonstrated diametrically different 
results, with exposure to exogenous or endogenous excessive ROS inhibiting HIF-1a 
stabilization and/or binding (Huang et al., 1996, Hellfritsch et al., 2015). From an alternative 
perspective, it has been ascertained that hypoxia itself paradoxically stimulates mitochondrial 
ROS production, enhancing electron leakage in the ETC (Guzy and Schumacker, 2006). 
 
1.3.6.3 Role of ROS in cellular proliferation.  
The ability of ROS to enhance cellular proliferation has been demonstrated in a large number 
of in vitro and in vivo studies using various cancer types. This also applies to healthy cells, as 
redox signalling can augment growth factor-mediated cellular proliferation (Schumacker, 
2006). Molecular targets through which the proliferative effect of excess ROS is facilitated 
include ERK (extracellular signal-regulated kinases), Nf-κB (nuclear-factor-kappa-light-chain 
enhancer of activated B cells), Cyclin E, EGFR, JNK (c-Jun N-terminal kinases) and others 
(Fruehauf and Meyskens, 2007, Gupta et al., 2012, Liu et al., 2002, Ruiz-Ramos et al., 2009). 
In cancer studies, exogenous H2O2 stimulated proliferation in hepatoma cells through 
activation of protein kinase B (Liu et al., 2002), while arsenite-induced ROS reproduced the 
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same effect on breast cancer cells (Ruiz-Ramos et al., 2009). Similarly, increase in 
endogenous ROS production has been associated with enhanced proliferation in lung cancer, 
breast cancer and ovarian cancer cells (Hu et al., 2005, Na et al., 2008). In keeping with these 
findings, treatment with ROS scavengers (e.g. catalase, N-acetylcysteine) has demonstrated 
anti-proliferative effects in vitro (Saunders et al., 2010, Martin et al., 2007, Policastro et al., 
2004). Conversely, a smaller number of studies have demonstrated suppression of cellular 
proliferation in response to ROS loads, suggesting that the net effect of ROS on cellular 
proliferation may be dose-dependent, with modest rises stimulating and steep elevations 
inhibiting proliferation (Koka et al., 2010, Donadelli et al., 2007, Qu et al., 2011).  
 
1.3.6.4 ROS and cell death 
ROS excess can trigger cell death by apoptosis, necrosis or autophagy. Apoptosis is a 
controlled form of cell death induced either by the mitochondria (intrinsic pathway) or non-
mitochondrial death receptors (extrinsic pathway) (Gupta et al., 2012). ROS can induce 
apoptosis through the extrinsic pathway: death receptor Fas can be activated by ROS, 
eventually leading to caspase 8 activation and apoptosis (Denning et al., 2002, Medan et al., 
2005, Reinehr et al., 2005, Uchikura et al., 2004). Mitochondrial ROS-dependent apoptosis 
involves opening of the mitochondrial permeability transition pore complex (MPTP), a 
multimeric channel consisting of adenine nucleotide translocase, cyclophilin D, creatine 
kinase and a voltage dependent ion channel (VDAC). ROS-induced pore opening is mediated 
by activation of pore-destabilising proteins (Bcl-2-associated X protein, Bcl-2 homologous 
antagonist) as well as inactivation of pore-stabilising proteins (Bcl-2 and Bcl-Xl) (Martindale 
and Holbrook, 2002). MPTP opening is followed by cytochrome c release, apoptosome 
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formation and caspase activation, effectuating the apoptotic demise of the cell (Martindale 
and Holbrook, 2002, Gupta et al., 2012) (Fig 1-18). When ROS accumulation becomes even 
more excessive, it can act as a trigger of necrosis rather than apoptosis, in a caspase-
independent fashion. Necrosis is a rapid and uncontrolled form of cell death, involving 
disruption of cell membranes and release of cell contents to the extracellular space (Krysko et 
al., 2008). The capacity of excessive ROS to act as triggers of necrosis has been demonstrated 
in a number of cell lines in vitro, including Jurkat T-lymphocytes, multiple myeloma, 
lymphoma and prostate cancer cells (Nair et al., 2009, Hampton and Orrenius, 1997, 
Garbarino et al., 2007). A third mode of cell death associated with ROS excess is autophagy. 
Autophagy comprises a self-catabolic process of lysosomic degradation of cellular organelles 
and proteins. Autophagy in response to ROS accumulation has been demonstrated in various 
cancer types in vitro, including colon cancer, gliomas, glioblastomas and breast cancer (Chen 
et al., 2008, Xie et al., 2011, Shrivastava et al., 2011, Park et al., 2011).  
As with proliferation, the interaction between ROS and cell death is not entirely straight-
forward, and more modest levels of ROS have been shown, in a smaller number of studies, to 
have the opposite effects, promoting cell survival (Yang et al., 2007, Brar et al., 2003). Sub-
cellular localisation also seems to be important, with moderate elevations in cytoplasmic ROS 
supporting cell survival while mitochondrial ROS inducing apoptosis (Deshpande et al., 
2003). Overall, there appears to be a multi-phasic relationship between ROS and cellular 
growth kinetics, whereby low ROS levels can promote cell survival and stimulate 
proliferation, higher (supra-physiological) levels trigger apoptosis and more overwhelming 
rises can directly induce necrosis or autophagy (Gupta et al., 2012, Schafer and Buettner, 
2001). 
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1.3.6.5 ROS and cell invasion/ angiogenesis 
Similar to their effect on cell proliferation, modest ROS rises can also promote angiogenesis 
and tissue invasion and enhance the metastatic potential of malignant cells in vitro and in 
vivo. Signalling pathways mediating this effect include mitogen-activated protein kinase 
(MAPK), CXC chemokine receptor, VEGF and VEGF receptors 1 and 2 (Ho et al., 2011, 
Arbiser et al., 2002, Chetram et al., 2011).  Suppression of invasion/ angiogenesis by ROS has 
also been described in a smaller number of studies, suggesting that, as with other previously 
Figure 1-18 H2O2-induced apoptosis through mitochondrial permeability transition pore 
(MPTP) opening. H2O2 destabilises MTP through direct oxidation of ANT (adenine 
nucleotide translocase) and/or the pore-stabilising protein Bcl-2.  Resulting VDAC 
(voltage-dependent anion channel) opening allows influx of anions and water into the 
mitochondria, cytochrome c activation and, eventually, apoptosis. Source: (Fruehauf and 
Meyskens, 2007) . Adapted and reproduced with permission of the American Association of 
Cancer Research.  
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described effects, this impact may also be dosage/location-dependent (Adhikary et al., 2010, 
Qu et al., 2011, Hellfritsch et al., 2015). 
 
1.3.6.6 ROS and resistance to chemotherapy 
Adaptation to chronic exogenous oxidative stress has been observed in various cancer cell 
lines in vitro (Trachootham et al., 2009, Gupta et al., 2012). This can be explained by two 
interacting factors: 
a) The toxicity (to the extent of cell death) of excessive ROS accumulation creates a 
selective pressure under which cells that manage to adapt (e.g. by strengthening their 
antioxidant pathways) have an advantage and dominate the population. 
b) An oxidized intracellular microenvironment creates genomic instability due to 
oxidative DNA damage and defective DNA repair, augmenting the genetic plasticity 
of malignant cells and accelerating their adaptation to new metabolic challenges. 
Molecular pathways through which adaptation to oxidative stress is achieved often involve 
Nf-κΒ, Nrf-2 (nuclear  factor E2- related factor 2) and HIF-1 (hypoxia inducible factor 1); all 
of them converge to the up-regulation of antioxidant genes (Trachootham et al., 2009). Redox 
adaptation can be a dynamic process following a ‘vicious cycle’ pattern, eventually resulting 
in late-stage cancer cells that manage to survive despite high endogenous ROS by virtue of 
their hypertrophic antioxidant defence mechanisms. Not only does successful redox 
adaptation allow malignant cells to survive despite high ROS levels, but it can often enhance 
their resilience to chemotherapy, especially when it comes to drugs that exert part of their 
cytotoxic effect through oxidative stress (Fig.1-19) (Trachootham et al., 2009). From a 
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different perspective, the dependence of such cells on their antioxidant capacity may represent 
a metabolic ‘Achilles’ heel’ that can be targeted therapeutically. This is discussed 
comprehensively in a separate section, after an overview of the antioxidant defence 
mechanisms.     
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1.3.7 ROS scavenging (antioxidant pathways) 
Given the versatile role of ROS in intracellular signalling and cell viability, a number of 
antioxidant pathways have evolved to create an efficient buffering system that can maintain 
these potentially toxic metabolic by-products at sustainable levels and respond promptly to 
exogenous stressors. The key players in these systems are described below: 
Superoxide dismutases (SODs). SODs catalyse the dismutation of superoxide (O2-) to 
hydrogen peroxide (H2O2), in order to protect mitochondrial iron-sulfur cluster-containing 
enzymes from superoxide toxicity (Andreyev et al., 2005). Two isoforms of SOD can be 
distinguished in mammalian cells: Cu,Zn-SOD (cytoplasm, nucleus) and MnSOD 
(mitochondria).  SODs cannot act as ROS scavengers independently, as they require systems 
that can react with H2O2. Expression of MnSOD is often low in malignant cells, and cell lines 
overexpressing SOD have reduced proliferation rates and cellular viability in vitro and in 
vivo, presumably due to accumulation of H2O2 (Andreyev et al., 2005). In mice, homozygous 
MnSOD mutations result in a lethal phenotype, but MnSOD overexpression is also 
Figure 1-19 ROS as a double-edged sword in cancer pathophysiology. Increase in 
intracellular ROS levels in cancer cells, both constitutively and exogenously, can lead to 
diametrically different outcomes. Excessive/ uncontrolled rises can induce lethal oxidising 
toxicity, leading directly to cell death. With more modest increases cells may manage to adapt 
to the increased oxidative stress, upregulating ROS scavenging pathways and survival agents 
(e.g. Bcl-2). This response is often orchestrated by multi-target transcription factors such as 
NF-κΒ and/or Nrf2. When successful, this response may lead to a more aggressive phenotype, 
characterised by chemo- and radio-resistance and rapid proliferation.  
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detrimental, begetting a phenotype of developmental delay and subfertility (Li et al., 1995, 
Raineri et al., 2001).  
The glutathione pathway. Glutathione (L-c-glutamyl-L-cysteinyl-glycine or GSH) is the most 
abundant antioxidant molecule in most tissues (Lee et al., 2008). It is a tripeptide with a thiol 
(–SH) group in its cysteine residue when at a reduced state.  GSH synthesis is performed in 
the cytoplasm via the action of c-glutamylcysteine ligase (GCL) and GSH synthetase, which 
are ubiquitously expressed in all tissues. From there it can be transferred to cellular 
organelles, including the mitochondria, through numerous transporters and carriers (Andreyev 
et al., 2005). Glutathione peroxidases (GPXs) use reduced glutathione as an electron donor to 
reduce H2O2 to H2O. GPXs are selenoproteins which possess redox-active selenocysteine 
residues at their catalytic sites (Mari et al., 2009, Lee et al., 2008). Overall, reduced 
glutathione is a versatile antioxidant molecule which acts to maintain cellular redox balance 
in the following ways: 
a) It serves as a substrate to glutathione peroxidase type 1 (GPX1) and peroxiredoxin in 
reactions that detoxify H2O2 to H2O, both in the cytosol and the mitochondrial matrix 
b)  It protects mitochondrial membrane lipids from oxidative damage through reduction 
of hydroperoxide groups, in reactions that are catalysed by mitochondrial glutathione-
S-transferases and glutathione peroxidase type 4 (GPX4). This reaction is of vital 
importance, as indicated by the fact that GPX4 knockout in mice results in embryonal 
lethality, while GPX1 knockout is viable. 
c) It can react non-enzymatically with toxic electrophilic compounds (endogenous or 
exogenous). 
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d) It serves as a substrate to glutaredoxin, a disulfide oxidoreductase able to reduce 
disulfides in various proteins to prevent oxidative damage (cytosol and mitochondria) 
(Mari et al., 2009). 
Upon reducing ROS or oxidised protein/ lipids, either enzymatically or non-enzymatically, 
glutathione switches to its oxidised form (GSSG). The ratio of reduced to oxidised glutathione 
is a widely-used marker of cellular antioxidant capacity. Within the mitochondria, 
approximately 90% of total glutathione is at its reduced form (Mari et al., 2009, Andreyev et 
al., 2005). Importantly, GSSG cannot cross the mitochondrial membrane; therefore, 
mitochondria are dependent on NADPH to reduce GSSG back to GSH within the 
mitochondrial matrix, in a reaction catalysed by glutathione reductase (Andreyev et al., 2005) 
(Fig. 1-20). 
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Figure 1-20 The glutathione pathway. Oxidised and reduced molecules are presented in 
yellow and green, respectively. Reduced glutathione (GSH) is regenerated from oxidised 
glutathione (GSSG) by glutathione reductase (GSR), using NADPH as a donor of reducing 
equivalents. GSH can be used by glutathione peroxidase type I (GPX1) to reduce H2O2 to 
H2O, or interact with oxidised glutaredoxin (GRX-S2) to generate its reduced form (GRX-
(SH)2). GRX-(SH)2 can act non-enzymatically to break disulphide bonds in proteins to 
reverse oxidative damage.  
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The thioredoxin pathway. Thioredoxins are a group of small, redox-active proteins 
characterised by the presence of a conserved -Trp-Cys-Gly-Pro-Cys-Lys- catalytic site that 
can undergo oxidation/reduction of the two Cys residues reversibly, with concurrent transfer 
of reducing equivalents to or from a disulfide substrate. Oxidised thioredoxin (TXN-S2) can 
be reduced back to its reduced form (TXN-(SH)2) by thioredoxin reductase (TXNRD), in a 
reaction requiring electron donation by NADPH.  
TXN-(SH)2 + X-S2               TXN-S2 + X(SH)2 
TXN-S2 + NADPH            TXN-(SH)2 + NADP+ 
Two isoforms of thioredoxin reductase have been described: thioredoxin reductase 1 
(cytosolic) and thioredoxin reductase 2 (mitochondrial) (Powis and Montfort, 2001, 
Mustacich and Powis, 2000). Reduced thioredoxin in its turn offers its reducing equivalents to 
peroxiredoxins type 1-5 (PRDX 1-5). Peroxiredoxins can then act directly with H2O2 and 
detoxify it to H2O, in a reaction during which two reduced PRDX subunits are converted to an 
oxidised disulphide-linked dimer. PRDX type 3 and, to a lesser extent, PRDX type 5 are 
located in the mitochondria, the former being mitochondria-specific (Prasad et al., 2014b, 
Powis and Montfort, 2001).  Like glutathione peroxidase, peroxiredoxins are also involved in 
the detoxification of lipid peroxides, protecting the mitochondrial membrane. Kinetic analysis 
has suggested that peroxiredoxin type 3 reacts with 90% of the total H2O2 concentration 
within the mitochondrial matrix (Cox et al., 2010).  Of note, regeneration of reduced 
peroxiredoxin can be alternatively facilitated by glutaredoxin, in which case reduced 
glutathione acts as the reducing agent (Cox et al., 2010). Thioredoxin reductase type 2 
knockout (but not peroxiredoxin knockout) is lethal in mice (Andreyev et al., 2005) (Fig. 1-
21).  
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Taken together, the glutathione and thioredoxin/peroxiredoxin pathways comprise the bulk of 
the antioxidant armamentarium of eukaryotic mitochondria. Some important points to 
consider regarding their interaction are the following: a) both pathways use NADPH as an 
essential donor of reducing equivalents – therefore, the antioxidant capacity of mitochondria 
Figure 1-21 The mitochondrial thioredoxin pathway. TXN: thioredoxin; TXNRD2: 
thioredoxin reductase 2; PRDX3: peroxiredoxin 3; H2O2: hydrogen peroxide. 
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is vitally dependent on their ability to produce ample NADPH; b) each of the two pathways 
can be up-regulated to compensate for dysfunctions in the other pathway (redundancy) (Ueda 
et al., 2002) and c) exogenous oxidants as well as certain endogenous oxidative stress-
inducing agents may occasionally preferentially interact with one of the two pathways, 
indicating that this redundancy is not complete (Halvey et al., 2005, Hansen et al., 2006). 
Catalase. Catalase is a non-NADPH-dependent, enzymatic ROS scavenger. Structurally, it is 
a tetrameric molecule with four haeme groups, through which its antioxidant activity is 
facilitated (Nagem et al., 1999). Catalase is ubiquitously expressed in all major organs, but 
predominantly in the liver, kidneys and erythrocytes. The main catalatic reaction involves 
detoxification of H2O2 to H2O and O2. Intracellularly, catalase is mostly expressed in the 
peroxisomes and the cytoplasm (Glorieux et al., 2015). Catalase expression in low 
concentrations has also been detected in rat heart and liver mitochondria, as well as the 
cytoplasmic membrane of cancer cells (Bauer, 2012, Glorieux et al., 2015). Catalase 
expression in malignant cells is variable.  Suppressed catalase levels in comparison to healthy 
cells of the corresponding organ have been observed in a number of malignancies; conversely, 
high catalase expression has been demonstrated in certain aggressive malignancies with 
pronounced resistance to chemotherapy and radiotherapy (gliomas, mesotheliomas). Of note, 
up-regulation of catalase seems to mediate resistance to prolonged treatment with oxidising 
agents (cisplatin, ionising radiation, bleomycin) in vitro (Glorieux et al., 2015). 
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1.3.8 ROS modulation as a treatment strategy in oncology 
1.3.8.1 Chemotherapy  
Cytotoxic chemotherapy has been the mainstay of advanced cancer treatment since 1945. A 
broad range of chemotherapy agents have been developed since then, with various molecular 
mechanisms of action largely converging to a single output: inhibition of cell division. A 
number of commonly used cytotoxic chemotherapy agents have the additional capacity to 
induce oxidative stress, an effect to which part of their therapeutic potential has been ascribed 
(Table 1-6). It should be noted that these drugs’ impact on redox balance is rather a 
secondary effect, alongside the primary molecular toxicity mechanisms on whose grounds 
they were originally developed (e.g. disruption of DNA replication, disruption of mitotic 
spindle). Consequently, it is difficult to ascertain how much of the cytotoxic effect is directly 
attributable to oxidative stress. A classic example of a routinely used chemotherapy agent 
which also acts as oxidative stressor is doxorubicin. Doxorubicin is an anthracycline 
compound used in the treatment of various cancer types, including ACC, by virtue of its 
ability to disrupt DNA synthesis. It has also been shown that doxorubicin acts as a ‘redox 
cycler’: it reacts with flavoprotein reductases (e.g. NADPH:quinine oxidoredictase – NQO1) 
and generates superoxide, especially when intracellular NADPH is low. Doxorubicin also 
contributes to intracellular iron chelation, which may eventually generate highly reactive 
hydroxyl radicals through a Fenton type reaction (Kotamraju et al., 2002). 
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Drug Effect on redox 
balance 
Other cytotoxic 
effects 
Reference 
Arsenic trioxide ROS generation, 
oxidation of reduced 
glutathione 
Degradation of the 
promyelocytic 
leukaemia protein 
(Fruehauf and 
Meyskens, 
2007, Lu et al., 
2007) 
Bleomycin Metal-dependent 
ROS generation 
Disruption of cellular 
division 
(Chen and 
Stubbe, 2005, 
Chow et al., 
2008) 
Cisplatin ROS generation, 
ROS-triggered 
apoptosis 
DNA damage (Berndtsson et 
al., 2007) 
Anthracyclines 
(doxorubicin, 
epirubicin) 
ROS generation, 
ROS-triggered 
apoptosis 
Disruption of cellular 
division 
(Wondrak, 
2009) 
Topoisomerase II 
inhibitors 
(etoposide) 
ROS generation, 
ROS-triggered 
apoptosis 
Inhibition of DNA 
replication 
(Oh et al., 2007) 
Taxanes (paclitaxel, 
docetaxel) 
ROS generation, 
ROS-triggered 
apoptosis 
Inhibition of mitotic 
spindle formation 
(Alexandre et 
al., 2006, 
Alexandre et al., 
2007) 
 
 Chemical induction of oxidative stress with a view to inducing cell death has been used as a 
strategy to develop novel anti-cancer agents in experimental oncology in the last two decades. 
This can be effectuated either through direct ROS generation or abrogation of antioxidant 
Table 1-6 Approved chemotherapy agents which can induce oxidative stress. Source:  
(Montero and Jassem, 2011).  Adapted and reproduced with permission of Springer. 
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pathways. As described above, malignant cells are characterised by higher baseline ROS 
levels than healthy cells, which brings them closer to the toxic threshold beyond which cell 
death is triggered. Therefore this treatment strategy is expected to exert a selective toxic effect 
on cancer cells (Gupta et al., 2012, Fruehauf and Meyskens, 2007, Trachootham et al., 2006). 
Novel agents currently under study which act as exogenous ROS inducers include redox 
cyclers (MGd), iron chelators (Dp44mT) and electron transfer chain modulators (arsenic 
trioxide) (Trachootham et al., 2009). Elesclomol is another ROS generator that received 
considerable attention after prolonging recurrence-free survival in malignant melanoma 
patients (phase II trial). The drug (used in combination with paclitaxel) had to be withdrawn 
due to concerns regarding unacceptable toxicity in phase III trials (Kirshner et al., 2008). 
The limitation of exogenous ROS induction in oncology is that cancer cells, especially in 
aggressive/ advanced disease types, can be notoriously adaptable to environmental challenges, 
including oxidative stress. Up-regulation of antioxidant defence mechanisms can result in the 
development of resistant phenotypes (Fruehauf and Meyskens, 2007, Trachootham et al., 
2009). An alternative ROS-centred strategy involves antioxidant pathway inhibition, aiming 
to provoke a gradual accumulation of endogenous ROS. This option has been explored both 
as monotherapy and as part of combination chemotherapy, with a view to enhancing cellular 
sensitivity to oxidative stress (Fruehauf and Meyskens, 2007, Watson, 2013). ROS 
scavenging pathways targeted so far include: 
The glutathione pathway, largely considered the most important pillar of cellular antioxidant 
defence. Up-regulation of glutathione synthesis (e.g. glutathione sulfotransferase) often 
accompanies malignancy and is associated with tumour aggressiveness (Hsu et al., 2002). A 
number of agents have been developed to target glutathione synthesis and action (Renschler, 
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2004, Trachootham et al., 2006, Trachootham et al., 2009).  BSO (buthionine sulfoximine) is 
an inhibitor of GSH synthesis which has demonstrated in vitro ability to suppress growth in 
pancreatic cancer cells, reverse BCL-2-mediated cisplatin resistance in breast cancer cells and 
enhance oxidative stress-induced cytotoxicity in leukemic cells (Schnelldorfer et al., 2000, 
Rudin et al., 2003). In vivo, BSO enhanced the cytotoxic effects of melphalan and arsenic 
trioxide (both intracellular ROS inducers) in xenograft models of multiple myeloma and solid 
tumours (Tagde et al., 2014, Maeda et al., 2004). Beta-phenylethyl-isothiocyanate. (PEITC) is 
another agent which depletes reduced glutathione and inhibits glutathione peroxidase. Anti-
tumour activity has been demonstrated in vitro in ovarian cancer, leukaemia and 
osteosarcoma models (Trachootham et al., 2009, Gupta et al., 2012).  NOV-002 is a 
compound that decreases the intracellular ratio of reduced to oxidised glutathione. It has 
demonstrated an in vitro capacity to suppress cellular proliferation and invasion, through 
interference with redox signalling pathways. Clinically, it has shown promising cytotoxic 
effects in combination treatment regimens in phase II clinical trials on non-small cell lung 
cancer, breast cancer and ovarian cancer. In a phase III trial however, it failed to demonstrate 
any additional cytotoxic activity in combination with paclitaxel and carboplatin in non-small 
cell cancer patients (Uys et al., 2010, Townsend and Tew, 2009, Montero et al., 2012, 
Gumireddy et al., 2013, Montero and Jassem, 2011).  
Drugs inhibiting glutathione-S-transferase have also been developed: canfosfamide and 
ezatiostat hydrochloride. Confosfamide was used successfully in combination with 
carboplatin/ paclitaxel for advanced non-small cell carcinoma, but failed to demonstrate 
superiority to routine chemotherapy as third line chemotherapy in advanced ovarian 
carcinoma (Sequist et al., 2009, Vergote et al., 2009). Ezatiostat has been applied in the 
treatment of myelodysplastic symptoms and was beneficial improving haematological 
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parameters and reducing transfusion needs in a substantial proportion of patients (Raza et al., 
2009). Finally, Imexon is another developing agent that depletes reduced glutathione. 
Correlation of efficiency against beta-cell lymphoma with tumour expression levels of 
glutathione peroxidase and superoxide dismutase 2 has been demonstrated (Barr et al., 2014).  
The thioredoxin pathway. Considerable effort has been recently expended on targeting this 
antioxidant pathway, given its habitual up-regulation in cancer cells which is associated with 
a more aggressive clinical course (Trachootham et al., 2009, Ceccarelli et al., 2008, Kaimul et 
al., 2007). Agents targeting this pathway include PX-12, Dimensa, motexafin gadolinium and 
arsenic trioxide (Montero and Jassem, 2011, Gupta et al., 2012, Trachootham et al., 2009). 
PX-12 irreversibly inhibits thioredoxin type I. It has been used in clinical trials (phase II) 
against advanced pancreatic cancer; its effect on progression-free survival, however, was 
evidently inferior to standard second line chemotherapy agents (Kona et al., 2011, Baker et 
al., 2013). Auranofin, a gold complex agent traditionally used in rheumatoid arthritis, is also 
able to act as a thioredoxin reductase inhibitor. It has displayed cytotoxicity against a number 
of cell lines in vitro (e.g. melanoma, leukemia, lung cancer) as well as lung cancer in vivo 
(Cox et al., 2008, Gandin et al., 2010, Park and Kim, 2005, Talbot et al., 2008). Dimensa is a 
novel disulphide drug which inhibits thioredoxin reductase and glutathione reductase. It has 
demonstrated clinical efficacy at prolonging progression-free and overall survival in patients 
with metastatic non-small cell lung carcinoma in phase II and III clinical trials (Montero and 
Jassem, 2011). Motexafin gadolinium inhibits thioredoxin reductase and transfers electrons 
from antioxidant molecules (NADPH, glutathione, ascorbate) to oxygen. A phase III clinical 
trial of motexafin in combination with radiotherapy in non-small cell lung cancer patients 
with brain metastases showed promising results (Mehta et al., 2009). Finally, arsenic trioxide 
(As2O3) is a cytotoxic agent which can induce major redox perturbations through superoxide 
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generation, thioredoxin reductase inhibition and interference with mitochondrial respiration 
(Jing et al., 1999, Maeda et al., 2004, Niu et al., 1999, Shen et al., 1997, Pelicano et al., 2003, 
Lu et al., 2007). As2O3 efficacy against promyelocytic leukaemia has been demonstrated in a 
number of in vitro studies, as well as phase III clinical trials (Lo-Coco et al., 2013). In vitro, it 
has also been used successful against other types of CLL and ALL, as well as in neuronal, 
liver and lung cancer cell lines (Gupta et al., 2012). 
Superoxide dismutase (SOD). SOD catalyses the conversion of superoxide to hydrogen 
peroxide, which can then be detoxified to water by the various antioxidant pathways 
(glutathione, peroxiredoxin, catalase). SOD inhibitors used in clinical trials include ATN-224 
and 2-methoxyestradiol.  ATN-224 has displayed modest efficacy against recurrent prostate 
cancer in phase II clinical trials (Lin et al., 2013). 2-methoxyestradiol (2-ME) showed some 
anti-tumour effect against metastatic carcinoid tumours in combination with procarbazine in 
phase II clinical trials; conversely, it failed to show clinical efficacy against metastatic renal 
cell carcinoma and recurrent prostate cancer (James et al., 2007, Sweeney et al., 2005). 
Another intriguing strategy which has been tentatively explored in recent years involves 
combination of two redox ‘hits’ to limit the possibility of successful metabolic adaptation, 
especially in highly resistant tumour types. A classic example of this approach is the use of 
ascorbic acid -resulting in glutathione depletion- to enhance arsenic trioxide cytotoxicity in 
refractory multiple myeloma (Bahlis et al., 2002). In vitro, introduction of arsenic trioxide 
alongside 2-ME reversed leukemia cell resistance to 2-ME (Zhou et al., 2003). Similarly, the 
combination of BSO with auranofin (thioredoxin reductase inhibitor) resulted in impressive 
synergy against glioblastoma cells (Sobhakumari et al., 2012). An obvious concern with such 
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approaches is the potential side effects of combined redox manipulation; future clinical data 
will be required before this question can be convincingly answered.  
 
1.3.8.2 Radiotherapy  
Radiotherapy is used in oncology to suppress proliferation and induce apoptotic death of 
malignant cells. A number of in vitro and in vivo studies in various cancer types (breast, lung, 
prostate cancer) have indicated that part of this cytotoxic effect is due to oxidative stress 
induction by radiotherapy (Di Pietro et al., 2006, Gordan et al., 2007, Shil et al., 2005, Gupta 
et al., 2012). Findings from clinical studies have also been in support of this concept (Bhosle 
et al., 2002, Gupta et al., 2010, Jones et al., 2011). On these grounds, employing drugs that 
generate ROS or interfere with antioxidant pathways may be an attractive ancillary strategy to 
enhance radiotherapy sensitivity. This concept has been successfully applied in a range of 
tumours in recent studies (Gupta et al., 2012). 
 
 
1.4 Summary, hypotheses and project objectives 
1.4.1 In vitro work to evaluate NNT as a novel therapeutic target in ACC 
ACC is a rare but aggressive malignancy, with the majority of patients presenting with, or 
eventually developing, metastatic disease (Libe, 2015, Else et al., 2014, Fassnacht and 
Allolio, 2011). No current medical treatments are particularly efficient at controlling disease 
progression. A recent randomised-controlled trial revealed a dismal median survival of < 15 
months for patients with disseminated disease receiving combination chemotherapy, 
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underscoring the urgent need to develop more effective management strategies (Fassnacht et 
al., 2012). Unfortunately, the rapid progress in our understanding of the genetic make-up and 
molecular biology of ACC in the last two decades has so far failed to enrich the meagre 
pharmacological armamentarium of attending clinicians (Libe, 2015). 
Recent studies revealed that inactivating mutations of genes encoding mitochondrial 
antioxidant enzymes (NNT, TXNRD2) cause a rare, hereditary form of primary adrenal 
insufficiency (Familial Glucocorticoid Deficiency), interestingly manifesting in isolation 
without involvement of other target organs (Meimaridou et al., 2012, Prasad et al., 2014a). 
These findings suggest a selective susceptibility of the adrenal glands to oxidative stress. It is 
still unclear whether the adrenal insufficiency of these patients results from oxidative stress-
induced adrenocortical cell death, functional inhibition of steroidogenesis or a combination 
thereof. Oxidative stress also represents a known area of metabolic vulnerability in cancer cell 
biology. Malignant cells have constitutively higher levels of oxidative stress than healthy 
cells; antioxidant pathway targeting has been employed successfully as a treatment strategy in 
a number of in vitro and in vivo studies in various cancer types, but never in ACC (Gupta et 
al., 2012, Trachootham et al., 2009). The objective of such approaches is to increase 
intracellular oxidative stress, leading to oxidative cell toxicity and, eventually, triggering cell 
death. 
Within this context, the first aim of this project is to explore the value of antioxidant targeting 
as a therapeutic approach in ACC, focusing on NNT as a putative treatment target. 
Therapeutic merit may be afforded either by inhibition of cell proliferation or suppression of 
steroidogenesis.  My specific hypotheses are outlined below: 
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Hypothesis 1: NNT silencing in ACC cells will induce deleterious oxidative stress, resulting 
in cell death and/or impaired cellular proliferation (Fig. 1-21). 
I will explore this hypothesis in vitro using NCI-H295R ACC cells, the only existing human 
immortalised ACC cell line, with the following approaches juxtaposing different temporal 
frames: 
a) I will acutely inhibit NNT expression [transient NNT knockdown by small interfering 
RNA (siRNA) transfection] and evaluate the immediate effects of this manipulation 
on cellular redox balance, mitochondrial respiration, cell proliferation and apoptotic 
rates.  
 
b) I will chronically inhibit NNT expression [stable NNT knockdown by short hairpin 
RNA (shRNA) transfection] and evaluate the longer-term effects of this manipulation 
on the same outputs. 
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Figure 1-22 A) NNT as a mitochondrial NADPH generator feeding the antioxidant pathways 
B) Hypothesis 1: NNT inhibition is expected to compromise the mitochondrial pool of 
NADPH, disrupting the function of the mitochondrial antioxidant pathways. The consequent 
accumulation of H2O2 will increase oxidative stress and eventually trigger cellular apoptosis. 
ETC: electron transfer chain; ATP: adenosine triphosphate; GSR: glutathione reductase; 
GSSG: oxidised glutathione; GSH: reduced glutathione; GPX1: Glutathione peroxidase 1; 
TXNRD2: thioredoxin reductase 2; TXN: oxidised thioredoxin; TXN-SH: reduced 
thioredoxin; GPX3: peroxiredoxin 3; O2
.-: superoxide; H2O2: hydrogen peroxide                 
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Hypothesis 2: NNT silencing in ACC cells will inhibit steroidogenesis  
I propose to explore this hypothesis in vitro using NCI-H295R ACC cells, which have long 
been established as the main cell model of human adrenal steroidogenesis, using the following 
approaches: 
a) I will acutely inhibit NNT expression (transient NNT KD by siRNA transfection) and 
evaluate the immediate impact of this manipulation on steroidogenesis through a 
combination of gene expression analysis (real-time PCR) and comprehensive steroid 
profiling in cell media by liquid chromatography/ tandem mass spectrometry (LC-
MS/MS).  
b) I will chronically inhibit NNT expression (stable NNT KD by shRNA transfection – 
duration: weeks/months) and evaluate the longer-term effects of this manipulation on 
steroidogenesis by gene expression analysis and steroid profiling (Fig. 1-22). 
                  
 
 Figure 1-23 Overview of in vitro project objectives 
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1.4.2 Clinical study to provide proof-of-concept for the use of urine steroid 
metabolomics in detecting ACC recurrence 
Adrenocortical carcinoma is a rare (incidence 1-2 cases/ million/ year) but aggressive 
malignancy. Disease recurrence rates are high, exceeding 50% even in patients with 
microscopically complete (R0) resection, necessitating close follow-up in all cases for several 
years (Libe, 2015, Else et al., 2014). Cross-sectional imaging remains the mainstay of the 
surveillance strategy, but has important disadvantages including cost, prolonged radiation 
exposure and frequent diagnostic ambiguity in early stages of recurrent/ metastatic disease 
(Cawood et al., 2009). Early detection of disease recurrence is important, as it may allow 
either radical re-do surgery in cases of limited metastatic disease volume, or early institution 
of mitotane and/or cytotoxic chemotherapy, potentially prolonging survival (Libe, 2015, Else 
et al., 2014, Erdogan et al., 2013, Datrice et al., 2012, Mihai, 2015, Schulick and Brennan, 
1999). 
Most ACCs are biochemically active, but tend to present an immature steroidogenic pattern 
characterized by abundance of steroid precursor metabolites (Arlt et al., 2011). This pattern 
appears to be a distinguishing feature of ACC that can be diagnostically relevant. Urine 
steroid profiling by gas chromatography-mass spectrometry (GC-MS) in conjunction with 
sophisticated machine learning analysis (steroid metabolomics) has recently been introduced 
as a sensitive and specific biomarker tool for the original diagnosis of primary ACCs in a 
large retrospective study (Arlt et al., 2011). Building on these promising results, I intend to 
explore the value of this approach as a surveillance tool to detect disease recurrence in 
patients who have undergone complete ACC resection. 
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Hypothesis 3: Urine steroid metabolomics can be employed diagnostically to detect disease 
recurrence in patients who have undergone complete ACC resection. 
To test this hypothesis, we collected longitudinal 24-h urine samples from ACC patients 
having undergone complete (R0) resection of their tumour and used gas chromatography/ 
mass spectrometry to derive comprehensive steroid profiles. Collaboration with several major 
adrenal centres in Europe facilitated the accretion of a sizeable cohort of operated ACC 
patients. I will evaluate the diagnostic performance of machine learning analysis of these 
profiles at detecting disease recurrence by the time of its first radiological manifestation.
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2 General Methods 
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2.1  Description of adrenocortical carcinoma cell line (NCI-H295R) and cell 
line validation 
NCI-H295R adrenocortical carcinoma cells were provided as a gift by Professor Enzo Lali 
(University of Nice, France). This cell line was initially established in late 1980s from a 
female patient with ACC, which later metastasised (Gazdar et al, 1990). The parental cell line 
(NCI-H295) represented a mixed cell population from the original tumour; to circumvent the 
problem presented by the slow growth of these cells, a sub-population of cells able to grow in 
a monolayer was selected over a period of 3 months during which cells were repeatedly 
flushed with growth medium. The new cell line (NCI-H295R)  expresses all major human 
steroidogenic enzymes, including CYP11A1, CYP11B1, CYP17A1, CYP21A2, CYP11B2 
and HSD3B2, and secretes all 3 classes of adrenocortical steroid hormones (glucocorticoids, 
mineralocorticoids and androgens) (Wang and Rainey, 2012, Xing et al., 2011). NCI-H295R 
cells respond well to angiotensin II and K+ as inducers of mineralocorticoid synthesis but are 
minimally responsive to ACTH. This problem can be overcome by use of either forskolin 
(adenyl cyclase activator) or CAMP analogues. NCI-H295R cells were cultured under 
standard conditions using Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s F-12 
medium (Gibco, Thermo Fisher) supplemented with 2.5% Nu serum (Sigma), 1% penicillin-
streptomycin (Gibco, Thermo Fisher) and 1% ITS+ universal cell culture premix (BD 
Biosciences). ITS+ is a proliferation-promoting supplement containing human insulin, human 
transferrin, selenous acid, BSA and linoleic acid. Media was refreshed twice weekly. Cells 
were grown in 25cm2 or 75 cm2 cell culture flasks (Corning) and split to new flasks when 
they reached 70-80% confluence. Splitting involved washing with Phosphate-Buffered Saline 
(Sigma) followed by addition of 2 ml trypsin (Thermo Fisher) and incubation at 37oC for 2 
min. Trypsin was inactivated by addition of cell media; cells were centrifuged at 12,000 rpm 
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for 5 min. The resulting pellet was re-suspended in cell media and transferred to new flasks 
using a 1:3–1:5 ratio. During experimental work described in the succeeding sections, 6-well 
plates (Corning) and 96-well (Falcon) cell culture plates were also used.  All experiments 
were performed using passage numbers 10-25.  
 
 
 
Cell line identity was confirmed through Short Tandem Repeat (STR) genetic analysis 
performed by the DNA Diagnostics Company (London, UK) followed by comparison to 
genetic profiles provided by the American Tissue Culture Collection (ATCC) ( 
http://www.lgcstandards-atcc.org). STRs are microsatellite DNA areas consisting of series of 
2-13 nucleotides repeated several times in a row. Analysis identifies the number of repeats for 
each STR; combination of multiple STRs generates a profile which is unique for each cell 
line.   
 
Figure 2-1 Microscopic caption (10x) of NCI-H295R cells growing in a 6-well plate. 
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2.2 Gene expression   
2.2.1 RNA extraction 
RNA extraction was performed using the RNeasy mini kit (Qiagen) following the 
manufacturer’s instructions. The kit uses a silica-based membrane and a high-salt buffer 
system which allows purification of RNA molecules comprising > 200 nucleotides from cell 
lysates. Cells were grown in 6-well plates at loading concentrations of 300,000 – 500,000 
cells/ well, and cultured for 1-9 days prior to RNA extraction.  At the selected time-points, 
cells were washed with Phosphate Buffered Saline and detached by tapping after incubation 
with 500 µl trypsin for 2 minutes at 37oC. Trypsin was inactivated by addition of quadruple 
volumes of serum-replete culture media and cells were pelleted with 5-10 min centrifugation 
Figure 2-2. Genetic STR analysis of H295R cells used in this project, including 22 highly 
polymorphic areas (loci). Number of sequence repeats is indicated for each locus. 
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at room temperature (12,000 rpm). Supernatant was removed and pelleted cells were 
disrupted by mixing with 350 µl RLT buffer, supplemented with 1% β-mercaptoethanol 
(Sigma-Aldrich). Cells were homogenised using a sterile, 21-gauge needle (10 aspirations per 
sample) and then diluted with 350 µl of 70% ethanol in de-ionised H2O to promote selective 
binding of RNA to the RNeasy membrane. Samples were transferred to spin columns and 
centrifuged at 15,000 rpm for 15 seconds. Subsequently, 700 µl RW1 buffer was added to 
each column and samples were centrifuged at 15,000 rpm for 15 seconds. 500 µl of RPE 
buffer was next loaded to each column, followed by centrifugation at 15,000 rpm for 15 
seconds and, after reloading 500 µl RPE, for 2 min. The follow-through was decanted after 
each centrifugation. To minimise ethanol carry-over, spin columns were then transferred to 
new microtubes and centrifuged for an additional minute. Finally, 30 µl of RNase-free water 
was added to each column and centrifuged at 15,000 rpm for 1 minute. The follow-through 
solutions, containing all eluted RNA, were collected in 1.5 ml Eppendorf tubes and stored at -
20oC, or -80oC for prolonged storage. RNA concentration was determined by 
spectrophotometry (Labtech Nanodrop Spectrophotometer ND-1000), by addition of 1.5 µl of 
each RNA sample. A 260/280 nm absorbance ratio of at least 2 was considered suggestive of 
satisfactory RNA purity. 
 
2.2.2 Reverse transcription 
Reverse transcription to generate complementary DNA (CDNA) was carried out using the 
TetrocDNA Synthesis Kit (Bioline), following the manufacturer’s instructions. 200ng - 2µg 
CDNA (volume up to 12 µl) were added to 8 µl of a reaction mix, consisting of 1µl reverse 
transcriptase, 1µl oligo(dT)18 primer, 1 µl dNTP mix, 1 µl Ribosafe RNAse inhibitor and 4 µl 
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Reverse Transcription Buffer. Total volume was complemented to 20 µl by addition of 
nuclease-free water if required. Reactions were incubated at 45oC for 30 min, followed by 
heat-blocking at 85oC for 5 min to terminate. All handling of RNA and CDNA samples was 
performed on ice, to avoid nucleic acid degradation. 
 
2.2.3 cDNA concentration measurement 
cDNA concentration was measured using a fluorescent DNA dye (Picogreen assay®, 
Invitrogen). The assay is based on a fluorescent DNA dye (Quant-iT™ PicoGreen® dsDNA 
reagent) which allows accurate estimation of cDNA concentration by comparison of sample 
fluorescence to the fluorescence exhibited by a dilution series of DNA samples with known 
concentrations (standard curve). Samples to be measured were loaded to a flat-bottomed 96-
well plate with transparent wells (Corning) at a volume of 1 µl/ well, and diluted in 99 µl of 
buffering solution (1xTE). A standard curve was prepared by serial dilutions of a stock cDNA 
solution (2 mcg/ml) in 1x TE buffer, to end-concentrations of 0, 10, 100 and 1,000 ng/ml. The 
fluorescent DNA dye was diluted 200x in TE and added to all wells at a volume of 100 µl/ 
well. After 5 min incubation at room temperature, fluorescence was measured (excitation 480 
nm, emission 520 nm) (Wallac Victor 1420 multilabel counter) and cDNA concentrations 
were determined based on fluorescence readings, using an equation derived from the standard 
curve. Results were multiplied by 200 to derive the cDNA concentration in the samples of 
interest. 
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2.2.4 Real-time PCR 
Gene expression (NNT and steroidogenic enzymes) was quantified by Real-Time polymerase 
chain reaction (qPCR), using TaqmanTM Gene Expression Assays (Thermo Fisher). With 
Real-Time PCR, the DNA template of interest is subjected to consecutive cycles of 
replication by use of sequence-specific primers, with synchronous measurement of the end-
product at the end of each cycle by fluorescence. The higher the concentration of the specific 
sequence (template) in the original sample, the earlier the cycle in which fluorescence first 
becomes detectable. With this principle, serial measurements of template fluorescence during 
the exponential replication phase allow reliable estimation of DNA concentration in the 
original sample. 
Each replication cycle consists of 3 steps:  
- Denaturation. During this step, high temperature is applied (typically 95oC) to ‘melt’ 
double-stranded DNA to single-stranded DNA.  
- Annealing. This step allows the primers to hybridize with their complementary 
sequences within the single strands of DNA. The temperature in this stage must be 
lower than the melting temperature of the primers.  
- Extension. At this stage DNA polymerase extends the primers, leading to replication 
of the sequence/ gene of interest. Typical temperatures at this stage range from 60-
72oC. In this project, annealing and extension stages were combined to a 1 min 
incubation at 60oC per cycle. 
With TaqMan technology, fluorescence emission is accomplished by use of specially 
designed probes. Each probe is complementary to a sequence within the gene of interest, 
where it promptly binds during annealing, downstream of the primer. The 5’ end of the probe 
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has an attached ‘reporter’ fluorescent dye, while the 3’ end has a ‘quencher’ dye of different 
wavelength, which quenches the reporter fluorescence. During replication cycles, DNA 
polymerase cleaves the probes that are attached to the DNA template releasing the reporter, 
whose fluorescence can now be emitted. The earliest cycle in which emitted fluorescence 
exceeds the threshold of ‘significant’ detection is termed Ct, and is inversely related to the 
original template concentration in the sample of interest. Gene expression is normalised to a 
housekeeping gene, i.e. a gene which is constitutively expressed in high levels in all human 
tissues.   
All reactions were carried out at a total volume of 12 µl, comprising: 
• 1-4 µl of cDNA (10-100 ng) 
• 8-11 µl of a reagent mix consisting of 2xTaqman Universal PCR Master mix (Thermo-
Fisher), probe-primer mix for gene of interest and housekeeping gene RPLPO 
(Thermo-Fisher) and nuclease-free water, using the following ratio: 6.25 µl Taqman 
Master Mix: 0.625 µl probes: 4 µl nuclease-free water. 
10-50 ng of cDNA were used per reaction, with the proviso that loading cDNA mass in all 
wells should be equal within each plate.   Reactions were run in a 7500 ABI qPCR analyser 
[50oC incubation for 2 minutes, 95oC incubation for 10 minutes, followed by 40 cycles of 
95oC incubation for 15 seconds (denaturation) then 60oC for 1 minute (annealing-extension)]. 
All reactions were normalised against the housekeeping gene RPLPO (large ribosomal 
protein). Data were expressed as the cycle number at which logarithmic PCR plots cross a 
calculated threshold line (Ct values) and used to determine ΔCt values [ΔCt= (Ct of the target 
gene) – (Ct of the housekeeping gene)].  To compare gene expression between a sample of 
interest and a control sample, ΔΔCt values were used, defined as ΔΔCt= ΔCt (sample) – ΔCt 
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(control). Results were also expressed as fold change in gene expression to control, derived 
using the equation fold change = 2-ΔCt. 
 
2.3 Protein expression 
2.3.1 Protein lysate generation 
Protein lysates were generated applying RIPA buffer (Sigma) with protease inhibitor cocktail 
(Sigma) to adherent cells grown in 6-well plates (30 µl of protease inhibitor cocktail per 1ml 
RIPA Buffer; 150 µl RIPA per well). Wells were washed with PBS before RIPA addition. 
Plates with RIPA were incubated on ice for 5 min. Cells were then detached by scraping and 
stores at -80oC for at least 1 h. Samples were subsequently thawed on ice and centrifuged for 
10 minutes at 8,000 g (4oC), followed by collection of the supernatant.  Lysates were stored at 
-80oC. 
 
2.3.2 Protein concentration measurement 
Total protein concentration was determined colorimetrically using the BCA Protein Assay Kit 
(Thermo Fisher) as per the manufacturer’s instructions. The reaction on which the assay is 
based involves protein-mediated reduction of Cu2+ to Cu+ in an alkaline environment; 
bicinchoninic acid (BCA) then reacts with Cu+ to generate an end-product that can be detected 
colorimetrically, generating strong absorbance at 562 nm.  4 µl of each protein sample were 
loaded to flat-bottomed, transparent-walled 96-well plates. A standard curve was prepared 
using serial dilutions of a stock protein solution to generate concentrations of 0 – 2,000 µg/ml. 
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BCA reagent B was added to reagent A using a 1:50 ratio, and the mix was added to wells at a 
volume of 76 µl/ well. After 30 min incubation at 37oC for 30 min, absorbance was measured 
at 560 nm using a Wallac Victor 1420 multilabel counter. 
 
2.3.3 Western Blotting 
 Protein expression was assessed using Western Blotting. Western Blotting involves 
separation of denatured proteins as they travel through a gel across an electric current, 
followed by detection of the protein of interest by use of protein-specific antibodies. 
 Sample volumes corresponding to 7.5 - 15 µg of protein were mixed with equal volumes of 
1x Laemmli buffer (Bio-rad), containing SDS (sodium dodecyl sulfate) detergent [475 ml 1x 
Laemmli buffer (Bio-rad) mixed with 25 µl 2-mercaptoethanol (Sigma)]. SDS induces protein 
denaturation and gives polypeptides a negative charge to facilitate separation; 2-
mercaptoethanol is added to reduce intra- and inter- molecular bonds. Samples were loaded to 
10% SDS-PAGE (polyacrylamide) Gels (Thermo Fisher) and subjected to electrophoresis at 
80 V for 15 min and 140 V for 90 min; this step achieves protein separation along the gel 
according to molecular weight. A mix of ten multicolour recombinant protein standards 
(Precision Plus ProteinTM KaleidoscopeTM Standards, Bio-Rad) was used as a guide (‘ladder’) 
to indicate molecular weight. Proteins were then transferred to a nitrocellulose membrane 
using the iBLOTTM Dry Transfer System (Thermo Fisher), a method which allows buffer-free 
transfer within 7 min.  
Membranes were washed with Tris-Buffered saline with Tween 20 (TBS-T; recipe: 50 ml 
Tris-HCL, 20g NaCl, 0.625 ml Tween80, 2447 ml deionized H2O), followed by overnight 
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incubation in TBS-T with 5% milk at 4oC overnight to reduce non-specific antibody binding. 
The next day, after 3 x 5 min washes with TBS-T, membranes were probed for 60 minutes 
with anti-NNT antibody produced in rabbit (HPA004829, Sigma), and diluted in tris-buffered 
TBS-T at a 1:500 dilution. After 3x15 min washes with TBS-T, membranes were probed with 
secondary anti-rabbit antibody, horseradish peroxidase (HPR) and alkaline phosphatase-
conjugated (sc-2030, Santa-Cruz), for 60 min (1:2000 dilution in TBS-T). After a further 
series of TBS-T washes, membranes were imbued with ECL. ECL is a chemiluminescent 
agent that reacts with HPR, allowing detection of the primary-secondary antibody complexes 
attached to the membrane. This was accomplished simply by exposing an X-Ray film to the 
membrane in a cassette protected from light, followed by film developing. Developing times 
of 20-30 mins were usually required to produce strong bands. 
B-actin was used as control protein, to normalise NNT expression to the actual protein load. 
Primary and secondary antibodies were stripped off by 2x10 min washes in a stripping buffer 
(15g Glycine, 1g SDS, 2.5 ml Tween80, 1L deionised H2O), followed by incubation with 
milk and antibodies as detailed above. Primary antibody for β-actin (produced in mice) was 
purchased from Sigma and used at a 1:10,000 dilution in TBS-T. Secondary antibody (anti-
mouse) was purchased from Santa-Cruz and was used at 1: 20,000 dilution. 
Initial Western Blotting attempts were unsuccessful, with no NNT bands despite strong β-
actin binding. These attempts involved a boiling step, whereby protein samples in Laemmli 
buffer were boiled at 95oC for 5 min before loading to the gel, to complete the process of 
protein denaturation and render the sample easier to load to the gel (less viscous). The 
problem resolved, and NNT bands started to appear, once this step was omitted from the 
protocol. 
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Ultra-Glo  rLuciferase + ATP 
2.4 Redox state 
The ratio of reduced to oxidized glutathione was used as a marker of intracellular oxidative 
stress in this work; the ratio is inversely proportional to oxidative stress (Sun et al., 1997, 
Rebrin and Sohal, 2008). Reduced glutathione (GSH), oxidized glutathione (GSSG) and total 
glutathione were measured by luminescence, using the GSH/GSSG-GloTM Assay (Promega) 
according to the manufacturer’s instructions. The assay takes place in white, opaque-walled 
96-well plates (Perkin-Elmer) and generates a luminescent signal which is proportional to the 
amount of reduced glutathione present in the well. This is achieved by use of a GSH-
dependent luciferin probe according to the following series of reactions: 
GSH + Luciferin-NT                                                 GSH-NT + Luciferin 
Luciferin                                               Light 
These reactions are used to measure total glutathione or oxidised glutathione separately, using 
two distinct biochemical manipulations after cell lysis (Fig. 2-3). To measure total 
glutathione, oxidised glutathione is first reduced to GSH, so that the end amount of GSH 
within the well represents the original sum of intracellular GSH and GSSG. To measure 
GSSG, GSH is blocked with N-ethylmaleidine (NEM), followed by GSSG reduction to GSH. 
This way, luminescence eventually reflects intracellular GSSG only. 
 
 
Glutathione sulfotransferase 
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Before the assay, NCI-H295R cells were grown in white, opaque-walled 96-well plates.  
Triplicate samples were assayed for total glutathione or GSSG after medium removal. 2 wells 
were pre-treated with Menadione (Sigma) 40 µM for 2 hours to induce oxidative stress as 
positive controls. First, cells were lysed by addition of 50 µl of either Total Glutathione 
Reagent (1 µl Luciferin-NT + 10 µl Passive Lysis Buffer + 39 µl deionised H2O) or Oxidised 
Glutathione Reagent (1 µl Luciferin-NT + 10 µl Passive Lysis Buffer + 0.5 µl NEM + 38.5 µl 
deionized H2O). After 5 minutes, an equal volume of Luciferin Generation Reagent was 
added, consisting of 1.25 µl 100 mm DTT, 3 µl Glutathione-S-Transferase and 45.75 µl 
Glutathione Reaction Buffer. After 30 min incubation, wells were treated with Luciferin 
Detection Reagent (100 µl/well) for 15 mins and luminescence was measured in a Wallac 
Figure 2-3 The GSH/GSSG-GloTM assay (Promega). GSH: reduced glutathione; GSSG: 
oxidized glutathione; GLR: glutathione lysis reagent. Adapted and reproduced with 
permission of Promega. 
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Victor 1420 multilabel counter. Blank measurements (no cells) were subtracted from sample 
values to produce net results. GSH /GSSG ratios were calculated directly from Net Relative 
Luminescence Units (RLU) measurements using the equation GSH/GSSG ratio = [Net total 
glutathione RLU-Net GSSG RLU]/ [Net GSSG RLU/2].  
 
2.5 Metabolic Flux Analysis (Seahorse XF) 
Metabolic Flux analysis was employed to assess the effect of NNT knockdown on 
mitochondrial bioenergetics, using the Seahorse XF 24 Analyser. Seahorse Analysers have 
the ability to measure changes in oxygen and proton concentration in a minute volume (< 2 
µL) of medium above a cell monolayer within a microplate, by use of solid-state sensor 
probes residing 200 microns above the cell monolayer. Changes in oxygen concentration 
provide the oxygen consumption rate (OCR), reflective of mitochondrial respiration. Changes 
in proton concentration (or pH) provide the extracellular acidification rate (ECAR), reflective 
of the rate of anaerobic glycolysis (glycolysis leads to the production of lactate, which 
increases extracellular proton concentration). Measurements are taken automatically at 
intervals of approximately 5-8 minutes until the rate of change is linear; the slope is then 
calculated and used to determine OCR and ECAR. Once a measurement is completed, the 
probes lift to allow the larger supernatant medium volume to mix with the medium in the 
‘transient microchamber’, restoring cell values to baseline. Up to four treatment compounds 
can be added sequentially at regular intervals through an integrated drug delivery system. For 
this project, the Seahorse XF Cell Mito Stress Test was used to measure a number of key 
parameters (Basal respiration, ATP-linked respiration, H+ (Proton) Leak, Maximal 
Respiration, Spare Respiratory Capacity, and Non-mitochondrial respiration). This is 
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achieved through serial treatments with the following reagents, each inhibiting a different 
complex within the mitochondrial electron transfer chain (Fig. 2-4): 
a) Oligomycin, inhibitor of ATP synthase (complex V). Oligomycin triggers a decline in 
OCR, as stage 3 oxidative phosphorylation has been blocked. This OCR decline 
reflects the component of oxygen consumption that is used for ATP production. 
ECAR increases as cells resort to anaerobic glycolysis, which releases lactic acid. 
b) FCCP (Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone), mitochondrial 
membrane uncoupler. FCCP causes proton leak from the mitochondrial 
intermembrane space to the mitochondrial matrix, resulting in a collapse of the 
mitochondrial membrane potential. Under these conditions, oxygen flow through the 
electron transfer chain is uninhibited and oxygen is maximally consumed by complex 
IV in an attempt to restore the proton gradient across the inner mitochondrial 
membrane. The difference between this stimulated OCR and baseline OCR provides 
the spare respiratory capacity, a measure of cellular ability to cope with increased 
energy demands. ECAR remains higher than baseline as anaerobic glycolysis is still 
employed to make up for the diminished aerobic energy production. 
c) Mix of rotenone and antimycin A, inhibitors of complex I and III, respectively. This 
combination generates a total inhibition of mitochondrial respiration. Remaining 
oxygen consumption reflects non-mitochondrial respiration. ECAR remains high 
(www.agilent.com). 
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One day before the planned metabolic flux analysis, NCI-H295R cells were trypsinised and 
transferred to Seahorse XF-24 plates at a density of 100,000 cells/well. Typical cell culture 
media volume per well was 100-150 µl. On the day of metabolic flux analysis, media was 
replaced with a DMEM-based medium supplemented with 25 mM glucose, 2 mM sodium 
pyruvate, 31 mM NaCl, 2 mM GlutaMax (pH 7.4) and incubated at 37 °C in a non-CO2 
Figure 2-4 The Seahorse XF Cell Mito Stress Test. Serial injections of Oligomycin, FCCP 
and Antimycin A-Rotenone alter mitochondrial respiration, generating characteristic, 
measurable changes in oxygen consumption. FCCP: Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone. Source: www.agilent.com. Adapted and reproduced with 
permission of Agilent. 
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incubator for 60 min. Baseline oxygen consumption rate (OCR, measured by oxygen 
concentration change) and extracellular acidification rate (ECAR, measured by pH change) 
were measured, followed by serial treatment with the following mitochondrial inhibitors: 
oligomycin (ATP synthase inhibitor, 2 µM), FCCP (mitochondrial respiration uncoupler, 1 
µM), and rotenone and antimycin A (Complex I inhibitor, 1 µM). After the assays, plates 
were stored at -80 C to be used for protein concentration measurements as surrogate markers 
of cell density. Results were normalised to protein concentration, measured by the BCA 
Protein Assay Kit (Thermo-Fisher). 
 
2.6 Cellular Proliferation  
Cellular proliferation was assessed after culturing cells in flat-bottomed, transparent-walled 
96-well plates, using the CyQUANT® Proliferation Assay Kit (Thermo Fisher) and following 
the manufacturer’s instructions. CyQUANT® uses of a proprietary green fluorescent dye, 
CyQUANT® GR, which exhibits strong fluorescence enhancement when bound to cellular 
nucleic acids after cell lysis. The fluorescence emitted by a given well is therefore 
proportional to the total amount of DNA, which in its turn is proportional to cell number 
before lysis. The linear detection range is wide (500 – 50,000 cells).  
In proliferation time-courses, NCI-H295R cells were grown in transparent, flat-bottomed 96-
well plates (Falcon), loaded at a concentration of 8,000 cells/well and cultured in 200 µl of 
plain culture media or treatment media. At least 5 biological replicates (wells) per group of 
cells were used in each experiment. Media was refreshed every 48h by removal and addition 
of 100 µl fresh media. At pre-determined time points, the media was removed and cells were 
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frozen at -80oC. The beginning of treatment was used as the baseline time point (t=0) at each 
proliferation series.  
On the day of the assay, plates were defrosted in room temperature for 30 min and a 
mastermix was freshly prepared, containing 19 ml of dH2O, 1 ml Lysis Buffer and 50 µl 
CyQUANT® GR fluorescent dye for every 100 wells to be assayed. After vortexing, 180 µl of 
the mastermix were added to each well. Blank wells were also used to measure background 
fluorescence. Plates were then run in a Wallac Victor 1420 multilabel counter using 480 nm 
excitation/ 520 nm emission maxima.  
 
2.7 Cellular apoptosis 
Cellular apoptosis was assessed after growing cells in white, opaque-walled 96-well plates, 
using the Caspase-Glo 3/7TM Assay kit (Promega).  The Caspase-Glo 3/7TM assay measures 
the activity of the effector caspases 3 and 7, which are activated during programmed cell 
death (apoptosis) through proteolytic cleavage by initiator caspases. Once activated, caspases 
3 and 7 swiftly proceed with proteolytic degradation of intracellular proteins, executing 
programmed cell death (Garcia-Calvo et al., 1999). The assay provides a luminogenic 
substance with a tetrapeptide sequence which is cleaved by caspases, releasing a substrate for 
luciferase. Therefore, emitted luminescence is proportional to caspase activity in the 
corresponding well.  
To perform this assay, cells were grown in white, opaque-walled, flat-bottomed 96-well plates 
(Perkin-Elmer) in 200 µl of growth media. At least 10 biological replicates were used per 
group of cells. At the assaying time-point, 4 wells/ group were randomly chosen to measure 
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caspase activity. 100 µl media were removed and replaced by 100 µl of a solution of the 
luminogenic Caspase-Glo 3/7 substrate in Caspase-Glo 3/7 buffer (Caspase-Glo 3/7 Reagent). 
The buffer facilitates cell lysis and also contains a thermostable luciferase. Plates were 
incubated at room temperature for 50 min after shaking briefly, protected from light. This 
period allows cell lysis to occur, followed by caspase 3 and 7-mediated cleavage and release 
of the luminogenic substrate. Luminescence was measured in a Wallac Victor 1420 multilabel 
counter. A blank well containing cell media and Caspase-Glo 3/7 Reagent only was also 
included, its luminescence deducted from sample measurements to produce net luminescence 
values. 
At the end of the assay, media and reagents were removed from all wells and stored at -80oC. 
The next day, relative quantification of cell number in the remaining wells (i.e. wells not used 
for caspase activity measurement) was performed by use of the CyQuant® Proliferation Assay 
Kit (Thermo Fisher), as described above. Luminescence values obtained in the apoptosis 
assay were normalised to the fluorescence results of the proliferation assay. 
During the course of this work, the above protocol was modified to allow culture of cells in 
transparent-walled plates, which allow microscopic evaluation of cell growth and are more 
suitable for fluorescence measurement. With the new protocol, cells were loaded and cultured 
in transparent-walled 96-well plates, using at least 10 biological replicates/ plate. On the day 
of the assay, the luminogenic solution was added to 4 wells/ group (100 µl of the solution 
replacing 100 µl of cell media) and, after 5 min of gentle shaking, solution and media were 
transferred to a white, opaque-walled plate. Caspase activity was measured as described 
above. The transparent-walled plate was frozen at -80oC and subsequently used for cell 
number quantification with the CyQuant® Proliferation Assay Kit. 
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2.8 In vitro steroid profiling by liquid chromatography and tandem mass 
spectrometry (LC-MS/MS)   
The impact of NNT loss on the hormonal output of ACC cells was delineated by use of 
comprehensive steroid profiling in cell media by LC-MS/MS. LC-MS/MS is a powerful 
analytical tool which combines the ability of liquid chromatography to separate substances in 
a sample according to their chemical properties with the capacity of mass spectrometry for 
separation according to mass.  With modern liquid chromatography (also called high-
performance LC – HPLC), the sample is carried through a column by a liquid (mobile phase).  
The column is equipped with a lining (‘stationary phase’) which binds the various molecules 
within the sample (analytes) with a strength that depends on the molecule polarity. The 
polarity of the mobile phase then increases progressively, leading to sequential elution of the 
analyte detachment at different times (retention times) according to their polarity (Taylor et 
al., 2015). 
Having been separated according to their polarity, analytes enter the mass spectrometry 
analysers. In LC-MS/MS, two sequential MS analysers are employed to enhance overall 
specificity.  Entering the first MS analyser, sample analytes are ionised and travel through a 
quadrupole at times that are determined by their mass-to-charge ratio. In the second analyser, 
molecules undergo fragmentation into smaller particles in a special collision cell; generated 
ionised fragments are then selected according to their mass-to-charge ratio with a second 
quadrupole. This results in highly specific detection, as the various analytes beget unique 
fragmented ions, leaving their very specific analytical fingerprint (Taylor et al., 2015). 
Modern mass spectrometry-based techniques (be it LC-MS/MS or GC-MS) have been 
established as the most sensitive and specific method of steroid hormone analysis, 
outperforming the traditional immunoassays with their significant analytical lacunae (cross-
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reactivity between similar analytes, low sensitivity, poor inter-lab standardisation) (Taylor et 
al., 2015). LC-MS/MS has distinct advantages over GC-MS as a high-throughput analytical 
test, by virtue of its short running times and relatively low cost.  
To explore steroidogenesis in our in vitro cell model, NCI-H295R cells were incubated in 6-
well plates in 1 ml of serum-free DMEM/Ham’s F-12 medium (Gibco, Thermo Fisher), 
supplemented with 1% penicillin-streptomycin and 1% ITS universal cell culture premix. 
Serum-free media was used as serum itself contains steroids which may confound results. 
Media was collected after 48 h incubation (120 hours post transfection) to silinised glass tubes 
and stored at -20oC.  
To extract steroid hormones from cell media, 20 µl of serum steroid internal standard solution 
was transferred to each tube and vortexed briefly, followed by addition of 3 ml Methyl tert-
butyl ether (MTBE, Sigma). After vigorous vortexing, samples were frozen at -20oC for at 
least 1 hour. The top layer (liquid phase) was transferred to a 96-well plate using Pasteur 
pipettes. MTBE was evaporated to dryness at 55oC and samples were reconstituted in 125 µl 
of 1:1 H2O/methanol. Steroid metabolite identification and quantification was performed by 
liquid chromatography/tandem mass spectrometry (LC/MS/MS), with reference to a linear 
calibration series and appropriate internal standards (AcquityTM Ultra Performance Liquid 
Chromatographer, Xevo TQ Mass Spectrometer) as described previously (Juhlen et al., 2015, 
Haring et al., 2013) (Table 2-1).  
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Calibration 
number 
Added volume of 
serum steroid 
stock (1µg/ml) 
Added volume of 
cell media (µl) 
Concentration (ng/ml) 
C0 0 1000 0 
C1 0.5 999.5 0.5 
C2 1 999 1 
C3 5 995 5 
C4 10 990 10 
C5 25 975 25 
C6 50 950 50 
C7 100 900 100 
C8 250 750 250 
C9 500 500 500 
 
 
2.9 Statistical analysis 
Statistical analysis and schematic depiction of data was completed using GraphPad Prism 
Software. Data are represented as mean ± standard error (mean ± SEM) values, unless 
otherwise stated. Data that are not normally distributed are presented as median ± interquartile 
range (IQR).  Two-group comparisons were made using Student’s paired t-test for normally 
distributed data or Wilcoxon’s signed-rank test for data not following a Gaussian distribution. 
Multiple comparisons (paraquat, BSO and auranofin treatment courses) were performed by 
one-way ANOVA followed by post-hoc multiple comparison testing (Turkey’s test).  
Table 2-1 Calibration series used to quantify steroid metabolites in cell media samples by LC-
MS/MS 
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3 Effects of transient NNT knockdown on 
ACC cell metabolism, proliferation and 
steroidogenesis 
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3.1 Introduction                        
NNT is a proton pump of the inner mitochondrial membrane that transfers reducing 
equivalents from NADH to NADP+, fuelling the main mitochondrial antioxidant pathways as 
well as anabolic cellular metabolism (Rydstrom, 2006, Leung et al., 2015).  NNT inactivation 
in a number of in vitro cell models has been associated with a multifaceted metabolic impact, 
including induction of oxidative stress, disruption of mitochondrial respiration and inhibition 
of glutamine utilisation in the TCA cycle (Arkblad et al., 2005, Meimaridou et al., 2012, 
Ripoll et al., 2012, Lopert and Patel, 2014, Yin et al., 2012, Gameiro et al., 2013). Limited 
pre-clinical data suggest an adverse effect of NNT inactivation on the proliferation and 
viability of certain malignant cell lines (apoptosis in PC12 rat phaeochromocytoma cells in 
vitro, suppression of melanoma xenografts in rodents), presumably due to the deleterious 
effects of high oxidative stress (Yin et al., 2012, Gameiro et al., 2013). Recent human genetic 
studies underscored the importance of NNT in adrenal (patho)physiology, demonstrating that 
NNT mutations underlie a rare hereditary form of primary adrenal insufficiency (Familial 
Glucocorticoid Deficiency) (Meimaridou et al., 2012, Roucher-Boulez et al., 2016). In 
keeping with this, 2-month-old Nnt mutant mice have low circulating levels of corticosterone; 
on histology, their adrenal glands displayed disorganised zonae fasciculatae with high levels 
of apoptosis (Meimaridou et al., 2012). The clinical phenotype of patients with inactivating 
NNT mutations is remarkably specific: the adrenals glands are the only affected organs in the 
majority of described cases, suggesting a particular vulnerability of adrenal cells to NNT loss. 
The roots of this vulnerability may be putatively  traced down to the high metabolic activity 
of the adrenal cortex and its steroidogenic commitment, both incurring a high oxidative toll 
on the adrenal mitochondria (Hanukoglu, 2006, Prasad et al., 2014b). On this background, 
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NNT emerges as an attractive treatment target in the clinical condition in which 
adrenocortical cell damage is most desirable therapeutically, i.e. ACC.  
Antioxidant enzyme targeting with a view to curtailing the capacity of malignant cells to deal 
with their high endogenous ROS levels is not new under the sun in the world of Experimental 
Oncology. Promising results have been delivered in preclinical models and a limited number 
of clinical studies (Gupta et al., 2012, Watson, 2013, Fruehauf and Meyskens, 2007, 
Trachootham et al., 2009). NNT has not been explored as a oncologic treatment target so far, 
with the only exception of recent pre-clinical studies on malignant melanoma where a 
detrimental effect of NNT inhibition was demonstrable both in vitro and in vivo (Gameiro et 
al., 2013).  
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3.2 Methods 
3.2.1 Research strategy 
In this Chapter, we will explore the acute effects of NNT silencing on ACC redox balance and 
mitochondrial bioenergetics, and try to ascertain whether these may have a detrimental impact 
on ACC tumour growth (increased cell death and/or suppressed proliferation) and steroid 
biosynthesis. Transient NNT silencing will be achieved through anti-NNT siRNA transfection 
of NCI-H295R ACC cells, using Viromers as transfection vehicles. Viromers are synthetic 
polymers emulating the structure of the influenza virus haemaglutinin, which can bind siRNA 
molecules forming complexes that are naturally taken up by cells through endocytosis. This 
way, they facilitate the introduction of the siRNA molecules directly into cells without 
compromising cell function and viability. SiRNA molecules break down the mRNA of their 
target gene, leading to temporary gene expression silencing (gene knock-down) for a period 
which typically lasts a few days. Having transiently knocked down NNT in NCI-H295 cells, 
we will explore the immediate ramifications of NNT loss with respect to  
a) Cellular redox balance, as reflected on the ratio of reduced to oxidised glutathione  
b) Mitochondrial bioenergetics, focusing on mitochondrial oxygen consumption rates 
and glycolytic rates (extracellular flux analysis – Seahorse XF) 
c) Cellular proliferation, using longitudinal assessment of cell numbers under routine cell 
culture conditions as well as under metabolic stressors (oxidative stress, glucose 
deprivation) 
d) Cellular apoptosis, measuring caspase 3 and 7 activity 
e) Steroidogenesis, through a combination of Real-Time PCR and steroid profiling by 
LC-MS/MS 
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All experiments were paired, NNT knockdown cells being plated and treated alongside their 
controls, to mitigate the confounding effects of inter-experiment variability and enhance the 
power of statistical analysis. 
 
3.2.2 SiRNA transfection  
Transient NNT gene silencing was achieved with introduction of small interfering RNA 
(siRNA) molecules into NCI-H295R cells. SiRNAs are short (20-25 base pairs), double-
stranded RNA molecules which are able to effect post-transcriptional silencing of their target 
gene through a process known as RNA interference (Agrawal et al., 2003). Once introduced 
into the cell, the two strands of each molecule are separated after binding of a protein 
complex called RNA-induced silencing complex (RISC). Following this, RISC is guided by 
the siRNA to its complementary sequence within the target mRNA; if base pairing is precise, 
RISC degrades the mRNA, leading to silencing of the corresponding gene. This effect lasts 
until the siRNA molecules become themselves degraded, typically a few days. RNA 
inhibition by siRNA transfection is a cost-effective way of inhibiting gene function in vitro, 
with the limitation that the effect is short-lived and may not necessarily recapitulate the long-
term sequelae of the particular gene loss. A second caveat is that inadvertent silencing of 
other genes with partially complementary sequences may also occur, especially with high 
transfection concentrations (Jackson and Linsley, 2010). This phenomenon is widely known 
as ‘off target effects’ and suggests that the biological effect seen with a given siRNA may not 
be caused by the target gene of interest. This risk can be mitigated through independent 
application of two different siRNAs targeting different areas of the gene of interest.  
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Viromers (Viromer Blue®, Lipocalyx, Germany) were used as transfection vehicles. Viromers 
are polymeric molecules which bind siRNAs and introduce them into cells deploying a viral 
fusion mechanism akin to the one used by the influenza virus (https://viromer-
transfection.com). The siRNA-viromer complex is taken up by cells through endocytosis. The 
acidic environment of the endosomes triggers a structural change whereby the fusion peptide 
loses its charge, becomes hydrophobic and penetrates the endosomic membrane, escaping into 
the cytosol. Once in the cytosol, viromers regain charge, which precludes regression into the 
endosomes. siRNAs then dissociate from them into the cytosol and the process of RNA 
interference begins.  
Three different siRNAs against human NNT were assessed, all purchased from Thermo 
Fisher:  
a) HSS118902 siRNA, targeting exon 21; this siRNA is referred to in the Results section 
as KD SiRNA1. NCI-H295R cells transfected with SiRNA1 are referred to in the 
Results section as KD SIRNA1 cells. 
b) HSS118901 siRNA, targeting exons 20 and 21; this siRNA is referred to in the results 
section as KD SiRNA2. NCI-H295R cells transfected with SiRNA2 are referred to in 
the Results section as KD SIRNA2 cell. 
c) HSS118900 siRNA, targeting exons 16 and 17; this siRNA is referred to in the results 
section as KD SiRNA3. 
d) A scramble, non-sense siRNA (Silencer Select 1 negative control) not targeting any 
genes was used as negative control; this siRNA is referred to in the Results section as 
SCR SiRNA. NCI-H295R cells transfected with SCR SiRNA are referred to in the 
Results section as SCR SIRNA. 
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Viromer transfection was performed according to the following protocol: 
NCI-H295R cells were grown in 75 cm2 flasks (Corning) in full culture media as described in 
Chapter 2. When 70-80% confluence was attained, media was removed and cells were 
washed with Phosphate Buffered Saline (PBS, Sigma), followed by 37oC incubation in 2 ml 
of Trypsin (Gibco, Thermo Fisher) for 2 min. Cells were detached by gentle tapping and 
diluted in full media in plastic tubes (Corning) to be centrifuged at 12,000 rpm for 5 min. 
Pelleted cells were re-suspended in 10-15 ml of full media and cell density was estimated by 
microscopy. Following this, cells were loaded to a) 6-well plates at a concentration of 
300,000 cells/well in 2 ml media, or b) 96-well plates at a concentration of 8,000 cells/ well in 
100 µl media, and incubated overnight at 37oC. The next day, working solutions of siRNAs in 
Buffer F (Viromer Blue kit, Lipocalyx, pH 7.2) were prepared at a concentration of 11 µM. 
Working solutions of Viromers in Buffer F were also prepared (by addition of 1000 µl Buffer 
F to 11 µl Viromer Blue stock solution) and vortexed for 5 sec. The working solutions of 
Viromers were then added to each siRNA solution (989 µl of diluted Viromers per 100 µl 
diluted siRNA) and mixed well by pipetting. After 15 min incubation at room temperature to 
allow formation of siRNA-Viromer complexes, the Viromer-siRNA mix was  
a) applied directly to cells in 6-well plates (100-300 µl to 2 ml media for optimisation, 200 µl/ 
well in subsequent experiments) and mixed by gentle plate rocking or  
b) diluted in cell media in falcon tubes at a concentration of 80 µl per 1 ml of media and then 
added to cells in 96-well plates -after complete removal of old media- at a volume of 108 µl/ 
well.  
Gene knockdown efficiency was assessed by Real-Time PCR and Western Blotting from 2-7 
days post-transfection. Media was changed on day 3 post-transfection and every 48 h 
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thereafter. In 96-well plates, 100 µl of media was added to each well 48 h post transfection to 
avoid disruption of cell proliferation by media evaporation. 6-well plates were used to assess 
knockdown efficiency by Real-Time PCR and Western Blotting, as well as for steroid 
profiling in cell media (LC-MS/MS). 96-well plates were used for proliferation, apoptosis and 
redox balance assessment. 
The above protocol had to be modified temporarily for a period of three months during the 
course of this project due to changes introduced by the manufacturing company (Lipocalyx). 
The modification consisted of substitution of Opti-MEM media (Gibco, Thermo Fisher) for 
Buffer F. SiRNA and Viromer concentrations in the working solution were maintained. 
Transfection efficiency was not affected. After three months, Lipocalyx reinstated Buffer F 
and the protocol was resumed as detailed above. 
An important problem encountered during 6-well transfection was the eventual loss of cells in 
the centre of the wells (both in the knockdown and control transfection group), which limited 
the RNA yield and required pooling of several wells to achieve sufficient RNA concentrations 
to proceed with cDNA synthesis and quantitative PCR. This problem resolved with a protocol 
modification whereby cell media was not changed on the day of transfection. This suggested 
the previously observed cell loss was due to cell detachment during media change on the day 
of transfection, as H295R cells adhere poorly to the bottom of the wells in the first 24-48 h. 
 
3.2.3 Redox balance assessment 
To assess the effect of NNT knockdown on cellular redox balance, NCI-H295R cells (passage 
10-20) were loaded onto white opaque-walled, flat-bottomed 96-well plates (Perkin-Elmer) at 
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a concentration of 8,000 cells/well. The next day, media was removed carefully trying not to 
disrupt plated cells. Cells were transfected with siRNA-Viromer complexes as described 
above, using 100 µl media and 8 µl siRNA-Viromer solution per well. 48 h post-transfection, 
100 µl growth media was added to each well, and media was refreshed by removal and 
addition of 100 µl media the next day. 96 h post-transfection, the intracellular ratio of 
reduced/oxidised glutathione was measured (in triplicates) using the GSH/GSSG-GloTM assay 
(Promega) as described in Chapter 2. 
 
3.2.4 Metabolic Flux analysis 
NCI-H295R cells were transfected in 6-well plates as described above and cultured for 6 
days. On day 6 (144h post-transfection), cells were washed with PBS and collected by 
trypsinisation. Cell density was measured microscopically and cells were loaded to Seahorse 
XF 24-well microplates at a loading density of 100,000 cells/well (media volume 100-150 µl). 
The next day (166 h post-transfection), metabolic flux analysis was completed as described in 
Chapter 2. 
 
3.2.5 Proliferation time-courses 
Assessment of cellular proliferation and viability was performed in flat-bottomed, 
transparent-walled 96-well plates (Falcon). At the beginning of each proliferation series, NCI-
H295R cells (passage 10-25) were loaded onto plates, at a loading concentration of 8,000 
cells/ well, in 110 µl of cell media. This loading concentration was selected after optimisation 
experiments comparing proliferation rates with various loading concentrations (5,000 - 15,000 
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cells/ well, data not shown). The next day, media was removed carefully trying not to disrupt 
plated cells and cells were transfected with siRNA as described above, using a total cell media 
volume of 108 µl of media per well. 48 h post-transfection, 100 µl of growth media was added 
to each well. At 72 h post-transfection (baseline point), media was replenished and one plate 
was frozen at -80oC to determine ‘baseline’ cell numbers. In the remaining plates, cells were 
cultured for a further 96 h (i.e. until 166 h post-transfection), with intermediate media 
replenishment at 120 h hour post transfection (removal of 100 µl old media and addition of 
100 µl fresh media per well). At least 5 biological replicates (wells) per group (i.e. NNT 
knock-down or scramble siRNA-transfected cells) were used in each time-course. At the end 
of the time-course, cell numbers were derived using DNA fluorescence, as described earlier. 
Proliferation rates were established using the formula 
 Proliferation rate = %(fluorescence at 166 h – fluorescence at 72 h)/ fluorescence at 72 h. 
In some time-courses, concurrent drug treatment or conditioned culture media was applied to 
evaluate cellular proliferation and viability under special conditions (chemically-induced 
oxidative stress, adrenotoxic chemotherapy, glucose deprivation). Treatment was started 72h 
post-transfection (baseline time-point) and lasted 96 h. Treatment courses applied in the 
course of this project included: 
a) Paraquat (N,N′-dimethyl-4,4′-bipyridinium dichloride, Sigma). Paraquat is a herbicide 
which is widely used as a chemical inducer of oxidative stress (superoxide generation) 
(Lei et al., 2014). Paraquat was administered for a total duration of 96 h and was 
replenished once in cell media during the proliferation course (48h). Stock solution of 
paraquat in sterile-filtered dH2O was stored in 4oC. 
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b) Glucose-deplete media (DMEM, L-Glutamine (+), glucose 1 g/dl, sodium pyruvate, 
catalogue number 11966025, Gibco). Media was supplemented with 2.5% Nu Serum 
(Sigma) and 1% ITS+ premix (BD Biosciences). This formulation contains 1/3 of the 
glucose concentration of regular NCI-H295R culture media. Glucose-deplete media 
was administered for a total duration of 96 h and was replenished once during the 
proliferation course (48h). 
c) L-buthionine sulfoximine (BSO, Cayman Scientific). BSO is a potent, specific 
inhibitor of g-glutamylcysteine synthetase, the rate-limiting step in glutathione (GSH) 
biosynthesis (Bailey, 1998).  BSO was administered for a total duration of 96 h and 
was replenished once in cell media during the proliferation course (48h). Doses ranged 
from 10-4,000 nM. Sterile-filtered solution of BSO in sterile-filtered dH2O was 
generated fresh on the day of the experiments, as the substance is unstable in liquid 
form. Powder BSO was stored at -20oC.  
d) Auranofin (Sigma). Auranofin is a gold-complex agent and the most potent inhibitor 
of thioredoxin reductase. In proliferation series, it was administered for a total 
duration of 96 h and was replenished once in cell media during the proliferation course 
(48h). Doses ranged from 200-2,000 nM. Sterile-filtered liquid stock solution of 
auranofin in DMSO was stored at 4oC.  
 
3.2.6 Apoptosis  
To evaluate the effects of NNT knockdown on cellular redox balance and apoptosis, NCI-
H295R cells were loaded to opaque-walled, flat-bottomed 96-well plates (Perkin-Elmer) at a 
loading concentration of 8,000 cells/well, and transfected the next day as described above 
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(10-15 wells/ transfection group). Media was refreshed on days 2 and 4 post-transfection. On 
day 5 (120 h post-transfection), caspase activity was measured as described in Chapter 2 
(Caspase 3/7-GloTM assay, Promega) using 4 wells (replicates) per transfection group. After 
the end of the assay, plates were frozen at -80oC and relative cell density in the remaining 
wells was assessed the next day using the CyQuantâ Cell Proliferation kit (Thermo Fisher). 
 
3.2.7 Steroid profiling by Liquid Chromatography/ Tandem mass spectrometry 
To outline the impact of NNT knockdown on steroid production, NCI-H295R cells 
transfected in 6-well plates were incubated in 1 ml of serum-free media (DMEM/F12 
supplemented with 1% ITS+ premix and 1% Penicillin-Sterptomycin) for 48h, starting 72h 
post-transfection. At the end of the incubation, media was collected in silinised glass tubes 
and stored at -20oC. Protein was harvested as described in Chapter 2 and used to standardise 
the results to protein concentration. Steroid extraction from stored cell media was 
subsequently completed as described in Chapter 2. 
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3.3 Results 
3.3.1 NNT silencing by siRNA transfection 
The efficacy and duration of NNT silencing in NCI-H295R cells transfected with siRNA in 6-
well plates was evaluated by Western Blotting and Real-Time PCR. Three different siRNAs 
against NNT were evaluated (KD SiRNA 1, 2 and 3). Scramble, non-sense siRNA was used 
as negative control (SCR SiRNA). Gene silencing at a translational level was assessed by 
Western Blotting, from 24 h to 166 h post-transfection (Fig. 3-1). KD SiRNA1 was selected 
as the siRNA of choice as it displayed the most consistent knockdown efficiency, and was 
used in all subsequent experiments. KD SiRNA2 was used to corroborate results in 
proliferation and apoptosis assays, whose results are most likely to be confounded by off-
target effects. KD SiRNA3 produced less satisfactory knock-down and thus was not used in 
subsequent experiments. Real-time PCR was deployed to measure NNT expression at a 
transcriptional level 72 h – 166 h post-transfection. Good levels of NNT silencing were 
achieved with both KD SiRNA1 and KD SiRNA 2 throughout this time window (Fig. 3-1). 
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Figure 3-1 Assessment of NNT knockdown in siRNA-transfected NCI-H295R cells by Western 
Blotting and Real-Time PCR. A) Protein expression at serial time-points in the first week 
post-transfection with KD SiRNA 1. Cells transfected with SCR siRNA were used as controls 
[indicated as (-)]. B) Comparison of NNT expression in cells transfected with scramble, non-
sense siRNA (SCR SiRNA, negative control) and three alternative SiRNAs against NNT (KD 
SiRNA 1, 2 and 3) 72 h post-transfection. C) Whole NNT blot from time-series displayed in 
panel A, added to demonstrate antibody specificity. D) Real-time PCR comparing NNT 
expression in SCR SIRNA cells, KD SIRNA1 and KD SIRNA2 cells, 72 h post-transfection. 
****p<0.0001, ***p<0.001; n>5 independent experiments. 
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3.3.2 Cellular redox balance 
The effect of acute NNT silencing on NCI-H295R cellular redox balance was determined by 
measurement of the cellular ratio of reduced to oxidised glutathione (GSH/GSSG ratio), 96 h  
post-transfection (GSH/GSSG-GloTM assay, Promega). Lower GSH/GSSG ratios suggest 
higher intarcellular levels of oxidative stress and impaired residual antioxidant capacity 
(Rebrin and Sohal, 2008). In keeping with our hypothesis, NNT silencing by KD SiRNA1 
increased intracellular oxidative stress, as suggested by a statistically significant decrease in 
the GSH/GSSG ratio compared to cells transfected with SCR SiRNA [median (IQR) 
GSH/GSSG ratio in KD SIRNA1 cells normalised to SCR SIRNA cells 0.83 (0.41 – 0.9); 
p<0.05, n=8 independent experiments] (Fig. 3-2).  
                                    
 
Figure 3-2 GSH/GSSG ratio in NCI-H295R cells transfected with KD SiRNA1, normalised to 
the GSH/GSSG ratio of SCR SiRNA-transfected cells. Low GSH/GSSG ratio levels suggest 
higher intracellular oxidative stress, as a result of NNT loss. Menadione: NCI-H295R cells 
treated with the potent oxidising agent Menadione (40 µM) for 2h as positive control 
(*p<0.05, n=8 independent experiments). 
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3.3.3 Mitochondrial bioenergetics 
 Changes in mitochondrial respiration were evaluated by direct measurement of cellular 
oxygen consumption, using Extracellular Flux analysis (Seahorse XF analyser). We observed 
no statistically significant difference between SCR SiRNA-transfected cells and KD SiRNA1-
transfected cells [median (IQR) oxygen consumption rates 6 (4.4-7.8) and 7 (5-8.2) pmol/min/ 
µg protein, respectively; n=4 independent experiments, p>0.05). After baseline OCR 
measurement, oligomycin was used to inhibit respiratory chain complex V (ATP synthase); 
this led to a similar OCR decrease in both transfection groups [post-oligomycin OCR 2.5 (1.9-
3.2) in SCR SIRNA wells vs 2.7 (2.2-3.9) pmol/min/ µg protein in KD SIRNA1 cells, p> 
0.05]. Treatment with the mitochondrial uncoupler FCCP (Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone) led to an expected sharp rise in OCR in both cell groups; 
again, no differences were observed [post-FCCP OCR 5.3 (3.1-7.3) pmol/min/µg in SCR 
SIRNA cells vs 5.6 (4-6.7) pmol/min/µg in KD SIRNA1 cells, p>0.05]. Of note, the maximal 
oxygen consumption displayed post-FCCP was similar to the baseline OCR of NCI-H295R 
cells, an unusual but reproducible finding which may suggest that NCI-H295R cells tend to 
operate close to their maximal respiratory capacity even under normal growing conditions. 
Finally, combination treatment with Antimycin A and Rotenone was deployed to inhibit all 
mitochondrial respiration; residual oxygen consumption (non-mitochondrial respiration) was 
also comparable between the two groups [1 (0.8-1.2) pmol/min/ µg for SCR SIRNA cells vs 
1.1 (0.7-2.3) pmol/min/ µg for KD SIRNA1 cells]. Baseline extracellular acidification rates, 
representative of baseline glycolytic rates, did not differ between the two groups (0.69 ± 0.13 
mpH/min/protein for SCR SiRNA cells vs 0.63 ± 0.08 mpH/min/protein for KD SIRNA1 
cells; p> 0.05, n=4) (Fig. 3-3). 
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Figure 3-3 A) Seahorse XF24 analysis of cellular oxygen consumption rates (OCR) in siRNA-
transfected NCI-H295R cells at baseline and after successive application of three 
mitochondrial respiration inhibitors. Bars represent median ± IQR values. No significant 
difference was detected between KD SIRNA1 and SCR SIRNA cells. FCCP: Carbonyl 
cyanide-p-trifluoromethoxyphenylhydrazone. A&R: Antimycin A plus Rotenone (p>0.05, n= 4 
independent experiments); B) Baseline extracellular acidification rates in siRNA-transfected 
NCI-H295R cells. Bars represent mean ± SEM values. No significant difference was detected 
between KD SIRNA1 and SCR SIRNA cells (p>0.05, n= 4 independent experiments). 
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3.3.4 Cellular proliferation 
Cellular proliferation rates were assessed over the time window from 72h-166 h post-
transfection, a period during which consistent NNT knock-down had been confirmed on a 
protein level. NNT knock-down by KD SiRNA1 transfection led to a decrease in proliferation 
rates from 111.8% ± 11.3% in SCR SIRNA cells to 39.2% ± 11.3% in KD SIRNA1 cells 
(p=0.0001, n=13 independent experiments). To exclude the possibility that this impact was 
driven by non-specific, off-target siRNA effects, these results were corroborated by use of a 
second siRNA against NNT (KD SiRNA2), which had an even more striking effect, 
completely obliterating cell proliferation (proliferation rate -4.6% ± 15.1% vs 115.0% ± 
19.1%; p<0.01, n=5 independent experiments) (Fig. 3-4).  
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3.3.5 Apoptosis 
In order to establish whether the increased oxidative stress observed with NNT knockdown 
leads to higher rates of apoptosis -as predicted by ROS physiology- we measured intracellular 
caspase 3 and 7 activity 120 h post-transfection. We also quantified relative cell numbers 
(DNA fluorescence) at the same time-point to standardise the results to cell numbers. KD 
SIRNA1 cells exhibited significantly higher caspase 3/7 activity than SCR SIRNA cells 
[median (IQR) ratio KD SIRNA1 to SCR SIRNA cells 1.27 (1.05-2.1); p<0.001, n=8 
independent experiments], confirming that NNT KD triggers cell death by apoptosis in 
keeping with our core hypothesis. The effect was even more marked with KD SiRNA2 
transfection [median (IQR) ratio KD SIRNA2 to SCR SIRNA cells 3.9 (2-5.4); p<0.05, n=4 
independent experiments], paralleling the results of the proliferation assays (Fig. 3-5). 
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Figure 3-4 Proliferation rates observed in siRNA-transfected NCI-H295R cells, 72-166 h 
post-transfection, using DNA fluorescence. NNT knock-down with two different siRNAs 
suppressed cell proliferation. Proliferation rate = %[(DNA fluorescence emitted at 166 h 
post-transfection - DNA fluorescence emitted at 72h post-transfection)]/ DNA fluorescence 
emitted at 72h post-transfection. ***p<0.001,   **p<0.01; n³ 5 independent experiments.  
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3.3.6 Proliferation under chemically-induced oxidative stress and glucose deprivation 
Given the integral role of NNT in mitochondrial antioxidant defence and the detrimental 
effect of NNT inhibition on redox balance, we further hypothesised that NNT loss will render 
NCI-H295R cells more sensitive to chemically induced oxidative stress. To assess this 
assumption, we treated NCI-H295R cells with a low dose of paraquat, a pesticide which 
induces oxidative stress in vitro, generating superoxide. Treatment with 10 µM of paraquat for 
96 h (72 h -166 h post-transfection) led to a statistically significant impairment of cellular 
proliferation and viability in cells transfected with KD SiRNA1, but not in their counterparts 
that were treated with SCR SiRNA (ratio of cell fluorescence after 96 h paraquat treatment to 
cell fluorescence without paraquat treatment 0.98 ± 0.07 in SCR SIRNA cells vs 0.79 ± 0.05 
in KD SIRNA1 cells; p<0.05, n=6 independent experiments) (Fig. 3-6).  These results have 
implications of potential translational importance, suggesting that NNT knockdown may 
potentiate the cytotoxic effects of chemotherapy agents which induce oxidative stress. 
SCR SIRNA KD SIRNA1 KD SIRNA2
0
1
2
3
4
5
C
as
pa
se
 a
ct
iv
ity
 ra
tio
 to
 c
on
tro
l 
st
an
da
rd
is
ed
 fo
r c
el
l n
um
be
r
Caspase 3/7 activity (apoptosis) 
ratio to control
*
*
Figure 3-5 Caspase 3/7 activity ratio in KD SIRNA1 and KD SIRNA2 cells to SCR SIRNA 
cells, after standardization for cell numbers. Increased caspase activity indicates higher 
apoptotic rates in KD SIRNA cells (*p<0.05, n³ 4 independent experiments).  
Chapter 3                                Effects of transient NNT knockdown on ACC cell metabolism, proliferation and steroidogenesis  
140 
 
 
 
 
Previous work has suggested that NNT inhibition can impede glutamine utilisation in the 
TCA cycle (Gameiro et al., 2013). In response to this, cells have to resort to glucose to derive 
the missing carbons to fuel their anabolic needs and continue to proliferate. To establish 
whether NNT silencing renders ACC cells more sensitive to glucose deprivation, we cultured 
cells in low-glucose DMEM/F12 media, containing 1/3 of the glucose concentration of 
regular NCI-H295R culture media (1 g/L vs 3.1 g/L). Culturing cells under these conditions 
for 96 h (72-166 h post-transfection), we observed a more pronounced effect on the 
proliferation of KD SIRNA1 cells than of SCR SIRNA cells (Fig. 3-7). 
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Figure 3-6 Effect of low-dose Parquat treatment (10 µΜ) on NCI-H295R cell proliferation, 
72-166 h post siRNA transfection. KD SIRNA1 cells are more sensitive to chemically-induced 
oxidative stress (*p<0.05, n=7 independent experiments). 
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3.3.7 Alternative antioxidant targeting 
Given the auspicious effects of NNT inhibition on NCI-H295R cell growth, we went on to 
evaluate the sensitivity of ACC cells to isolated inhibition of each of the two pillars of cellular 
antioxidant defence: the glutathione pathway and the thioredoxin pathway. We used 
buthionine sulfoximine (BSO, a potent inhibitor of the glutathione-producing enzyme c-
glutamylcysteine ligase), to deplete intracellular glutathione. BSO has a proven capacity to 
inhibit > 90% of total glutathione synthesis in vitro, with excellent tolerability in clinical 
studies (Bailey, 1998). We observed a significant cytostatic effect with BSO doses of 200 µM 
after 96 h of treatment (Fig. 3-8A).   
Pharmacological manipulation of the alternative mitochondrial antioxidant pathway, the 
thioredoxin pathway, was achieved by auranofin, a gold complex with well-established 
capacity to inhibit thioredoxin reductase  (Madeira et al., 2012). Auranofin has exhibited anti-
tumour effects against certain cancer types in vitro (e.g. leukemia, melanoma, non-small cell 
Figure 3-7 NCI-H295R cell proliferation in low-glucose media, 72-166 h post siRNA 
transfection. Glucose deprivation suppresses proliferation in KD SIRNA1 cells (*p<0.05, n=5 
independent experiments). 
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lung cancer) and is currently being studied in clinical trials against leukemia (Gandin et al., 
2010, Weir et al., 2012, Sobhakumari et al., 2012).  NCI-H295R treatment with auranofin 
concentrations of 1 µM led to a substantial suppression of proliferation, while higher 
concentrations effected massive cytotoxicity (Fig. 3-8B). 
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Figure 3-8 Effects of glutathione and thioredoxin pathway inhibitors on NCI-H295R cell 
proliferation. A) 96 h treatment with incremental doses of BSO (0-200 µM), inhibitor of 
glutathione synthesis. Control cells were treated with vehicle only. *p<0.05; n= 9 
independent experiments. B) 96 h treatment with incremental doses of auranofin (0-5 µM), 
thioredoxin reductase inhibitor. Control cells were treated with vehicle only. **p<0.01, 
***p<0.001,****p<0.0001; n=8. 
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3.3.8 Steroidogenesis 
The effects of transient NNT silencing on steroidogenesis were evaluated through 
comprehensive steroid profiling in cell media by LC-MS/MS, as well as gene expression 
analysis by Real-Time PCR. We postulated that NNT silencing will disrupt steroidogenesis 
either depriving mitochondrial steroidogenic monooxygenases -Cholesterol side-chain 
cleaving enzyme (CYP11A1), 11b-hydroxylase (CYP11B1), aldosterone synthase 
(CYP11B2)- of their essential electron donor NADPH, or due to oxidative stress-induced 
down-regulation of key steroidogenic enzymes. Surprisingly, we observed the opposite 
response in the acute aftermath of NNT inhibition: KD SiRNA1-transfected cells produced 
significantly more cortisol (0.13 ± 0.03 nM/µg vs 0.05 ± 0.01 nM/µg protein; p<0.01, n=5 
independent experiments) and androstenedione (1.25 ± 0.29 nM/µg vs 0.57 ± 0.17 nM/µg; 
p<0.05, n=5) than their SCR SiRNA-transfected controls (Fig. 3-9). Individual enzyme 
activity was measured by computation of the corresponding product to substrate ratios for 
three key steroidogenic enzymes [11b-hydroxylase (CYP11B1), 21-hydroxylase (CY21A2), 
17/20-lyase (CYP17A1)]; all three displayed higher activity in KD SiRNA1-transfected cells, 
in keeping with a paradoxical generalised stimulation of steroidogenesis by acute NNT loss 
(Table 3-1). Interestingly, the ratio of cortisol/cortisone was also consistently higher in NNT 
KD cells. Other steroid metabolites were below the threshold of quantification in most 
experiments, therefore no other product-to-substrate ratios could be computated. 
We also explored the gene expression alterations underpinning the enhanced steroidogenic 
capacity of cells transfected with KD SiRNA1, comparing the expression of core 
steroidogenic genes (STAR, CYP11A1, CYP21A2, CYP17A1, 3bHSD2, CYP11B1, 
CYP11B2) between KD SIRNA1 and SCR SIRNA cells. There was a statistically significant 
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increase in the expression of CYP21A2 (p<0.05), CYP17A1 (p<0.05) and 3bHSD2 (p<0.01) 
in KD SIRNA1 cells (Table 3-2). Expression of CYP11B1 and CYP11B2 was below 
detection in both groups due to low baseline expression levels of these enzymes in NCI-
H295R cells.   
 
 
 
 
 
 
 
 
Figure 3-9 Effect of transient NNT knockdown on NCI-H295R cell cortisol and 
androstenedione production. NNT knockdown stimulates cortisol and androstenedione 
synthesis. *p<0.05, **p<0.01; n=5 independent experiments 
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Table 3-1 Steroidogenic enzyme activity in SCR SIRNA and KD SIRNA1 cells, derived from 
product-to-substrate ratios (LC-MS/MS). Results are expressed as mean ± SE values (n=6 
independent experiments). HSD11B1: cortisone reductase. 
 
 
 
Table 3-2 Effects of transient NNT KD on steroidogenic enzyme expression as assessed by 
Real-Time PCR. ΔCt= Ct (NNT) – Ct (RPLPO). n³ 6 independent experiments   
 SCR SIRNA 
median ΔCt 
(IQR) 
KD SIRNA1 
median ΔCt 
(IQR) 
P value Median fold 
change 
KD SIRNA1/ 
SCR SIRNA 
StAR    4.0  (2.3-6.8)    2.2   (1.9 - 3.0) > 0.05  
CYP11A1    5.9  (3.3 - 9)   4.8   (3.5 - 4.9) > 0.05  
3bHSD2    8.7  (7.6 -10.3)   8.0   (7.4 - 8.8) < 0.01 2 
CYP17A1    2.8  (1.5 - 5.2)    1.8   (0.7 - 2.9) < 0.01 2.5 
CYP21A2    9.3  (4.2 -12.9)    6.4   (0.4 - 9.2) < 0.05 11.5 
 
 
  
Enzyme Product/  
substrate ratio 
SCR SiRNA 
(nM/µg) 
KD SiRNA1 
(nM/µg) 
P value 
CYP11B1 cortisol/ 
11-deoxycortisol 
0.011±0.001 0.021±0.005 P<0.01 
CYP21A2 11-deoxycortisol/  
17-OH-progesterone 
37.6±9 81.1±15.2 P<0.01 
CYP17A1 androstenedione/  
17-OH-progesterone 
4.7±1 17.1±2.5 P<0.01 
HSD11B1 cortisol/cortisone 5.1±1.1 13.1±2.9 P<0.001 
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3.4 Discussion 
With this work, we explored the immediate impact of NNT silencing on ACC cells with 
respect to redox balance, mitochondrial bioenergetics and cellular proliferation, using 
transient NNT knockdown in NCI-H295R cells by siRNA transfection. Our aim was to 
establish whether NNT inhibition can have therapeutically beneficial effects, limiting tumour 
growth or suppressing steroidogenesis, as is suggested by the development of adrenal 
insufficiency in patients with inactivating NNT mutations. We hypothesised that NNT 
inhibition will compromise the ability of adrenocortical mitochondria to effectively deal with 
oxidative stress, leading to progressive accumulation of ROS. ROS excess has multiple toxic 
sequelae, and can directly impair cell viability triggering apoptosis (Gupta et al., 2012, 
Fruehauf and Meyskens, 2007). We also postulated that NNT inhibition will suppress 
steroidogenesis. 
In the acute setting (transient knockdown), NNT loss increased intracellular oxidative stress, 
leading to a dramatic suppression of cell proliferation and increased rates of apoptosis. Redox 
balance perturbations in response to NNT loss have been previously demonstrated in a limited 
number of cell lines in vitro (rat phaechromocytoma, human melanoma) as well as in 
lymphocytes derived from NNT mutant patients ex vivo (Yin et al., 2012, Gameiro et al., 
2013, Fujisawa et al., 2015). Meimaridou et al. reported increased levels of oxidative stress in 
NCI-H295R cells with chronic NNT silencing (shRNA knockdown) (Meimaridou et al., 
2012). These findings are in keeping with the biological role of NNT as a major 
mitochondrial generator of NADPH, which is the essential provider of reducing equivalents to 
the two main antioxidant pathways (Rydstrom, 2006, Leung et al., 2015). Importantly, NNT 
silencing led to a swift inhibition of cell proliferation (by > 60% in comparison to controls), 
with increased rates of apoptotic death. The association between excessive oxidative stress 
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and mitochondrial apoptosis has been well established in the literature (Martindale and 
Holbrook, 2002, Nair et al., 2009, Hampton and Orrenius, 1997, Garbarino et al., 2007, Gupta 
et al., 2012), but data on the effects of NNT loss on cellular proliferation and viability are 
scarce. Transient NNT silencing increased rates of apoptosis in PC12 (rat 
phaechromocytoma) cells (Yin et al., 2012). Stable NNT knockdown in human melanoma 
cells, another cancer type particularly vulnerable to oxidative stress, was associated with 
reduced cellular viability and high apoptotic rates in vitro, as well as deceleration of 
melanoma xenograft growth in mice (though the latter was statistically significant for only 
one of the two anti-NNT shRNAs that were used) (Gameiro et al., 2013). Meimaridou et al. 
reported high levels of apoptosis in the zona fasciculata of adrenals derived from NNT mutant 
mice, as well as in NCI-H295R cells stably transfected with shRNA against NNT in vitro; 
effects on cell proliferation were not explored in their study (Meimaridou et al., 2012). It is 
not clear whether the pronounced suppression of cell proliferation we observed with NNT 
knockdown can be ascribed entirely to the cumulative effects of increased apoptotic death 
(cytotoxicity), or whether NNT loss had an additional cytostatic effect, suppressing cell 
division. Although ROS have been typically associated with a stimulation of cellular 
proliferation, a number of in vitro models have demonstrated the opposite effect (suppression 
of cell division), in a complex relationship that may depend on the magnitude of ROS excess 
and/or tissue type (Gupta et al., 2012, Koka et al., 2010, Donadelli et al., 2007). NNT 
inhibition may also interfere with cellular proliferation in a ROS-independent way, curtailing 
the amount of NADPH available to fuel the voracious anabolic needs of malignant cells. 
 An additional interesting feature observed in KD SIRNA1 cells, also predicted by our 
hypothesis, is their sensitivity to chemically induced oxidative stress - even at sub-toxic doses 
of oxidising agents- as demonstrated by treatment with the superoxide-generating agent 
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paraquat. This finding is of translational importance, as oxidative stress induction is also a 
feature of a number of classic chemotherapy agents and is considered to contribute to their 
cytotoxic effect (Trachootham et al., 2009, Montero and Jassem, 2011). NNT inhibition may 
thus be envisaged as a meaningful strategy to sensitize ACC to such drugs. Synergy with 
mitotane would also appear theoretically plausible, as the latter has been associated with 
endoplasmic reticulum stress induction (Sbiera et al., 2015).  
Monitoring of cell growth in low-glucose media suggested that NNT KD renders ACC cells 
more sensitive to glucose deprivation. This corroborates previous work demonstrating 
diminution of cell proliferation in melanoma cells under low-glucose culture conditions 
(Gameiro et al., 2013). The underlying mechanism involved inhibition of glutamine utilisation 
in the TCA cycle; consequently, cells were more dependent on glucose as an alternative 
source of anabolic carbons. It should be noted, however, that our Metabolic Flux analysis did 
not demonstrate a difference in baseline glycolytic rates between KD SIRNA1 and SCR 
SIRNA cells, which seems to be at odds with the proliferation results. A potential explanation 
for this ostensible discrepancy arises if we consider cell proliferation as a relevant factor: KD 
SIRNA1 cells consume glucose at the same rate as the SCR SIRNA cells despite having 
lower proliferation rates and, consequently, lower overall anabolic needs. 
The effects of NNT silencing on NCI-H295R steroidogenesis were surprising and refuted our 
initial hypothesis. In the acute setting (siRNA knockdown) we observed a generalised 
stimulation of steroidogenesis leading to increased production of cortisol and 
androstenedione, respectively the main glucocorticoid and androgen metabolites excreted by 
these cells. This is contrary to what one would have anticipated considering that 
mitochondrial NADPH is an essential cofactor to CYP11A1, CYP11B1 and CYP11B2. 
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Furthermore, most of the few published studies exploring the relationship between ROS and 
steroidogenesis (mostly on testicular Leydig cell tumour cells) have reported down-regulation 
of steroidogenic enzymes with oxidative stress (most notably CYP11A1) (Diemer et al., 2003, 
Stocco et al., 1993, Prasad et al., 2013, Behrman and Aten, 1991, Stocco and Ascoli, 1993, 
Zhao et al., 2012) (Diemer et al., 2003, Stocco et al., 1993, Prasad et al., 2013, Behrman and 
Aten, 1991, Stocco and Ascoli, 1993, Zhao et al., 2012) (Diemer et al., 2003, Stocco et al., 
1993, Prasad et al., 2013, Behrman and Aten, 1991, Stocco and Ascoli, 1993, Zhao et al., 
2012) (Diemer et al., 2003, Stocco et al., 1993, Prasad et al., 2013, Behrman and Aten, 1991, 
Stocco and Ascoli, 1993, Zhao et al., 2012) (Diemer et al., 2003, Stocco et al., 1993, Prasad et 
al., 2013, Behrman and Aten, 1991, Stocco and Ascoli, 1993, Zhao et al., 2012) (Diemer et 
al., 2003, Stocco et al., 1993, Prasad et al., 2013, Behrman and Aten, 1991, Stocco and 
Ascoli, 1993, Zhao et al., 2012) (Diemer et al., 2003, Stocco et al., 1993, Prasad et al., 2013, 
Behrman and Aten, 1991, Stocco and Ascoli, 1993, Zhao et al., 2012). Interestingly, Zhao et 
al. demonstrated a biphasic relationship between ROS and steroidogenesis, which suggests 
that the direction of the effect may be dose-dependent (Zhao et al., 2012)(Zhao et al., 
2012)(Zhao et al., 2012)(Zhao et al., 2012)(Zhao et al., 2012)(Zhao et al., 2012)(Zhao et al., 
2012). Two relevant studies on NCI-H295R cells focused on ALADIN, a gene whose 
dysfunction is associated with a constellation of adrenal insufficiency, neurological disorders 
and oxidative stress. Prasad et al. reported deficient cortisol synthesis and suppressed 
expression of CYP11B1 and StAR with ALADIN knockdown in these cells; CYP11A1 did 
not appear to be affected (Prasad et al., 2013). These results were contradicted by Juhlen et 
al., who found that ALADIN knockdown in H295R-S1 (substrain 1) cells only has an impact 
on the CYP450 type II microsomal enzymes CYP17A1 and CYP21A2, and their electron 
donor POR. Steroidogenically, only 17-hydroxyprogesterone, 11-deoxycortisol and 
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androstenedione were significantly suppressed, with no demonstrable effect on cortisol 
production (Juhlen et al., 2015).  
Of note, the enhanced steroidogenic output we observed would be expected to incur a 
substantial oxidative burden on ACC cells, as CYP11B1 and, to a lesser extent, CYP11A1 
generate ROS through electron leakage as detailed in Chapter 1. Therefore, this response 
appears counter-intuitive from a redox economy standpoint. A potential explanation is that the 
observed stimulation of steroidogenesis is but an incidental event in the context of a 
generalized acute-phase response to an insult (NNT loss) that threatens cell viability. The 
possibility of off-target siRNA effects contributing to the observed phenotype cannot be 
excluded. Despite the limitations of in vitro work, NCI-H295R cells remain the most widely 
used model to study disorders of adrenal steroidogenesis. To the extent that this model can 
recapitulate in vivo adrenal physiology, our data suggest that the degree of NADPH shortage 
generated by NNT loss is not limiting for adrenal steroidogenesis; furthermore, it indicates 
that oxidative stress does not functionally inhibit steroidogenesis in the human adrenal cortex. 
Mechanistic conjectures aside, our results indicate that there is no role for NNT targeting to 
inhibit adrenal steroidogenesis. 
Finally, within the same framework we also explored the anti-tumour potential of alternative 
antioxidant targets, focusing on the glutathione and thioredoxin pathways. We used 
buthionine sulfoximine (BSO) to inhibit glutathione synthesis. BSO is a specific and 
competitive inhibitor of γ-glutamylcysteine synthetase, the rate-limiting enzyme in 
glutathione synthesis (Bailey, 1998). It has long been known that intratumoural glutathione 
levels correlate with resistance to cytotoxic chemotherapy (Traverso et al., 2013). BSO has 
exhibited anti-tumour effects (inhibition of cell proliferation and/ or increased rates of 
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apoptosis) against neuroblastoma, ovarian cancer, breast cancer, pancreatic cancer and small 
cell lung cancer in vitro (Bailey, 1998, Maeda et al., 2004, Schnelldorfer et al., 2000, Tagde et 
al., 2014, Anderson et al., 1999).  It can also augment cell sensitivity to oxidative stress, 
especially in combination with alkylating agents such as melphalan (Dusre et al., 1989). In 
vivo, a combination of intravenous BSO and melphalan has been used in three phase I clinical 
trials, with good tolerability except for a possibly increased incidence of melphalan-induced 
bone marrow toxicity (Bailey et al., 1994, Bailey, 1998, O'Dwyer et al., 1996, Bailey et al., 
1997). Successful intratumoural GSH depletion was demonstrated in these studies. More 
recently, the same regimen was administered to 38 children with refractory neuroblastoma, 
inducing a clinical response in six of them (Anderson et al., 2015). In our work, we observed 
a suppression of  NCI-H295R cell growth with doses ³ 200 µΜ, i.e. at a dose that is clinically 
attainable in plasma without substantial toxicity (Bailey, 1998). These findings suggest that 
ACC is susceptible to the anti-tumour effects of glutathione depletion.  
Auranofin, a gold complex-based agent able to inhibit thioredoxin reductase, was used to 
evaluate the sensitivity of NCI-H295R cells to thioredoxin pathway abrogation. Auranofin 
was initially applied in the treatment of rheumatoid and psoriatic arthritis in the ‘80s, by 
virtue of its versatile anti-inflammatory properties [activation of mitogen-activated protein 
kinases (MAPK), inhibition of nuclear factor kappa-light-chain-enhancer of activated-B-cells 
(NF-κB) and suppression of pro-inflammatory cytokines] (Madeira et al., 2012). Chronic 
administration is very well tolerated, with similar dropout rates to placebo (Glennas et al., 
1997). More recently, attention shifted to the drug’s newfound ability to inhibit thioredoxin 
reductase (cytosolic and mitochondrial), thereby inducing oxidative stress and inhibiting 
DNA synthesis (Brown et al., 2010, Cox et al., 2008, Hill et al., 1997). This has translated 
into cytotoxicity against a number of cell lines in vitro (e.g. melanoma, leukemia, lung 
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cancer), most notably through mitochondrial apoptosis (Gandin et al., 2010, Li et al., 2016, 
Sobhakumari et al., 2012, Weir et al., 2012, Park and Kim, 2005).  Of note, auranofin has the 
additional ability to interfere with selenium metabolism, potentially also causing some 
inhibition of glutathione peroxidase (Talbot et al., 2008). In vivo, efficacy was demonstrated 
against non-small cell lung cancer in a xenograft model (Li et al., 2016).  Auranofin is 
currently being investigated in clinical trials against leukemia, non-small cell lung cancer and 
ovarian cancer (www.clinicaltrials.gov).  
Taken together, our in vitro work supports the value of antioxidant targeting as a novel 
therapeutic approach to suppress tumour growth in ACC. Further work, e.g. in the context of 
in vivo animal studies, will be required to confirm these promising results and identify the 
most effective of available targets. 
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4 Effects of stable NNT knockdown on ACC 
cell metabolism, proliferation and 
steroidogenesis 
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4.1 Introduction 
In the previous chapter, we explored the acute ramifications of NNT silencing on ACC redox 
balance, mitochondrial respiration, cell proliferation/ viability and resistance to oxidative 
stress. We ascertained that NNT knockdown impairs cellular redox balance, suppresses cell 
proliferation, induces apoptosis and renders cells more susceptible to chemically-induced 
oxidative stress. We also observed a paradoxical stimulation of steroidogenesis. Our findings 
support the value of NNT targeting as a novel therapeutic approach to control ACC 
proliferation and/ or enhance the cytotoxic activity of chemotherapy agents that are associated 
with oxidative stress. A limitation of our model was that it can only outline the short-term 
effects of NNT knockdown, as siRNA-induced gene silencing only lasts a few days. The 
plasticity of malignant cells and their notorious adaptability to exogenous insults is well 
known to any clinical or experimental oncologist and constitutes a major obstacle to the 
development of durable treatments (Watson, 2013).  The eventual development of resistance 
to cytotoxic chemotherapy is all but inexorable in the vast majority of solid organ 
malignancies, ACC being no exception (Gupta et al., 2012, Fassnacht et al., 2012). 
Interestingly, redox adaptation (that is the ability of cells to adapt to higher ROS scavenging 
requirements) is now believed to comprise an important part of the molecular changes 
mediating chemotherapy (and radiotherapy) resistance (Gupta et al., 2012, Trachootham et al., 
2009, Watson, 2013). Indeed, cell resistance to pro-oxidant chemotherapy agents such as 
doxorubicin, paclitaxel or platinum-based agents has been shown to correlate with the 
endogenous antioxidant capacity of various cell lines in vitro (Ramanathan et al., 2005, 
Hoshida et al., 2007, Trachootham et al., 2009).   Redox adaptation, achieved through 
successful stimulation of various antioxidant pathways, can boost malignant cell survival not 
only by neutralising chemotherapy or radiotherapy-induced oxidative stress but also by 
Chapter 4                                    Effects of stable NNT knockdown on ACC cell metabolism, proliferation and steroidogenesis  
155 
 
inhibiting cell death signalling (such as caspases), stimulating pro-survival molecules (such as 
Bcl-2) and augmenting DNA repair (Trachootham et al., 2009).  
In this chapter, we will try to delineate the long-term effects of NNT loss on ACC cell 
metabolism, proliferation and steroid synthesis, establishing whether progressive redox 
adaptation is possible and to what extent this can alter the response we described in the 
transient silencing model of Chapter 3. 
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4.2 Methods 
4.2.1 Research strategy 
In order to characterise the chronic effects of NNT silencing on NCI-H295R cells, we used a 
stable, short-hairpin RNA (shRNA)-mediated knockdown system established by lentiviral 
transfection. Mirroring the experimental work undertaken with the transient knockdown 
model, we evaluated the chronic effects of NNT knockdown on: 
a) Cellular redox balance, as reflected on the ratio of reduced to oxidised glutathione  
b) Mitochondrial bioenergetics, focusing on mitochondrial oxygen consumption rates 
and glycolytic rates (extracellular flux analysis – Seahorse XF) 
c) Cellular proliferation, using longitudinal assessment of cell numbers under routine cell 
culture conditions as well as under metabolic stressors (oxidative stress, glucose 
deprivation) 
d) Cellular apoptosis, measuring caspase 3 and 7 activity  
e) Steroidogenesis, by steroid profiling in cell media (LC-MS/MS) 
All experiments were paired, NNT knockdown cells being plated and treated alongside their 
controls. 
 
4.2.2 Lentiviral transfection for shRNA knockdown 
ShRNAs are oligonucleotides consisting of two complementary 19–22 base pair RNA 
sequences connected by a short, hairpin-like loop of 4–11 nucleotides. Stable expression of 
shRNAs against the gene of interest within cells is accomplished through transfection with 
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genetically modified lentiviruses containing plasmids into which a shRNA-coding sequence 
has been introduced. The plasmid integrates into the host cell genome, allowing continuous 
transcription of shRNA. Within the cytosol, shRNA molecules are recognized by an 
endogenous Dicer enzyme which processes the shRNAs into siRNA duplexes; following this, 
silencing of the target gene is effected through the RNA interference mechanism described in 
Chapter 3 (Moore et al., 2010).  
Lentiviruses belong to the the Retroviridae family and are widely used to transfect 
mammalian cell lines in vitro by virtue of their unique biological properties, most notably 
their ability to infect both dividing and non-dividing cells with high efficiency and  integrate 
permanently into the host cell genome (Ramezani and Hawley, 2002). Most lentiviral vectors 
are based on the Human Immunodeficiency type I Virus (HIV-1). Plasmids used in lentiviral 
transfection often also possess an antibiotic resistance gene which allows selection of 
transfected from non-transfected cells and a green fluorescence protein (GFP) allowing 
visualization of transfected cells in fluorescent microscopes (https://www.addgene.org). To 
increase the safety of lentiviral use, the genes required for viral replication are distributed in 3 
plasmids (2nd generation lentiviral systems): 
- A plasmid expressing the viral envelope 
- A packaging plasmid containing the Gag, Pol, Rev and Tat genes, required for viral 
replication 
- A plasmid containing the sequence encoding the shRNA of interest, flanked by long 
terminal repeats (LTRs) that facilitate integration into the genome of host cells. 
(https://www.addgene.org). 
For this project, the following plasmids were used: 
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a) Pmd2.g (https://www.addgene.org/12259/) 
Purpose:  VSV-G envelope expressing plasmid (2nd generation) 
This plasmid expresses the VSV-G gene under the control of the human CMV promoter. The 
gene encodes the Vesicular Stomatitis Virus envelope G glycoprotein (VSV-G) to allow 
production of a pseudotyped retrovirus with a broad host range. It also contains an ampicillin 
resistance gene to allow selection of the plasmid in Escherichia Coli.  
b) PCMV delta r8.2  (https://www.addgene.org/12263/) 
Purpose: Packaging lentiviral plasmid  
This is a packaging plasmid (2nd generation) containing the HIV-1 gag, pol, tat and rev coding 
sequences, which encode the viral core proteins and replication enzymes required for the 
formation of the lentiviral structure and for replication and integration of the lentivirus. 
Expression is controlled by the CMV promoter. The plasmid also encodes an HIV-1 Rev 
response element (RRE) to allow Rev-dependent expression of the tet genes. An ampicillin 
resistance gene is also included to allow selection of the plasmid in E.coli. An SV40 early 
promoter and origin sequence facilitate high-level expression of the selection marker and 
episomal replication in cells expressing the SV40 large T antigen. 
c) pGIPZ lentiviral vectors expressing shRNA against NNT (RHS4430-98851990; 
RHS4430-98913600; RHS4430-98524425; RHS4430-101033169 RHS4430-
101025114 from Dharmacon) (http://dharmacon.gelifesciences.com) 
 
Purpose: lentiviral Gateway destination vectors, shRNA expression 
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These are the lentiviral expression vectors which will express the shRNA of interest in the 
transfected mammalian cells. They include 2 bacteriophage-derived recombination sites; 
puromycin resistance genes for plasmid selection in mammalian cell cultures and bacterial 
cultures, respectively; a turboGFP (green fluorescent protein)-encoding sequence for 
microscopic confirmation of transfection; an human CMV promoter driving strong trans-gene 
expression; a packaging sequence; a Rev response element to enhance packaging efficiency. 
For additional safety, the 3' long terminal repeat (LTR) is self-inactivating. A mix of the 5 
different plasmids detailed above was used, all containing anti-NNT shRNAs. Plasmids 
containing scramble, nonsense shRNA (SCR ShRNA) were used separately to generate 
negative controls.  
All plasmids were kindly donated by Dr Eirini Meimaridou and Dr Lou Metherell from 
Queen Mary University of London, in the context of collaborative work.  
Plasmids were applied to 6-well plates containing HEK-293T (human embryonic kidney 
tumour) cells. HEK-293T cells contain the SV-40 large T-antigen, thus allowing the fast 
replication of plasmids containing the SV40 reference sequence. Cells were transfected in 
Opti-MEM reduced serum media (Thermo Fisher), using the following plasmid quantities 
(per well) and employing lipofectamine (Thermo Fisher) as transfection vehicle: 
a) Pmd2.g: 500 ng 
b) PCMV delta r8.2: 1,000 ng 
c) ShRNA-expressing plasmids: 1,500 ng 
d) Lipofectamin 2000 Reagent (Thermo Fisher): 9 µl 
Cells were incubated overnight at 37oC; the next day, media was changed to normal HEK-
293T culture media [Dulbecco’s Modified Eagle Medium (DMEM - Gibco, Thermo Fisher) 
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supplemented with 10% Fetal Bovine Serum (Sigma), 2 mM L-glutamine (Sigma) and 1% 
Penicillin-Streptomycin (Sigma)]. After 24h, media was again changed to NCI-H295R cell 
culture media (DMEM-F12 supplemented with 2.5% Nu serum, 1% ITS+ Premix and 1% 
Penicillin-Streptomycin). The next day, media was collected, centrifuged at 1200 rpm, filtered 
using a 0.2 µm filter and applied to NCI-H295R cells, which had been plated at 6-well plates 
at 70-80% confluence. At the same time, fresh NCI-H295R media was added to the HEK-
293T wells. The next day, the same process was repeated and virus-containing media was 
again applied to the same NCI-H295R cells. After 3-day incubation, transduction efficiency 
on microscopic evaluation (% fluorescent cells) exceeded 80%. At that point, selection with 
Puromycin (4 µg/ml) was commenced, boosting the percentage of fluorescent cells to over 
90-95%. 
All subsequent experiments/ assays were undertaken from 4-12 weeks post-transfection 
(passage 17-30, passage from transfection 5-18). 4 weeks was the earliest time-point for 
which the growth of a cell population sufficient to facilitate the desired experimental work 
was accomplished. Cells transfected with shRNA against NNT will hence be referred to as 
KD SHRNA cells, while their controls transfected with non-sense, scramble shRNA will be 
referred to as SCR SHRNA cells. Puromycin was regularly added to cell media for 1-week 
periods to maintain high percentage of transfected cells, but was not used during any of the 
experiments described below. 
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4.2.3 Redox balance assessment 
To assess the effect of NNT knockdown on cellular redox balance, KD SHRNA cells and 
SCR SHRNA cells were loaded onto white opaque-walled, flat-bottomed 96-well plates at a 
concentration of 15,000 cells/well. After 24 hours, the intracellular ratio of reduced/ oxidised 
glutathione was measured (in triplicates) using the GSG/GSSG-GloTM assay (Promega) as 
described in Chapter 2. Menadione was applied to a pair of wells as positive control (potent 
inducer of oxidative stress) 2h before the assay. 
 
4.2.4 Metabolic Flux Analysis 
KD SHRNA and SCR SHRNA cells of the same passage growing in flasks were collected by 
trypsinisation and cell density was established by microscopy. Cells were loaded to Seahorse 
XF 24-well microplates at a loading density of 100,000 cells/well (media volume 100-150 µl). 
The next day, metabolic flux analysis was completed as described in Chapter 2. 
 
4.2.5 Proliferation time-courses 
Assessment of cellular proliferation and viability was performed in flat-bottomed, 
transparent-walled 96-well plates. At the beginning of each proliferation series, KD SHRNA 
and SCR SHRNA cells were loaded at a concentration of 8,000 cells/ well, in 100 µl of cell 
media. This loading concentration was selected after optimisation experiments comparing 
proliferation rates observed with various loading concentrations (5,000 – 15,000 cells/ well, 
data not shown). The next day, media was removed carefully to avoid disruption of plated 
cells and replaced by 200 µl of fresh media. One plate was frozen down at -80OC to provide 
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baseline cell numbers (t=0 h). Cells were cultured for a further 96 h; media was replenished at 
48h by removal of 100 µl old media and addition of 100 µl fresh media (per well). At least 5 
wells per group (i.e. knockdown or control) were used in each time-course. At the end of the 
time-course, cell numbers were measured using DNA fluorescence, as described earlier 
(Chapter 2). Proliferation rates were established using the formula 
 Proliferation rate (%) = %(fluorescence at 96 h – fluorescence at 0 h)/ fluorescence at 0 h 
In some time-courses, concurrent drug treatment or special growth media was applied to 
evaluate cellular proliferation and viability under special conditions (chemically-induced 
oxidative stress, glucose deprivation). Treatment was started 24h post cell loading (baseline 
time-point) and lasted 96 h. Treatment courses applied in the course of this project included: 
a) Paraquat (N,N′-dimethyl-4,4′-bipyridinium dichloride, Sigma). Paraquat is a herbicide 
which is widely used as a chemical inducer of oxidative stress (superoxide generation) 
(Lei et al., 2014). Paraquat was administered for a total duration of 96 h and was 
replenished once in cell media during the proliferation course (48 h). Doses ranged 
from 10-30 µM. Stock solution of paraquat in sterile-filtered dH2O was stored at 4oC. 
b) Glucose-deplete media (DMEM, L-Glutamine (+), glucose 1 g/dl, sodium pyruvate –  
Gibco, Thermo Fisher). Media was supplemented with 10% Foetal Bovine Serum 
(Sigma) and 1% ITS+ premix (BD Biosciences). Glucose-deplete media was 
administered for a total duration of 96 h and was replenished once during the 
proliferation course (48 h). 
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4.2.6 Apoptosis  
To evaluate the effects of NNT knockdown on cellular apoptosis rates, KD SHRNA and SCR 
SHRNA cells were loaded to opaque-walled, flat-bottomed 96-well plates (Perkin-Elmer) at a 
loading concentration of 8,000 cells/well (10 wells/ group). Media was refreshed after 48 h by 
addition of 100 µl of cell media. Caspase activity was measured as described in Chapter 2 
using 4 wells (replicates) per transfection group. At the end of the assay, plates were frozen at 
-80oC and relative cell density in the remaining wells was assessed the next day using the the 
CyQuant® Proliferation Assay Kit (Thermo Fisher). Results from the proliferation assay were 
deployed to normalise the caspase assay results. 
 
4.2.7 Steroid profiling by Liquid Chromatography/ Tandem mass spectrometry 
To outline the impact of NNT knockdown on steroid production, stably transfected NCI-
H295R cells were loaded to 6-well plates at a concentration of 500,000 cells/ well and 
incubated at 37oC overnight. The next day, media was carefully removed and replaced by 1 
ml of serum-free media (DMEM/F12 supplemented with 1% ITS+ premix and 1% Penicillin-
Sterptomycin). Cells were incubated for 48 h at 37oC. At the end of the incubation, media was 
collected in silinised glass tubes and stored at -20oC. Protein was harvested as described in 
Chapter 2 and used to standardise the results to protein concentration. Steroid extraction from 
stored cell media was subsequently completed as described in Chapter 2.  
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4.3 Results 
4.3.1 NNT silencing by shRNA transfection 
The efficacy and duration of NNT silencing in NCI-H295R cells transfected with shRNA in 
6-well plates was evaluated by Western Blotting and Real-Time PCR. We observed consistent 
suppression of NNT expression by > 80% in cells transfected with anti-NNT shRNA (KD 
SHRNA) in comparison to cells transfected with scramble, non-sense shRNA (SCR SHRNA). 
Gene silencing at a translational level was confirmed by Western Blotting, demonstrating all 
but complete elimination of the corresponding band (Fig. 4-1A). Real-time PCR was used to 
measure NNT expression at a transcriptional level 2-16 weeks post-transfection (Fig. 4-1B). 
The durability of NNT silencing was confirmed by repeated Real-Time PCR/ Western 
Blotting at regular intervals and microscopic evaluation confirming green fluorescence 
emission by > 90% of cultured cells. 
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4.3.2 Cellular redox balance 
The effect of stable NNT silencing on NCI-H295R cellular redox balance was determined by 
measurement of the cellular ratio of reduced to oxidised glutathione (GSH/GSSG ratio), 96 h  
post-transfection (GSH/GSSG-GloTM assay, Promega). Lower GSH/GSSG ratios suggest 
higher intracellular levels of oxidative stress and compromised residual antioxidant capacity. 
Contrary to the phenotype observed in the transient KD model (where acute NNT loss was 
associated with a decrease in the ratio of reduced/ oxidised glutathione), we observed no 
Figure 4-1. Assessment of NNT knockdown in shRNA-transfected NCI-H295R cells by Real-
Time PCR and Western Blotting. A) Western Blotting comparing NNT expression in cells 
transfected with SCR ShRNA vs KD ShRNA; B) Comparison of NNT mRNA expression in 
cells transfected with scramble, non-sense shRNA (SCR SHRNA, negative control) and 
shRNA against NNT (KD SHRNA). Results are expressed as fold-change to control 
(****p<0.0001; n>10 independent experiments).  
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significant differences between the redox status of SCR SHRNA and KD SHRNA cells 
[median (IQR) GSH/GSSG ratio in KD SHRNA cells normalised to SCR SHRNA cells 0.96 
(0.83 – 1.03); p>0.05, n=10 independent experiments] (Fig. 4-2). This suggests development 
of redox adaptation with time in this cell model to compensate for NNT loss.  
 
 
 
4.3.3 Mitochondrial bioenergetics 
Changes in mitochondrial respiration were evaluated by direct measurement of cellular 
oxygen consumption, using Extracellular Flux analysis (Seahorse XF analyser). We observed 
a statistically significant increase in baseline oxygen consumption rates (OCR) in KD 
SHRNA cells in comparison to SCR SHRNA cells [median (IQR) OCR for SCR SHRNA 
cells 10 (4.3-11) pmol/l/µg protein, KD SHRNA cells 15 (7.8-16.5) pmol/l/µg; p<0.05, n=7 
independent experiments]. This difference was sustained in response to successive 
Figure 4-2 GSH-GSSG ratio in stably transfected NCI-H295R cells. No significant difference 
was observed between KD SHRNA and SCR SHRNA cells. Menadione: NCI-H295R cells 
treated with Menadione (40 µM) for 2 h as positive control. Bars represent median ± IQR 
values (p>0.05, n=10 independent experiments).    
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administrations of mitochondrial respiration inhibitors (oligomycin, FCCP, Antimycin A & 
Rotenone), though narrowly missing statistical significance (Fig. 4-3A). Similar to the 
transient KD model, we observed that the maximal oxygen consumption displayed post-FCCP 
was similar to the baseline OCR of NCI-H295R cells, although post-FCCP OCRs exhibited 
considerable variability. There was also a trend towards higher baseline extracellular 
acidification rates (ECAR), representative of glycolytic rates, with stable NNT KD (1.85 ± 
0.24 mpH/min/protein for SCR SHRNA cells vs 2.3 ± 0.30 mpH/min/protein for KD SHRNA 
cells; p=0.063, n=7) (Fig. 4-3B). 
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Figure 4-3 A) Seahorse XF24 analysis of cellular oxygen consumption rate (OCR) in stably 
transfected NCI-H295R cells, at baseline and after successive application of three 
mitochondrial respiration inhibitors. Results were standardised for cell number using 
protein content as a surrogate marker. Bars represent median ± IQR values. KD SHRNA 
cells displayed higher baseline OCR than their controls. O/mycin: Oligomycin; FCCP: 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; A&R: Antimycin A plus Rotenone. 
*P<0.05, n=7 independent experiments.  B) Baseline extracellular acidification rate 
standardised for protein content. Bars represent mean ± SEM values. A tendency towards 
higher ECAR was observed in KD SHRNA cells, without reaching statistical significance 
(p=0.06, n=7). 
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4.3.4 Cellular proliferation 
Cellular proliferation was assessed over a 96h period; repeat experiments were conducted 
from 4-12 weeks from initial transfection. Proliferation rates were provided by the following 
ratio: %[(DNA fluorescence emitted at end point - DNA fluorescence emitted at baseline)]/ 
DNA fluorescence emitted at baseline. In this model, NNT knockdown was also associated 
with slower proliferation, but the effect was evidently less marked than the one observed in 
the acute knockdown model (proliferation rate of SCR SHRNA cells 164% ± 17%, KD 
SHRNA cells 135 ± 17%; p<0.05, n=13 independent experiments) (Fig. 4-4).  
 
 
 
  
Figure 4-4 Proliferation rate of NCI-H295R cells over a 96h period of growth, measured by 
DNA fluorescence. KD SHRNA cells displayed significantly lower proliferation than SCR 
SHRNA cells. Proliferation rate = %[(DNA fluorescence emitted after 96 h - DNA 
fluorescence emitted at baseline)/ DNA fluorescence emitted at baseline] (*p<0.05, n=13 
independent experiments). 
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4.3.5 Apoptosis 
We explored the effect of chronic NNT silencing on cell death measuring intracellular activity 
of caspase 3 and 7, effector caspases of cellular apoptosis. In antithesis with our findings in 
the transient KD model, we observed no effect of NNT knockdown on cellular apoptosis rates 
with chronic gene silencing [median (IQR) caspase activity ratio normalised for cell number 
KD SHRNA vs SCR SHRNA cells 0.925 (0.74-1.15); p>0.05, n=4 independent experiments] 
(Fig. 4-5). 
 
 
4.3.6 Proliferation under chemically induced oxidative stress and glucose deprivation 
Paraquat was administered over a 96 h period to establish whether chronic NNT silencing 
renders NCI-H295R cells more sensitive to chemically induced oxidative stress, as was the 
case with acute NNT knockdown. We observed no difference in cellular proliferation between 
KD SHRNA and SCR SHRNA cells with either low- or high-dose paraquat exposure (Fig. 4-
Figure 4-5 Effect of stable NNT knockdown on cellular apoptosis, measured by determination 
of caspase 3 and 7 activity. No significant difference was observed in apoptotic rates between 
KD SHRNA and SCR SHRNA cells (p>0.05, n=4 independent experiments). 
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6). These results are congruous with the evaluation of baseline redox balance in the same 
model, which also revealed no difference between KD and control cells.  
 
 
We also explored the effect of glucose deprivation on ACC cell proliferation, culturing KD 
SHRNA and SCR SHRNA cells in low-glucose media. We observed that proliferation was 
similarly suppressed in the two groups of cells, with no statistically significant difference 
between them (Fig. 4-7).  
 
Figure 4-6 Effect of stable NNT KD on cellular response to chemically-induced oxidative 
stress. The pro-oxidant agent paraquat was administered to KD SHRNA and SCR SHRNA 
cells for 96 h at incremental doses (10, 20 and 30 µΜ) and cell proliferation was assessed. No 
difference was observed between the two groups (p>0.05, n=13 independent experiments). 
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Figure 4-7 Proliferation of stably transfected NCI-H295R cells in low-glucose media. No 
significant difference was observed between KD SHRNA and SCR SHRNA cells (p>0.05, n=5 
independent experiments). 
 
 
4.3.7 Steroidogenesis 
The compensated phenotype we observed with chronic (shRNA-mediated) NNT knockdown 
extended to steroidogenesis. We observed no statistically significant difference in cortisol 
(SCR SHRNA cells 0.039 ± 0.008 nM/ µg protein, KD SHRNA 0.049 ± 0.005 nM/ µg 
protein; p>0.05, n=6 independent experiments) or androstenedione synthesis (SCR SHRNA 
cells 0.44 ± 0.05 nM/ µg protein, KD SHRNA 0.41 ± 0.05 nM/ µg protein; p>0.05, n=6 
independent experiments) between KD SHRNA and SCR SHRNA cells (Fig. 4-8), although a 
trend towards higher cortisol production with NNT KD was noted. Likewise, activity of 
CYP11B1, CYP21A2 and CYP17 was not significantly different between the two groups, 
although a trend towards higher CYP11B1 and CYP21A2 activity for KD SHRNA cells was 
noted (Table 4-1). 
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Table 4-1 Steroidogenic enzyme activity in SCR SIRNA and KD SIRNA cells, derived from 
product-to-substrate ratios (LC-MS/MS). Results are expressed as mean ± SEM values (n=6 
independent experiments) 
 
Figure 4-8 Effects of stable NNT knockdown on adrenal glucocorticoid (cortisol) and 
androgen (androstenedione) synthesis. No differences were observed between KD SHRNA and 
SCR SHRNA cells (p>0.05, n=6 independent experiments). 
Enzyme Product/  
substrate ratio 
SCR SiRNA 
(nM/µg) 
KD SiRNA1 
(nM/µg) 
P value 
CYP11B1 cortisol/ 
11-deoxycortisol 
0.03 ± 0.005 0.04 ± 0.006 p>0.05 
CYP21A2 11-deoxycortisol/  
17-OH- 
progesterone 
18.9 ± 4.4 22.9 ± 5 p>0.05 
CYP17A1 androstenedione/  
17-OH-
progesterone 
3.8 ± 0.8 3.8 ± 0.6 p>0.05 
HSD11B1 cortisol/ cortisone 6.6 ± 3.7 7.3 ± 2.4 p>0.05 
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4.4 Discussion 
The longer-term effects of NNT loss on ACC cells, as delineated in the stable knockdown 
model we generated, were disparate from the ones encountered in the acute setting. 
Importantly, with long-term culture (4-12 weeks) under constant NNT silencing, NCI-H295R 
cells managed to restore their redox balance. This compensation abrogated the pro-apoptotic 
early impact of NNT loss. Interestingly, a persistent proliferative handicap was demonstrated, 
though this was less marked than the one observed in the acute setting. Extracellular flux 
analysis revealed higher rates of oxygen consumption in KD SHRNA cells, as well as a trend 
towards higher glycolytic rates. This response may reflect higher energy needs. Of note, these 
results contradict the findings of Yin et al. and Fuzisawa et al., who reported suppressed 
oxidative phosphorylation in response to NNT loss in rat phaeochromocytoma cells and 
human lymphocytes, respectively (Yin et al., 2012, Fujisawa et al., 2015).  
Said compensation appears to have developed during the first four weeks of culture post-
transfection. Successful knockdown was first confirmed 2 weeks post transfection, but 4 
weeks was the first time point at which an adequate bulk of transfected cells had been grown 
to allow repeat experiments. We observed no differences in the metabolic, proliferative or 
steroidogenic phenotype of cells from 4-12 weeks post-transfection. 
Redox adaptation to chronic oxidative stress has been previously described in tumour models 
in vitro; this process is driven by the strong selective pressure of oxidative toxicity and 
promoted by the genomic instability (oxidative DNA damage/ impaired DNA repair) which 
characterises the oxidised intracellular microenvironment (Trachootham et al., 2009). The 
adaptive response is often orchestrated by versatile transcription factors, most notably Nrf2 
and Nf-κB, which can up-regulate the expression of core antioxidant genes (superoxide 
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dismutase, catalase, glutathione pathway, thioredoxin pathway). Inactivation of apoptotic 
factors (e.g. caspases) and/or stimulation of pro-survival molecules (e.g. Bcl2) has also been 
described (Trachootham et al., 2009, Sullivan and Graham, 2008, Chen et al., 2007). In the 
absence of NNT, potential compensatory mechanisms that may mediate redox adaptation 
include alternative NADPH resources (e.g. malic enzyme, isocitrate dehydrogenase, 
tetrahydrofolate reductase) or NADPH-independent ROS scavengers (e.g. catalase). Ongoing 
work, which has not been completed at the time of submission of this thesis, involves 
comparative analysis of the complete molecular landscape that is shaped by acute and chronic 
NNT silencing, through whole-transcriptome RNA sequencing and whole metabolome 
analysis. This is expected to provide useful insights illuminating the adaptive cell response to 
NNT loss. 
It is noteworthy that no chronic impact of NNT loss on steroidogenesis was apparent in this 
model, completing the picture of successful metabolic adaptation. These results confirm that 
NNT deficiency does not functionally inhibit steroidogenesis as a result of the compromised 
NADPH supply within the mitochondria. This finding could be explained either by 
compensatory up-regulation of alternative NADPH resources or because the proportion of 
mitochondrial NADPH that is contributed by NNT is not high enough to constitute a limiting 
factor for steroidogenic monooxygenases. On the basis of our results, it appears most likely 
that the adrenal insufficiency of NNT-deficient patients is due to oxidative adrenocortical cell 
damage, which could potentially evolve already in utero. Of relevance, pathways with an 
integral role in adrenocortical development during embryogenesis (e.g. Sonic Hedgehoc 
pathway) can be disrupted by oxidative stress (Xiao et al., 2015).  
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Overall, our in vitro work suggests that NNT targeting as a treatment strategy in ACC merits 
further exploration with in vivo pre-clinical models (e.g. xenograft mouse models). It is 
difficult to predict whether the transient KD or the stable KD model better reflects the anti-
tumour potential of NNT silencing in vivo, but it is worth noting that the anti-proliferative 
effect was maintained even with chronic gene silencing, if to a lesser degree. Inducible 
knockdown may provide the most suitable xenograft model. An alternative option would be to 
employ pharmacological inhibitors of NNT. A caveat here is that although a number of 
inhibitors have been described in the literature (adenosine derivatives, palimityl-CoA 
derivatives, dicyclohexylcarbodiimide, dethylpyrocarbonate), all available data stem from in 
vitro studies (Phelps and Hatefi, 1981, Rydstrom, 1972). A major advantage of NNT targeting 
is the anticipated low toxicity of such an approach, given the adrenal-specific clinical 
phenotype of patients with NNT mutations. 
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5 Urinary steroid profiling as a novel 
surveillance tool to detect ACC 
recurrence  
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5.1 Introduction 
Adrenocortical carcinoma is a rare (incidence 1-2 cases/million/year) but aggressive 
malignancy (Kebebew et al., 2006, Libe et al., 2015). Disease recurrence rates are high, 
exceeding 50% even in patients with microscopically complete (R0) resection (Pommier and 
Brennan, 1992, Stojadinovic et al., 2002). Therefore, vigilant surveillance of all operated 
patients by regular cross-sectional imaging is essential for several years (Libe, 2015, 
Fassnacht et al., 2013, Else et al., 2014). Although the optimal surveillance protocol has yet to 
be established, a common approach in expert centres (including University Hospitals 
Birmingham) involves three-monthly CT scans (thorax and abdomen) in the first two post-
operative years, six-monthly CT scans in the next three years and annual scans in years 6-10 
post-operatively. This is associated with considerable costs, prolonged radiation exposure and 
frequent diagnostic ambiguity in early stages of recurrent/ metastatic disease (Cawood et al., 
2009). Early detection of disease recurrence is important, as it may allow either radical re-do 
surgery in cases of limited metastatic disease volume, or early institution of mitotane and/or 
cytotoxic chemotherapy, potentially prolonging survival (Libe, 2015, Else et al., 2014, 
Erdogan et al., 2013, Datrice et al., 2012, Mihai, 2015, Schulick and Brennan, 1999). The 
number of metastatic sites at diagnosis of recurrent disease has been shown to be an 
independent prognostic factor (Erdogan et al., 2013, Assie et al., 2007). 
Most ACCs (45-70%) are biochemically active, usually presenting an inefficient 
steroidogenic pattern dominated by steroid precursor metabolites (Arlt et al., 2011, Fassnacht 
and Allolio, 2009, Luton et al., 1990). The cause of this characteristic steroidogenic pattern 
has not been definitively elucidated, but it has been tentatively attributed to the relative 
dedifferentiation of malignant cells or the high frequency of mutations within the malignant 
cellular microenvironment (Arlt et al., 2011, Kerkhofs et al., 2015). Most of these hormones, 
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which represent intermediate steps along the three biosynthetic pathways, are not detectable 
in routine clinical biochemistry. Analysis of 24h urine collections by gas chromatography and 
mass spectrometry (GC-MS), however, can quantify the metabolites of every adrenal steroid 
(precursor) hormone, providing a truly comprehensive outline of steroidogenesis. This allows 
the detection of minute changes in steroidogenesis and the illumination of all intermediate 
steps that tend to be perturbed in the setting of adrenocortical malignancy (Arlt et al., 2011, 
Kerkhofs et al., 2015). This approach was first explored in a sizeable retrospective patient 
cohort by Arlt et al. in 2011 with a multi-centre European Study facilitated through the 
European Network for the Study of Adrenal Tumours (ENSAT) (Arlt et al., 2011). Urinary 
steroid metabolite profiles from 102 patients with benign adrenocortical adenomas and 56 
patients with ACC were compared using computational analysis (machine learning). The nine 
steroid biomarkers with the highest diagnostic performance were selected and integrated in a 
diagnostic algorithm which managed to differentiate between benign and malignant tumours 
with a sensitivity and specificity of 90%. Some degree of adrenal hormone/ hormone 
precursor hypersecretion was present in 95% of ACCs (Arlt et al., 2011). In this study, we are 
evaluating the diagnostic performance of this novel approach in a different clinical context: 
the post-operative surveillance of ACC patients following microscopically complete (R0) 
tumour resection. 
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5.2 Methods 
5.2.1 Study population 
Serial post-operative 24-hour urine samples were prospectively collected from patients with 
histologically confirmed ACC, who had undergone microscopically complete (R0) tumor 
resection in 12 clinical specialist referral centers participating in the European Network for 
the Study of Adrenal Tumors (ENS@T; www.ensat.org), after approval of local ethical 
review boards and informed patient consent. Participating countries included the UK 
(Birmingham), Germany (Wurzburg, Munich, Berlin), France (Paris), Italy (Florence, Turin), 
the Republic of Ireland (Dublin, Galway), Poland (Warsaw), Croatia (Zagreb) and Portugal 
(Lisbon). Urine samples were collected between 2007 and 2016. Inclusion criteria were 
defined as a) history of ACC with histological confirmation, b) complete (R0) tumor resection 
and c) provision of at least one post-operative urine sample at a disease-free state, i.e. before 
any radiological evidence of disease recurrence, and within two years from surgery.  ACC 
recurrence had to be confirmed by one of the following:  a) emergence of new lesions on 
cross-sectional imaging (CT, MRI) which either enlarge on follow-up scans, or regress in 
response to chemotherapy, b) emergence of enhancing lesions on PET or PET-CT scans, or c) 
histological evidence of recurrent/metastatic ACC on percutaneous biopsy or metastasectomy. 
Participating centres were prompted to provide urine samples every three months, but actual 
frequency of provided samples did not constitute an exclusion criterion as long as at least one 
post-operative sample at disease-free state had been provided. 
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5.2.2 Biochemical analysis 
Measurement of 24-h urinary steroid metabolite excretion in 129 recruited ACC patients as 
well as in a healthy control cohort (50 men, 77 women, age range 20–81 yr) was carried out 
by GC-MS. Urinary steroid profiling by GC-MS was established 40 years ago by Shackleton 
et al. (Shackleton and Snodgrass, 1974) and Sjovall (Sjovall, 1975), and still boasts the 
highest analytical sensitivity for steroid metabolite detection in biological samples (Arlt et al., 
2011). The first separation stage (gas chromatography) involves evaporation of purified and 
chemically processed (derivatised) steroid samples which run -in a gaseous form- through a 
liquid column (stationary phase) at different speeds according to their affinity to the column. 
At the end of the column, steroids reach the mass spectrometer, where they are bombarded 
with electrons and fragmented into molecule-specific ionised particles in a special collision 
cell. The resulting fragments are then selected according to their mass-to-charge ratio through 
acceleration within a quadrupole (Arlt et al., 2011, Taylor et al., 2015).   
 
To prepare samples for GC-MS analysis, free and conjugated steroids were extracted from 5 
ml urine samples by solid-phase extraction using SepPak columns (Waters, Milford, Ma, 
USA). Columns were prepared by washes with 4 ml methanol (Sigma) and 4 ml double-
distilled water (ddH2O). After sample loading, the columns were washed with 4 ml ddH2O 
and steroids were eluted in 4 ml methanol in a clean biosilicate tube. Samples were left to 
evaporate in a heat-block (55oC), aided by N2 steam. The remaining dry samples (steroids) 
were incubated for 3 hours at 55oC in a special hydrolysis buffer (3 ml 0.1M acetate buffer 
[pH 4.8-5.0] + 10 mg ascorbate + 10 mg sulfatase/glucoronidase; all ingredients purchased 
from Sigma) to remove glucuronide and sulphate groups (deconjugation). Deconjugated 
steroids were subsequently reloaded onto SepPak columns and eluted into glass tubes with 4 
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ml methanol.  The final stage of sample preparation consisted in chemical derivatisation, to 
enhance the sensitivity of mass spectrometry. To achieve this, samples were again evaporated 
and three drops of 2% methoxyamine-pyridine were added. After vortexing, tubes were 
incubated at 55oC for one hour, then evaporated under N2. In the next step, 75 µl of N-
trimethylsilylimidazole (Sigma) were added; tubes were vortexed again and incubated at 
120oC overnight. Subsequently, samples were extracted by adding 2 ml cyclohexane and 2 ml 
dH2O, each step followed by vortexing. After centrifugation (1,000 x g for 5 minutes), the 
bottom layer was discarded. Another 2 ml dH2O were added, followed by the same sequence 
of vortexing, centrifugation and removal of the bottom layer. The top layer, which contained 
the extracted steroids in cyclohexane, was transferred into injection vials. The samples were 
then injected into an Agilent 5973 GC mass-spectrometer operating in selected-ion-
monitoring (SIM) mode to achieve sensitive and specific detection and quantification of 33 
selected steroid metabolites (Table 5-1, Fig. 5-1). 
 
 
 
 
 
 
 
Table 5-1 Steroid metabolites detected in 24h urine collections by GC-MS, tabulated against 
the steroid hormones they originate from. 
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Steroid metabolite                                                            Metabolite of 
Androgen metabolites                                                         
Androsterone (An) Androstenedione, testosterone, 5α-
dihydrotestosterone 
Etiocholanolone (Et) 
   
Androstenedione, testosterone 
11β-hydroxyandrosterone (11β-OH-An) 11β-hydroxyandrostenedione 
Androgen precursor metabolites 
Dehydroepiandrosterone    
(DHEA) 
DHEA and DHEA sulphate (DHEAS) 
16α-hydroxy- DHEA  
(16α-OH-DHEA) 
DHEA + DHEAS 
Pregnenetriol (5-PT) 17-hydroxypregnenolone 
Pregnenediol (5-PD)/ Pregnadienol Pregnenolone 
Mineralocorticoid metabolites 
Tetrahydro-11-dehydrocorticosterone (THA) Corticosterone,  
11-dehydrocorticosterone 
5α- tetrahydro-11-dehydrocorticosterone  
(5α-THA) 
 
Corticosterone, 
11-dehydrocorticosterone 
18-hydroxy-dehydrocorticosterone (11-OH-THA) 11-oxo-corticosterone,  
11-dehydrocorticosterone 
Tetrahydrocorticosterone (THB) Corticosterone 
5α-tetrahydrocorticosterone (5α-THB) Corticosterone 
Tetrahydroaldosterone (3α5β-THALDO) Aldosterone 
Mineralocorticoid precursor metabolites 
Tetrahydro-11- deoxycorticosterone  (THDOC) 11-deoxycorticosterone 
5α-tetrahydro-11-deoxycorticosterone               
(5α-THDOC) 
11-doxycorticosterone 
Gluocorticoid precursor metabolites 
Pregnanediol (PD) Progesterone 
3α, 5α-17-hydroxypregnanolone (3α5α-17HP) 17-hydroxyprogesterone 
17-hydroxy-pregnanolone (17HP) 17-hydroxyprogesterone 
Pregnanetriol (PT) 17-hydroxyprogesterone 
Pregnanetriolone (PTONE) 21-deoxycortisol 
Tetrahydro-11-deoxycortisol (THS) 11-deoxycortisol 
Total glucocorticoid metabolites                                                                                  
Cortisol (F)                                                                            Cortisol 
6β-hydrocortisone (6β-OHF) Cortisol 
Tetrahydrocortisol (THF) Cortisol 
5α-tetrahydrocortisol (5α-THF) Cortisol 
α-cortol Cortisol 
β-cortol Cortisol 
11β-hydroxyetiocholanolone (11β-OH-Etio) Cortisol 
Cortisone (E) Cortisone 
Tetrahydrocortisone (THE) Cortisone 
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α-cortolone Cortisone 
β-cortolone Cortisone 
11-oxo-etiocholanolone (11-oxo-Etio) Cortisol 
Figure 5-1 Adrenal steroid hormones and precursor hormones along the steroidogenic 
pathways (small print) and their metabolites detected by GC-MS in urine (coloured bold 
print). AKR1C3: Alpha-Keto-Reductase Family 1 Member C3. 
Chapter 5                                                           Urinary steroid profiing as a novel surveillance tool to detect ACC recurrence 
185 
 
5.2.3 Expert review of steroid profile 
Three clinical endocrinologists with experience in adrenal disease were provided with 24-
steroid profiles derived from serial post-operative samples contributed by patients who either 
a) developed disease recurrence or b) remained recurrence-free over a follow-up period of at 
least 3 years. The latter comprised a negative control cohort, as the chances of disease 
recurrence past this time-point are relatively low (Beuschlein et al., 2015). Pre-operative 
steroid profiles were also provided when available. Clinicians were asked to independently 
review the longitudinal steroid profile series from each individual patient retrospectively and 
identify any samples which they considered highly suggestive of disease recurrence. 
Reference ranges derived from the healthy controls groups were provided for each steroid. All 
assessors were blinded with regard to clinical information other than basic patient 
demographics (age, sex), sampling time in relation to surgery and use of mitotane. Recurrence 
detection was considered successful only if it preceded or coincided with the earliest urine 
sample collected after the first radiological manifestation of recurrent disease (i.e. late 
biochemical detections in relation to imaging did not count as true positives). 
 
5.2.4 Statistical analysis 
Data analysis and graphic representation was completed using Graphpad Prism Software. 
Data are summarised as median (IQR) values unless otherwise stated. Two-group 
comparisons were performed using the Mann-Whitney test. Comparisons between multiple 
groups were performed using the Kruskal-Wallis test. 
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5.3 Results 
5.3.1 Patient characteristics 
129 patients (62 men, 67 women) who had undergone complete (R0) resection of a 
histologically confirmed ACC provided at least one 24-hour urine sample whilst considered 
disease-free according to the most recent clinical and radiological assessment and no later 
than 2 years post-operatively. Median age at diagnosis was 55 years (range 14-80 years). 
Frequency and total number of urine samples varied considerably among participants. The 
follow-up period, as determined by perusal of relevant clinical entries on the ENSAT online 
clinical registry, was variable with a median follow-up of 31 months (IQR 18-42 months). 
During this period, 41 patients developed disease recurrence; 9 of them had to be excluded as 
no post-recurrence urine could be provided (Fig. 5-2). Two patients developed serial 
recurrences (with intermediate complete metastasectomy), providing urine samples before and 
after each one of them, so that the total number of recurrences amounted to 34. Of the 
remaining patients, 40 were clinically and radiologically followed up for over 3 years; these 
were considered cured comprising a ‘negative control’ cohort for the purposes of this study, 
as the natural history of ACC rarely involves recurrences presenting after this post-operative 
time-point (Beuschlein et al., 2015). Relevant clinical details for the 32 recurred patients and 
the 40 disease-free controls are provided in Table 5-1.  
Of the 32 recurred patients, 13 had provided a urine sample before resection of the primary 
tumour; the remaining 19 patients only contributed post-operative urine samples. All samples 
provided by patients in these two subgroups are depicted in Fig. 5-3, plotted against time after 
surgery.  
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Figure 5-2 Recruitment flow chart. 32 patients with recurrence comprised the ‘disease-
positive’ cohort. 40 patients with no evidence of recurrence for over three years comprised 
the ‘disease-negative’ control group. 
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Figure 5-3 Urine samples provided by 32 patients who developed post-operative disease 
recurrence, plotted against time from surgery. Each line corresponds to a single patient. Red 
represents samples provided after the first radiological manifestation of recurrent disease; 
blue represents pre-recurrence samples. Purple dots represent pre-operative samples. A) 
Patients who provided both pre- and post-operative samples. B) Patients who provided post-
op urine samples only. 
      A 
       B 
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Table 5-2 Characteristics of study participants who developed ACC recurrence or remained 
disease-free for at least three years post-operatively. 
 
 
 
5.3.2 Steroid ratios  
The expected longitudinal biochemical trail of a gradually enlarging ACC mass (local 
recurrence or metastasis) would consist in a progressive rise in the value of one or more 
urinary steroid metabolites. Examples of such trends for some recurred patients in this study 
are provided in Figure 5-4.  Figure 5-5 presents two indicative heat-maps with longitudinal 
changes in urinary steroid metabolites during follow-up.  
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Figure 5-4 Longitudinal post-operative changes in the urinary steroid biomarker 5-PD 
(pregnenediol) in four female patients who eventually developed disease recurrence. Arrows 
point to the time of the first radiological detection of recurrent ACC for each patient. The 
shaded area of the graph represents the 5th-95th centile area for sex-matched healthy controls.    
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Figure 5-5 Heat-map representation of the longitudinal changes in the urinary steroid 
metabolome of two ACC patients who eventually developed disease recurrence. Arrows point 
to the time of surgery or the first radiological evidence of recurrent disease. Red represents 
metabolites that are raised above the mean control value; blue represents suppressed steroid 
metabolites. 
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In the proof-of-concept study for the use of urinary steroid metabolomics for differentiating 
benign from malignant adrenocortical tumors, Arlt et al. had distinguished 9 steroid 
biomarkers with the highest diagnostic value in detecting ACC: Etio, 5-PT, 5-PD (androgens 
and androgen precursors); THDOC, 5α-THA (mineralocorticoids and mineralocorticoid 
metabolites); PT, PD, THS, 5α-THF (glucocorticoids and glucocorticoid metabolites) (Arlt et 
al., 2011). 5α-reduced steroid biomarkers  5α-THA and 5α-THF are ill-suited for the specific 
clinical context of post-operative surveillance, as they are invariably suppressed in patients 
receiving adjuvant mitotane treatment due to the drug’s potent inhibitory effects on 5α-
reductase activity (Chortis et al., 2013). In this study, we have thus selected a modified 
version of this group, substituting DHEA for the two 5α-reduced steroids. DHEA had also 
been  significantly higher in ACCs than in ACAs in the adrenal incidentaloma study and had 
the highest average absolute excretion values than any other biomarker in ACCs (Arlt et al., 
2011).  
Considering the first post-operative urine as the ‘baseline’ sample for each patient, we 
calculated the following ratios for each of these 8 malignant biomarkers: a) Recurred patients: 
ratio of steroid excretion in the first post-recurrence sample to excretion of the same steroid in 
the ‘baseline’ post-operative sample (n=34 ratios) and b) non-recurred patients: ratio of 
steroid excretion in each follow-up sample to the the excretion of the same steroid in the 
‘baseline’ sample (n=163 ratios). We then selected the highest of these ratios for each sample. 
We divided the samples further into four groups, according to recurrence status and mitotane 
exposure, taking into consideration the inhibitory effect of mitotane on steroidogenesis (Fig. 
5-6). The median of selected (highest) ratios was significantly higher in samples from 
recurred than non-recurred patients, in non-mitotane-treated subjects. The same trend was 
observed in mitotane-treated patients, failing to reach statistical significance. In the sub-group 
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of patients with available pre-operative urine samples, we tried a different approach, selecting 
the three highest pre-operative steroid metabolites (when normalised to the 95th percentile of 
the reference range for the same metabolite). We then looked at the ratio of the value of each 
of the selected steroid biomarkers in the first post-recurrence urine sample to the value of the 
same metabolite in the first (‘baseline’) post-operative urine sample (n=15 ratios). For the 
four patients with available pre-operative urine in the ‘non-recurred’ cohort, we followed the 
same process and calculated the ratio of the value of each of the selected steroid biomarkers in 
every post-operative urine sample to the value of the same metabolite in the first (‘baseline’) 
post-operative urine sample (n=13 ratios). This method produced a better separation between 
‘recurred’ and ‘non-recurred’ samples (Fig. 5-7). 
 
 
 
Figure 5-6 Highest urinary steroid metabolite ratios (recurrence sample to baseline post-
operative sample) in recurred patients and non-recurred control patients. Patients have been 
further classified according to use of adjuvant mitotane. Bars represent median (IQR) values 
(***p<0.001). 
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5.3.3 Expert review of the urinary steroid metabolome 
Longitudinal series of urinary steroid profiles derived from 52 patients (n=32 with 
documented post-operative recurrence and n=20 with a recurrence-free history of at least 
three years) were reviewed independently by three clinical endocrinologists in a retrospective 
and blinded fashion. Only patients who had contributed at least 2 post-operative samples were 
included, as this was the minimum essential number of samples for patients who recurred 
according to our inclusion criteria. Clinicians were able to correctly identify recurrent disease 
by the time of the first post-recurrence sample (defined by reference to the first abnormal 
surveillance scan) with sensitivities of 65%, 53% and 74%. This improved substantially in the 
subgroup (n=15 recurrences) of patients who had provided pre-operative urine samples 
(sensitivities 73-93%) (Fig. 5-8A). Of note, 10/15 (67%) of recurrences in these patients were 
Figure 5-7 Highest post-operative urinary steroid ratio (recurred sample to first post-
operative sample) when focusing on the three steroid biomarkers that were the most elevated 
in the pre-operative sample. Samples from four non-recurred patients were used as controls. 
Bars represent median (IQR) values (****p<0.0001). 
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correctly detected unanimously by all reviewing clinicians. Absence of a pre-operative sample 
curtailed diagnostic sensitivities to 37-58% (Fig. 5-8A). Specificities, defined as the 
proportion of non-recurred patients who were correctly identified as such by perusal of the 
steroid profiles, varied considerably among the assessors (Fig. 5-8B). The effect of pre-
operative urine availability on specificity could not be reliably assessed as only four non-
recurred patients had provided a pre-operative sample.  It is worth noting that the diagnostic 
performance of the steroid profile review was not significantly altered by adjuvant mitotane 
treatment, despite the drug’s known inhibitory effect on steroidogenesis (Fig. 5-9). 
Importantly, the diagnosis of recurrence by assessing clinicians preceded the first radiological 
evidence of recurrent disease by more than two months in a substantial proportion of cases; 
with one exception, all these early detections pertained to mitotane-treated patients (Fig. 5-
10).  
 
Figure 5-8 Clinician review of serial urinary steroid profiles. A) Recurrence detection 
(Sensitivity) in ACC patients grouped according to availability of pre-operative urine. B) 
Recurrence exclusion (Specificity) in disease-free patients  
A 
B 
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Figure 5-9 Clinician review of serial urinary steroid profiles. A) Recurrence detection 
(Sensitivity) in ACC patients grouped according to pre-operative urine availability and 
mitotane treatment.  B) Recurrence exclusion (Specificity) in disease-free patients grouped 
according to mitotane treatment.  
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Figure 5-10 Recurrences detected biochemically by assessing clinicians on samples provided 
> 2 months before the first radiological manifestation of recurrent disease 
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5.4 Discussion 
In this study, we have explored a novel diagnostic tool to facilitate post-operative surveillance 
for recurrence in patients who have undergone resection of primary ACC. This involved high-
sensitivity urinary steroid profiling by GC-MS, a tool which has given highly promising 
results in the differentiation of benign from malignant adrenal tumours in recent retrospective 
studies (Arlt et al., 2011). We have assessed the diagnostic potential of urinary steroid 
profiling in the clinical context of post-operative monitoring in a subjective manner, based on 
blinded, retrospective clinician review of serial urinary steroid profiles from ACC patients 
who recurred (positive patient cohort) or remained disease-free for over 3 years (negative 
control cohort). Our next step will be to develop an automated, machine-learning-based model 
of analysis; this work has not been completed at the time of writing this thesis. 
The need for close post-operative monitoring of ACC patients is dictated by the high rates of 
disease recurrence, even after microscopically complete (R0) resection. In aggressive tumours 
(Ki67 > 10%), 5-year recurrence-free survival is lower than 25%. Importantly, histological 
evidence of less aggressive behaviour (Ki67 < 10%) does not obviate the need for close post-
operative follow-up, as recurrence-free survival does not exceed 50% in this patient cohort 
either (Beuschlein et al., 2015). Current follow-up protocols are based on clinical examination 
and routine biochemistry orientated towards detecting clinical or biochemical evidence of 
hormone excess, as well as regular cross-sectional imaging by CT or MRI scans. FDG-PET is 
also useful in this context but its use is limited by its high cost. Imaging is currently 
indispensable, as recurrences/ metastases can remain clinically and biochemically 
inconspicuous until they attain a sizeable volume, which usually exceeds the minimal 
detection limit of a modern CT/ MRI scan. The frequency of surveillance imaging is however 
limited by the considerable radiation exposure it ineluctably incurs (CT and FDG-PET scans) 
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or its high cost (MRI and FDG-PET scans). No consensus exists on the optimal surveillance 
imaging protocol; however, in most centres this is tailored to match the gradual decline in 
recurrence rates with time: recurrence rates are highest in the first two years post-operatively, 
lower in years 3-5 and lowest > 5 years post-operatively (Beuschlein et al., 2015). At 
University Hospitals Birmingham, the current follow-up protocol entails surveillance CT 
scans every three months post-operatively in the first two years, every six months in years 3-5 
and annually thereafter. Patients who have been disease-free for > 10 years can be discharged 
as no recurrences have been reported after this time-point.  
Our cohort consisted of adult patients with fully resected ACC who were able to provide a 24 
h urine sample within two years from surgery and whilst still considered disease free 
according to the most recent clinical and radiological assessment. This time point was used to 
increase the yield of recurred patients, as patients who have already been disease-free for two 
years are less likely to recur. The overall cohort was demographically representative of the 
general population of ACC patients, with a female preponderance and median age at 
presentation in the 6th decade of life. Of the 72 patients who completed three years of follow-
up, 32 (44%) recurred, a rate that is somewhat lower than previous retrospective studies 
(Beuschlein et al., 2015, Terzolo et al., 2007). This is likely to be due to selection bias related 
to the stipulation that a urine sample at a disease-free state must be provided for inclusion to 
the study – patients who recurred before a 24 h urine sample could be provided were 
excluded.  
On retrospective, blinded assessment of serial 24 h urine collections clinicians were able to 
detect recurrence by the time of its first radiological manifestation with high sensitivity in 
cases where a pre-operative urine sample was available. The diagnostic value of a pre-
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operative urine sample stems from its ability to impart the individual steroid profile of the 
particular tumour, which is likely to re-emerge in a future recurrence. With this information to 
hand, clinicians can focus on steroid biomarkers which were elevated pre-operatively and use 
a lower threshold to suspect recurrence when changes in their excretion are detected. Of note, 
10/15 (67%) of recurrences in these patients were detected unanimously by all reviewing 
clinicians. In patients who were only able to contribute post-operative urine samples, the 
ability of clinicians to detect recurrence was substantially lower. Specificity varied 
considerably among the three clinicians, and correlated inversely to their respective 
sensitivities.  The sub-optimal overall diagnostic accuracy for this patient cohort in 
comparison to previously reported sensitivities and specificities in patients with adrenal 
incidentalomas can be explained by the limited disease volume of recurrent/ metastatic ACC, 
with lesions that are often smaller than 1 cm in maximal diameter at the time of first 
radiological detection. By comparison, the median ACC size in the 2011 study on adrenal 
incidentalomas amounted to 9 cm in maximum diameter (Arlt et al., 2011). Consequently, the 
resulting perturbation of steroidogenesis might be very mild and not always distinguishable 
from normal sample-to-sample variability.  
Interestingly, adjuvant mitotane did not compromise the diagnostic performance of reviewing 
clinicians, despite the drug’s well documented ability to inhibit steroidogenesis. Mitotane 
interferes with adrenal steroidogenesis in a number of ways, including a) overall suppression 
of steroidogenesis resulting in lower excretion values for all steroid metabolites, b) rapid 
glucocorticoid breakdown by CYP3A4 necessitating high-dose hydrocortisone replacement; 
this means glucocorticoid metabolites are no longer diagnostically relevant in these patients 
and c) 5α-reductase inhibition, leading to a diminution of 5α-reduced steroids (Chortis et al., 
2013).  Although mitotane obtunds the ascending trends in steroid biomarkers in recurred 
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patients, it also suppresses the random sample-to-sample variability (noise), which can be 
diagnostically opportune.  
Obviously, an effective diagnostic tool should be able to produce objective and unbiased 
outputs which do not rely on the individual clinician’s experience and perspicacity. Due to the 
complexity of the system (multiple biomarkers, modest elevations due to small disease 
volumes), applying numerical diagnostic cut-offs appears to be too crude a way to predict the 
underlying disease status. Machine learning-based approaches would offer a good way of 
utilising the full wealth of information provided by 33-steroid profiles in a systematic, 
objective and reproducible fashion, as already demonstrated in the case of adrenal 
incidentalomas (Arlt et al., 2011).  
This is the first clinical study exploring the diagnostic potential of urine steroid profiling in 
the specific clinical setting of post-operative surveillance for recurrence in ACC patients, with 
only small case series previously reported on this subject. The limitations of our work pertain 
to the relatively small recurred patient numbers and inconsistency in quality of provided data 
(e.g. availability of pre-operative urine samples, frequency of post-operative urine samples). 
After completion of our current analysis by machine learning, we will endeavour to validate 
these findings in a dedicated prospective study with more stringent inclusion criteria which 
will address the aforementioned weaknesses (pre-operative urine collection mandatory and 
short intervals between post-operative urine). Our results so far do not suggest that urinary 
steroid profiling could obviate the need for follow-up imaging, but it can be useful as a 
complimentary surveillance tool that could expedite scans in patients with suspicious 
biochemistry, inform discussions in patients with ambiguous imaging results or suggest the 
need for institution of adjuvant mitotane treatment. 
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6.1 Antioxidant targeting as a novel therapeutic approach in ACC 
In this work, we have explored a novel therapeutic avenue in the treatment of ACC. The 
urgent need to develop new approaches in the management of this rare endocrine malignancy 
has been highlighted in recent studies demonstrating the disappointing performance of classic 
combination chemotherapy in patients with advanced disease (Fassnacht et al., 2012). 
Unfortunately, the substantial progress in our understanding of ACC molecular genetics has 
so far failed to translate into therapeutic advances. This in vitro project draws on recent 
studies revealing the implication of mitochondrial antioxidant pathway defects in the 
pathogenesis of congenital adrenal failure. In 2012, genetic studies in patients with Familial 
Glucocorticoid Deficiency (FGD), a rare hereditary form of adrenal insufficiency, revealed 
inactivating mutations in the mitochondrial NADPH generator Nicotinamide Nucleotide 
Transhydrogenase (NNT) (Meimaridou et al., 2012). The biological role of NNT is to provide 
the mitochondrial antioxidant pathways (glutathione pathway and thioredoxin pathway) with 
reducing equivalents in the form of NADPH (Rydstrom, 2006). Inactivating mutations of 
thioredoxin reductase have recently also been discovered in FGD patients. Antioxidant 
pathways have a crucial biological role within cells, detoxifying Reactive Oxygen Species 
(ROS), the harmful by-products of aerobic metabolism. Inordinate accumulation of ROS has 
deleterious effects (oxidative stress), which can culminate to cell death if not counterbalanced 
by an effective antioxidant defence system. The risk of ROS toxicity is highest in 
metabolically active tissues such as the adrenal cortex, and most relevant in malignant cells 
which tend to have higher baseline ROS levels than normal cells. Our hypothesis was that 
NNT inactivation will compromise the -metabolically highly active- ACC cells’ capacity to 
scavenge ROS, exposing them to oxidative toxicity and, eventually, cell death.  
Chapter 6                                                                                                                          Final conclusions and future directions 
205 
 
We validated this hypothesis transiently knocking down NNT in NCI-H295R ACC cells in 
vitro (siRNA transfection) and observing an increase in cellular levels of oxidative stress, 
suppression of cellular proliferation and induction of apoptotic cell death. Furthermore, NNT 
loss rendered cells sensitive to sub-toxic doses of paraquat, a chemical inducer of oxidative 
stress. These results provide a first in vitro characterisation of the therapeutic potential of 
NNT in the management of ACC. Next, we employed a long-term silencing model, involving 
stable NCI-H295R transfection with shRNA against NNT, to delineate the chronic 
consequences of NNT loss. Here we captured the emergence of a compensated phenotype, 
with reinstatement of redox homeostasis and abrogation of apoptosis. This compensation was 
underpinned by higher oxygen consumption and glycolytic rates, indicating higher energy 
needs. Importantly, a longstanding suppression of proliferation was observed, although this 
was clearly much less pronounced than the one we observed in the acute setting (Fig. 6-1).  
A second output of interest was the impact of NNT loss on steroidogenesis; inhibition of 
steroidogenesis by NNT silencing would be therapeutically useful in patients with adrenal 
hormone excess, a common clinical and biochemical attribute of ACC. Suppression of 
steroidogenesis with NNT inactivation appeared theoretically likely, given the glucocorticoid 
deficiency of NNT mutant patients and the role of NADPH as an essential cofactor to 
important mitochondrial steroidogenic enzymes (CYP11A1, CYP11B1, CYP11B2).  
Surprisingly, we observed a paradoxical stimulation of steroidogenesis in the acute setting 
(siRNA knockdown), with no lingering effect in the long term (shRNA knockdown). Overall, 
these findings suggest NNT is not a meaningful treatment target as far as inhibition of 
steroidogenesis is concerned.  
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We did not exhaust our in vitro work in the study of NNT, but we also selectively inhibited 
the glutathione pathway (by buthionine sulfoximine, BSO) and the thioredoxin pathway (by 
auranofin) and monitored the individual impact of these interventions on cellular proliferation 
and viability. Both drugs demonstrated a cytotoxic potential in clinically attainable doses. 
Overall, our work suggests that ACC cells are susceptible to pharmacological inhibition of 
antioxidant pathways. The relative efficiency of the various possible target options (NNT, 
glutathione pathway, thioredoxin pathway) would need to be explored further with in vivo 
studies, e.g. NCI-H295R xenografts in mice. It is difficult to predict whether a compensated 
phenotype akin to the one we observed in the stable knockdown model would emerge with in 
vivo inhibition, and if so how long it would take for this to be established. An inducible 
knockdown model would be particularly attractive given the discrepancy we observed 
between the acute and chronic NNT knockdown models. Pharmacological inhibition of the 
glutathione or thioredoxin pathways (e.g. by BSO or auranofin administration) would be more 
straightforward and in vivo studies employing these agents in different malignancies have 
already been published (Bailey et al., 1994, Bailey, 1998, O'Dwyer et al., 1996, Bailey et al., 
1997, Li et al., 2016). Importantly, the ability of malignant cells to adapt to oxidative stress is 
well described in the literature; therefore, achieving a marked and sustained anti-tumour 
effect may require concurrent use of a pro-oxidant chemotherapy agent. With this approach, 
antioxidant targeting would be used as a chemotherapy sensitising strategy. Our in vitro 
results with co-implementation of NNT inhibition and paraquat-induced oxidative stress are 
promising in this respect. An alternative approach could involve dual inhibition of the 
glutathione and thioredoxin pathways; this has not been formally explored so far, but recent 
pilot experiments in our lab have suggested a synergistic effect leading to marked cytotoxicity 
with low doses of BSO and auranofin. 
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Ongoing work which is approaching completion comprises RNA sequencing and whole 
metabolome analysis of both NNT knockdown models (siRNA and shRNA transfected cells). 
We expect that this additional effort will provide useful mechanistic insights, illuminating the 
complete molecular impact of NNT inhibition and unravelling the compensatory response 
which leads to the distinct phenotype of stable NNT silencing. 
 
 
 
 
 
Figure 6-1 Effects of NNT knockdown on ACC cell metabolism, proliferation/viability and 
steroidogenesis in the acute and chronic setting. Horizontal arrows demonstrate paucity of 
change in reference to control cells.   
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6.2 Urine steroid profiling as a new surveillance tool to detect ACC 
recurrence 
Our clinical work followed a different direction, aspiring to develop a novel diagnostic tool to 
facilitate prompt recurrence detection in operated ACC patients. The majority of patients with 
resected ACCs will experience post-operative disease recurrence. Therefore, close monitoring 
is essential for many years. Currently post-operative surveillance is largely imaging-based, 
with all the limitations this entails in terms of cost, cumulative radiation exposure and 
diagnostic ambiguity at early recurrence stages. A highly auspicious novel diagnostic 
modality was recently introduced in the clinical context of adrenal incidentalomas, involving 
urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS). The sensitivity 
of GC-MS supersedes the analytical capacity of traditional adrenal biochemistry; the method 
can quantify up to 34 steroid metabolites in 24h urine collections, spanning the whole 
spectrum of steroidogenesis. ACC presents a characteristic steroidogenic pattern, with a 
relative over-abundance of steroid precursors; this can be captured and utilised to differentiate 
malignant from benign adrenal tumours with high sensitivity and specificity.  
In our study, we evaluated the ability of the same technique to serve as a sensitive 
surveillance tool in the post-operative course of patients who have undergone full resection of 
ACC. On blinded retrospective review of serial steroid profiles by three clinical 
endocrinologists, recurrence was detected concurrently with or prior to cross-sectional 
imaging in the majority of cases. The single most important factor affecting the diagnostic 
success of subjective urinary steroid profile review was the availability of a pre-operative 
urine sample, which can reveal the individual steroidogenic fingerprint of the individual 
tumour. Importantly, adjuvant mitotane treatment did not seem to adversely impact on the 
results, despite the drug’s well-described inhibitory effect on steroidogenesis. We are 
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currently trying to introduce automated, machine learning-based analysis of the results as an 
objective and powerful analytical way of processing the complex data sets comprising the 
urinary steroid profile (urine steroid metabolomics). Upon completion of this work, we will 
endeavour to validate urine steroid profiling and metabolomics as a diagnostic tool for ACC 
recurrence detection with a dedicated prospective study with more stringent inclusion criteria 
(provision of pre-operative urine, high frequency of post-operative urine collection).  
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